Azetidin-3-ylmethanol derivatives as CCR6 receptor modulators

Abstract

The present invention relates to compounds of formula (I), their synthesis and their use as CCR6 receptor modulators for the treatment or prevention of various diseases, conditions or disorders. [Formula 1] TIFF2023523300000191.tif51156

Description

[Technical Field]

[0001] The present invention relates to novel compounds of formula (I) or pharmaceutically acceptable salts thereof, and their use as CCR6 receptor modulators in the treatment and prevention of various diseases, illnesses, or disorders ameliorated by modulating the CCR6 receptor. The present invention further relates to related aspects, such as pharmaceutical compositions comprising one or more compounds of formula (I) and methods for preparing the compounds. [Background technology]

[0002] Chemokine receptors comprise a family of G protein-coupled receptors (GPCRs) that recognize and bind to peptide chemokine ligands. The primary function of chemokine receptors and their ligands is to induce trafficking of leukocytes into and out of lymphoid organs and tissues, both in the steady state and in association with infection or inflammation. In addition, chemokine signaling events can induce activation of integrin molecules on the surface of immune cells, enabling firm adhesion to activated endothelium and promoting migration from the blood into inflamed tissues (Montresor A, Frontiers in Imm., 2012; Meissner A, Blood, 2003). Chemokine receptor 6 (CCR6, also known as BN-1, CC CKR-6, CD196, CKRL3, CMKBR6, DCR2, DRY6, GPR29, GPRCY4, STRL22) is a GPCR expressed primarily on effector CD4+ T helper cells, but also on B cells, CD8+ cytotoxic T cells, regulatory T cells (Tregs), immature dendritic cells (DCs), and type 3 innate lymphoid cells (ILCs) (Cua DJ, Nat Rev Immunol. 2010 Jul;10(7):479-89. doi:10.1038 / nri2800). CCR6 binds to the chemokine CCL20 (chemokine (CC motif) ligand 20) (Greaves DR, J Exp Med. 1997 Sep 15;186(6):837-44. doi:10.1084 / jem.186.6.837.) CCL20 is also known as macrophage inflammatory protein 3a (MIP-3a), liver and activation-regulated chemokine (LARC), or Exodus-1 (Schutyser E, Cytokine Growth Factor Rev. 2003 Oct;14(5):409-26. doi:10.1016 / s1359-6101(03)00049-2). The CCR6 / CCL20 interaction defines humoral responses in the intestinal mucosa and is required for lymphocyte homeostasis within the small intestinal mucosa (Cook DN, Immunity. 2000 May;12(5):495-503. doi:10.1016 / s1074-7613(00)80201-0). Under steady-state conditions, CCR6 and CCL20 regulate intestinal IgA production, and CCL20 expressed in Peyer's patches recruits CCR6+IgA+ B cells to the mucosa and releases secretory IgA into the intestinal lumen (Lin YL, Front Immunol. 2017;8:805. doi:10.3389 / fimmu.2017.00805; Reboldi A, Science. 2016 May 13;352(6287):aaf4822. doi:10.1126 / science.aaf4822). Under inflammatory conditions, CCL20 expression is strongly upregulated by pro-inflammatory cytokines, including IL-17A, TNFα, and IL-1b, in both endothelial and epithelial cells (Harper EG, J Invest Dermatol. 2009 Sep;129(9):2175-83. doi:10.1038 / jid.2009.65; PLoS One. 2015;10(11):e0141710. doi:10.1371 / journal.pone.0141710) and tissue fibroblasts (Hattori T, Mediators Inflamm. 2015;2015:436067. doi:10.1155 / 2015 / 436067). Expression of IL-17A is restricted to cells expressing the transcription factor RORgt (Cell. 2006 Sep 22;126(6):1121-33. doi:10.1016 / j.cell.2006.07.035). IL-17A expression has been shown to be dissociated from CCR6 expression on human T cells (Singh SP, J Immunol. 2008 Jan 1;180(1):214-21. doi:10.4049 / jimmunol.180.1.214; Nat Immunol. 2007 Jun;8(6):639-46. doi:10.1038 / ni1467). CCR6 is also described as a target gene of RORgt (PLoS One.2017;12(8):e0181868. doi:10.1371 / journal.pone.0181868; Skepner J, J Immunol. 2014 Mar 15;192(6):2564-75. doi:10.4049 / jimmunol.1302190), describing the co-expression of IL-17A and CCR6 in RORgt+ cell types.

[0003] Some prior art disclosures may be considered relevant to the modulation of CCR6. For example, Tawaraishia et al. (Bioorganic & Medicinal Chemistry Letters, Volume 28, Issue 18, 2018, pp. 3067-3072, ISSN 0960-894X, https: / / doi.Org / 10.1016 / j.bmcl.2018.07.042) disclose a series of benzenesulfonyl-aminocyclohexane derivatives as selective CCR6 inhibitors. CN103588697 teaches sulfonamide derivatives as CCR6 antagonists and their use in the treatment of CCR6-mediated diseases, such as autoimmune diseases, inflammation, psoriasis, multiple sclerosis, or cancer. WO2014 / 075580 describes the use of aurintricarboxylic acid to target chemokine receptors. WO2015 / 084842 teaches certain sulfonamides that may be used to treat CCR6-related diseases. WO2017 / 087607, WO2010 / 131145, WO2013 / 061004, WO2013 / 061005, WO2019 / 036374, and WO2020 / 058869 provide certain cyclobutenediones for use in treating chemokine / CCR6-related diseases. WO2019 / 136370 teaches methods for treating certain types of psoriasis. WO2019 / 147862 provides azetidine derivatives that may be used as chemokine modulators.

[0004] Furthermore, WO1999 / 43664 discloses certain pyrrolidinones with anti-inflammatory and analgesic properties. WO2019 / 105915 provides certain heterocyclic compounds that may be used as MAGL inhibitors. WO2015 / 057626, US2015 / 0105366, WO2014 / 062658, WO2015 / 057205 and Tanis VM et al. (Bioorg Med Chem Lett. 2019 Jun 15;29(12):1463-1470. doi:10.1016 / j.bmcl.2019.04.021) relates to RORyt receptor modulators that may be used to treat rheumatoid arthritis or psoriasis. WO 03 / 022808 proposes certain azetidine derivatives for use as insecticides. WO 2008 / 103426 and WO 2007 / 022351 disclose certain quaternary ammonium compounds useful as muscarinic receptor antagonists. WO 2006 / 136830 teaches certain heteroaryl-alkylamines as protein kinase inhibitors. WO 91 / 13359 proposes heterocyclic cholinergic neuroactivators. US 28141 teaches certain pyrrolidines that may be used to treat depression. GB1304650 discloses antispasmodic pyrrolidines. US3479370, US3489769, US3499002, US3542807 and US3651085 relate to certain pyrrolidines with analgesic / sedative activity.

[0005] The CCR6 modulators of the present invention, alone or in combination, may be useful in treating or preventing the following diseases or disorders: rheumatoid arthritis (RA), which causes chronic inflammation of the joints, and chemokines control the infiltration of the inflamed synovium by inflammatory cells. RA is characterized by increased CCL20 release, and subsequent recruitment of CCR6+ T cells to inflamed joints. CCL20 is highly expressed in synovial fluid of RA (Hirota, J Exp Med. 2007 Nov 26;204(12):2803-12. doi:10.1084 / jem.20071397; Matsui T, Clin Exp Immunol. 2001 Jul;125(1):155-61. doi:10.1046 / j.1365-2249.2001.01542.x). In patients with RA, CCR6+ Th cells have been found in the inflamed synovium, and patients with early RA have an increased proportion of CCR6+ Th cells in the peripheral blood (van Flamburg JP, Arthritis Rheum.2011 Jan;63(1):73-83. doi:10.1002 / art.30093; Leipe J Arthritis Rheum.2010 Oct;62(10):2876-85. doi:10.1002 / art.27622; Nistala K, Arthritis Rheum.2008 Mar;58(3):875-87. doi:10.1002 / art.23291). Following stimulation with TNF-α, IL-1b, and IL-17, CCL20 production is known to be upregulated in synovial explants or fibroblast-like synoviocytes from RA patients (Matsui T, Clin Exp Immunol. 2001 Jul;125(1):155-61. doi:10.1046 / j.1365-2249.2001.01542.x; J Immunol. 2001 Nov 15;167(10):6015-20. doi:10.4049 / jimmunol.167.10.6015; Chevrel G, Ann Rheum Dis. 2002 Aug;61(8):730-3. doi:10.1136 / ard.61.8.730). CCR6+ B cells have been reported in RA synovium and contribute to pathogenesis through antigen presentation, autoantibody production, and / or inflammatory cytokine production. Furthermore, rituximab is an effective treatment for RA (Cohen SB, Arthritis Rheum. 2006 Sep;54(9):2793-806. doi:10.1002 / art.22025), supporting the role of CCR6+ B cells in the pathogenesis of RA. Additionally, IgG1-dependent memory B cell responses are impaired in CCR6-deficient mice (J Immunol. 2015 Jan 15;194(2):505-13. doi:10.4049 / jimmunol.1401553).In preclinical rodent models, CCR6-deficient mice showed reduced joint inflammation in a collagen-induced arthritis (CIA) model. CCR6-deficient mice exhibited reduced production of collagen-specific antibodies compared to wild-type mice, and arthritic inflammation was also reduced (J Cell Mol Med. 2018 Nov;22(11):5278-5285. doi:10.1111 / jcmm.13783). Furthermore, depletion of CCR6+ cells reduced the severity of SKG arthritis (Hirota K, J Exp Med. 2007 Nov 26;204(12):2803-12. doi:10.1084 / jem.20071397).

[0006] CCR6+ Th17 are elevated in the peripheral blood of patients with ankylosing spondylitis (Shen H, Arthritis Rheum. 2009 Jun;60(6):1647-56. doi:10.1002 / art.24568). Circulating interleukin-17-secreting interleukin-23 receptor-positive gamma / delta T cells have also been reported in patients with active ankylosing spondylitis (Kenna TJ, Arthritis Rheum. 2012 May;64(5):1420-9. doi:10.1002 / art.33507). Secukinumab, an IL-17A inhibitor, has been shown to be effective in treating ankylosing spondylitis (AS) (Baeten D, N Engl J Med. 2015 Dec 24;373(26):2534-48. doi:10.1056 / NEJMoa1505066). In AS, CD32B expression on memory B cells was elevated and correlated with disease activity. Furthermore, CCR6 expression was elevated in the synovial compartment of AS patients. + Cytotoxic T cells and CD32B + Memory B cells were significantly enriched (Sucur A, Clin Exp Rheumatol. 2 019 Nov 20;PMID:31820725).

[0007] Psoriasis is a common autoimmune skin disease. The role of Th17-associated cytokines has been clinically confirmed, confirming their role in psoriatic inflammation (Paul C, J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1082-90. doi:10.1111 / jdv.12751). IL-17R-blocking antibody (brodalumab, AMG827) has been shown to reduce clinical symptoms of psoriasis and also reduce CCL20 expression in skin biopsies from psoriasis patients (Papp KA, N Engl J Med. 2012 Mar 29;366(13):1181-9. doi:10.1056 / NEJMoa1109017). Furthermore, the IL-23 neutralizing antibody (guselkumab) has been shown to be effective in reducing psoriatic inflammation (Reich K, Lancet. 2019 Sep 7;394(10201):831-839. doi:10.1016 / S0140-6736(19)31773-8). CCR6-deficient mice do not develop psoriasiform lesions after intradermal injection of IL-23 (Hedrick MN, J Clin Invest. 2009 Aug;119(8):2317-29. doi:10.1172 / jci37378). Small molecule CCR6 antagonists have also been shown to be effective in Aldara and IL-36a-injected mouse psoriasis models (Campbell JJ, J Immunol. 2019 Mar 15;202(6):1687-1692. doi:10.4049 / jimmunol.1801519; Campbell JJ, J Immunol. 2017 Nov 1;199(9):3129-3136. doi:10.4049 / jimmunol.1700826). Furthermore, CCR6-deficient mice were shown to be protected from imiquimod-induced ear swelling (Yu S, J Invest Dermatol. 2019 Feb;139(2):485-488. doi:10.1016 / j.jid.2018.07.036).

[0008] A neutralizing anti-CCR6 antibody was shown to be effective against Aldara-induced ear swelling in mice (Robert R, JCI Insight. 2017 Aug 3;2(15):e94821. Published online 2017 Aug 3. doi:10.1172 / jci.insight.94821). An engineered disulfide-bridged CCL20 dimer that binds to CCR6 but inhibits T cell migration was shown to reduce skin swelling in an IL-23-dependent mouse model of psoriasis (Getschman AE, Proc Natl Acad Sci USA. 2017 Nov 21;114(47):12460-12465. doi:10.1073 / pnas.1704958114). These data suggest that a positive feedback loop consisting of CCL20 production in the epidermis and dermis, potent recruitment of CCR6+ T cells into inflamed psoriatic skin, their activation by IL-23, and their expression of IL-17A and IL-22 leads to a pathogenic Th17 response in psoriatic skin lesions. Therefore, inhibition of CCR6 has been recognized as a potential therapeutic pathway for the treatment of psoriasis (Hedrick MN, Expert Opinion Ther. Targets. 2010 Sep;14(9):911-22. doi:10.1517 / 14728222.2010.504716; Mabuchi T, J Dermatol Sci. 2012 Jan;65(1):4-11. doi:10.1016 / j.jdermsci.2011.11.007). CCR6 expression has been shown to be upregulated in the synovium of patients with psoriatic arthritis (PsA) (Dolcino M, PLoS One. 2015 Jun 18;10(6):e0128262. doi:10.1371 / journal.pone.0128262). IL-17A- and GM-CSF-expressing CD4+ T cells isolated from the synovial fluid of PsA patients also expressed CCR6 (Al-Mossawi et al., Nat Commun. 2017 Nov 15;8(1):1510. doi:10.1038 / s41467-017-01771- 2) CCL20 has been shown to be strongly upregulated in synovial fluid collected from PsA patients (Melis L, Ann Rheum Dis. 2010 Mar;69(3):618-23. doi:10.1136 / ard.2009.107649).

[0009] Additional inflammatory skin disorders, including rosacea, have been shown to have significantly elevated levels of CCL20 in inflamed skin (Buhl T, JID, 2015).

[0010] CCR6 and CCL20 are significantly elevated in active Crohn's disease (CD) and ulcerative colitis (UC) (Skovdahl et al., PLoS One. 2015 Nov 4;10(11):e0141710. doi:10.1371 / journal.pone.0141710). Increased enterocyte CCL20 production has been proposed to play an important role in lymphocyte recruitment to the colonic epithelium in irritable bowel disease (IBD) (Kwon JH, Gut. 2002 Dec;51(6):818-26. doi:10.1136 / gut.51.6.818). CCL20 and CCR6 expression also correlates with the histological severity of rectal resections from UC patients. After pathological examination, CCL20 expression was higher in chronic UC than in acute UC (Uchida K, Gastroenterol Res Pract. 2015;2015:856532. doi:10.1155 / 2015 / 856532). CCL20 expression was significantly upregulated in PBMCs of UC patients compared with healthy controls. In the UC group treated with sulfasalazine and GC, CCL20 expression in PBMCs decreased with disease improvement. TNFα- or IL-1β-induced CCL20 secretion was significantly reduced by treating human intestinal epithelial cell lines with sulfasalazine and / or GC (Lee HJ, 2 Inflamm Bowel Dis. 2005 Dec;11(12):1070-9. doi:10.1097 / 01.mib.0000187576.26043.ac). CCR6 deficiency reduced intestinal pathology in mice treated with dextran sulfate sodium salt (DSS), which causes colonic inflammation (Varona R, Eur J Immunol. 2003 Oct;33(10):2937-46. doi:10.1002 / ej i.200324347).

[0011] CCR6-expressing Th17 cells have been shown to be key effectors in the pathogenesis of dry eye disease (DED), an inflammatory condition of the ocular surface that can lead to corneal perforation. In a mouse model of DED, antibody-mediated neutralization of CCL20 reduced Th17 recruitment to the ocular surface and improved clinical readouts (Dohlman TH, Invest Ophthalmol Vis Sci. 2013 Jun 12;54(6):4081-91. doi:10.1167 / iovs.12-11216). Therefore, inhibition of the CCR6 / CCL20 axis has been proposed as a therapeutic mechanism for DED.

[0012] CCR6 expression has been described on T cells isolated from the cerebrospinal fluid of patients with multiple sclerosis (MS) (van Langelaar J, Brain, 2018 May 1;141(5):1334-1349. doi:10.1093 / brai n / awy069). In experimental autoimmune encephalomyelitis (EAE), CCR6 expression was also observed on T cells infiltrating the inflamed CNS (Mony JT, Front Cell Neurosci. 2014;8:187. doi:10.3389 / fncel.2014.00187). Furthermore, a CCL20 gene polymorphism was shown to be associated with a cohort of MS patients (El Sharkav et al., Gene. 2019 Feb 15;685:164-169. doi:10.1016 / j.gene.2018.11.006). Preclinical data indicate that CCR6 is important in the pathogenesis of EAE (Reboldi A, Nat Immunol. 2009 May;10(5):514-23. doi:10.1038 / ni.1716). This finding was confirmed in subsequent studies, showing that CCR6-deficient mice were resistant to disease induction and had lower peak severity. In the same study, immunization with hCCL20 generated an anti-mouse CCL20 response in host mice that was sufficient to reduce clinical scores (Abraham M, Clin Immunol. 2017 Oct;183:316-324. doi:10.1016 / j.clim.2017.09.018). However, conflicting data exist regarding the role of CCR6 in EAE pathogenesis (J Neuroimmunol. 2009 Aug 18;213(1-2):91-9. doi:10.1016 / j.jneuroim.2009.05.011). EAE severity and histopathology were significantly reduced after injection of anti-CCL20 at the first clinical symptoms (Kohler RE, J Immunol. 2003 Jun 15;170(12):6298-306. doi:10.4049 / jimmunol.170.12.6298). Anti-CCR6 neutralizing antibodies have been shown to reduce the severity of EAE in mice (Robert R, JCI Insight. 2017 Aug 3;2(15):e94821. Published online 2017 Aug 3. doi:10.1172 / jci.insight.94821). IL-6 and IL-17 increase CCL20 expression from mouse astrocytes (Meares GP, Glia. 2012 May;60(5):771-81. doi:10.1002 / glia.22307).

[0013] CCR6 and CCL20 have been proposed to influence the dynamics of germinal center (GC) formation and B cell responses, and CCR6 is considered a marker of memory B cell precursors in both mouse and human germinal centers (Suan D, Immunity. 2017 Dec 19;47(6):1142-1153.e4. doi:10.1016 / j.immuni.2017.11.022). Increased CCR6 expression on naive, pre-GC, GC / plasma cells, and memory B cells was observed in peripheral B cells from patients with systemic lupus erythematosus (SLE) (Lee AYS, Clin Rheumatol. 2017 Jun;36(6):1453-1456. doi:10.1007 / s10067-017-3652-3). CD4+CCR6+ cells may also contribute to disease severity in SLE patients and have been shown to be increased in anti-DNA+ SLE patients, which correlated with disease severity and erythrocyte sedimentation rate (Zhong W, PeerJ. 2018;6:e4294. doi:10.7717 / peerj.4294).

[0014] Increased CCR6 expression has been demonstrated in the salivary glands of patients with primary Sjögren's syndrome (pSS) [Scand J Immunol. 2020 Mar;91(3):e12852. doi:10.1111 / sji.12852]. A trend toward increased CCL20 mRNA expression was also observed. Compared with healthy controls (HC), a significant decrease in circulating CCR6+ Th cells (both CCR9- and CCR9+) was demonstrated in patients with pSS [Scand J Immunol. 2020 Mar;91(3):e12852. doi:10.1111 / sji.12852].

[0015] In an animal model of autoimmune hepatitis (AIH), administration of anti-TNF-α suppressed hepatic CCL20 expression. Mice treated with anti-CCL20 showed reduced AIH. Furthermore, TNFα stimulation increased CCL20 expression in hepatocytes. These findings suggest that TNFα is essential for the induction of AIH through upregulation of hepatic CCL20 expression, which recruits CCR6+ T cells to drive pathology (Clin Immunol. 2013 Jan;146(1):15-25. doi:10.1016 / j.clim.2012.10.008).

[0016] The CCR6 modulators of the present invention, alone or in combination, may be useful in the treatment or prevention of autoimmune diseases or disorders including posterior uveitis, allergic conjunctivitis, gastrointestinal allergic diseases, type 1 diabetes, and endometriosis (Medicina (Kaunas). 2018 Nov 16;54(5). doi:10.3390 / medicina54050088). CCR6 modulators, alone or in combination, may also be useful in treating ocular surface diseases in which elevated IL-17A levels have been documented, including meibomian gland dysfunction; GVHD, graft-versus-host disease; dry eye syndrome associated with autoimmune keratitis, filamentous keratitis, and rheumatoid arthritis; dry eye syndrome without systemic disease; and Stevens-Johnson syndrome (J Korean Med Sci. 2011 JuI;26(7):938-44. doi:10.3346 / jkms.2011.26.7.938).

[0017] The CCR6 modulators of the present invention may be useful, alone or in combination, for the treatment or prevention of malignant diseases. Modulation of the CCR6 / CCL20 axis using siRNA, shRNA, CCR6 knockout animals, CCL20 ligand treatment, or antibodies has been shown to alter tumor growth and metastatic processes in experimental disease models, either as single agents or in combination with immunotherapy (e.g., PD1 and / or PDL1 blockade, among others) for the prevention or treatment of cancer.

[0018] The therapeutic potential of modulating this system for the treatment of malignant tumors has been described in tumor mouse models using small interfering RNA (siRNA) or short hairpin RNA (shRNA)-mediated silencing of CCR6 or CCL20. Specifically, in a mouse model of cutaneous T-cell lymphoma (My-La cells), Abe et al. reported that administration of CCR6-targeted siRNA prolonged animal survival compared with control animals (Oncotarget. 2017 Jan 31;8(5)7572-7585. doi:10.18632 / oncotarget.13810.). Using a different approach, Ito et al. showed that mice injected with T lymphoma cells (My-La) carrying a CCR6-silencing siRNA construct survived significantly longer than mice injected with control cells (Blood. 2014 Mar 6;123(10):1499-511. doi:10.1182 / blood-2013-09-527739.). Zhu and colleagues showed that silencing CCR6 in cancer cells using shRNA reduced the average volume and weight of tumor nodules in mice subcutaneously injected with a set of colorectal cancer cell lines (PMID Biochim Biophys Acta Mol Basis Dis. 2018 Feb;1864(2):387-397. doi:10.1016 / j.bbadis.2017.10.033.). In a glioblastoma xenograft model using patient-derived glioblastoma cell lines, mice injected with cells harboring shRNA constructs silencing CCR6 expression survived longer than those injected with control cells. Additionally, histological and immunohistochemical analyses revealed that tumors formed by glioma cells harboring CCR6-targeting shRNA were significantly smaller and exhibited significantly less tumor angiogenesis than control tumors. These data further support the notion that CCR6 signaling enhances the oncogenic potential of malignant tumors, including lymphoma, colorectal tumors, and glioblastoma (Oncogene. 2018 Jun;37(23):3070-3087. doi:10.1038 / s41388-018-0182-7.).Specifically, the involvement of the CCR6 / CCL20 system in tumorigenesis has been reported in the literature using CCR6 knockout animals. In the CMT93 mouse model of colorectal cancer (CRC), regulatory T cell infiltration was completely prevented in tumors from CCR6-deficient mice compared with wild-type animals. Furthermore, reported data suggest that homing and migration of tumor-infiltrating regulatory T cells to tumor masses in vivo depend on the chemokine receptor CCR6 (PLoS One. 2011 Apr 29;6(4):e19495. doi:10.1371 / journal.pone.0019495.). According to Nandi et al., in a mouse model of spontaneous intestinal tumorigenesis [APCMIN / + mice, heterozygous for a mutation in the adenomatous polyposis coli (APC) gene], the infiltration of regulatory T cells into tumor masses is significantly inhibited in vivo. Mice lacking CCR6 (heterozygous) had a lower incidence of spontaneous intestinal tumorigenesis (PLoS One. 2014;9(5):e97566. doi:10.1371 / journal.pone.0097566.).

[0019] The potential role of the CCR6 / CCL20 system in tumorigenesis was also demonstrated by administering recombinant CCL20 chemokine. Specifically, in a mouse model of colorectal cancer (CMT93 cells), Liu et al. showed that tumor size was significantly increased in mice treated with recombinant mouse CCL20 compared with PBS controls, suggesting an important role for CCL20 in colorectal cancer growth and development (PLoS One. 2011 Apr 29;6(4):e19495. doi:10.1371 / journal.pone.0019495.).

[0020] Specifically, the potential role of the CCR6 / CCL20 system in tumor promotion has been demonstrated in mouse models using neutralizing CCL20 antibodies. Ikeda and colleagues used a mouse model of specific cutaneous T-cell lymphoma (CTCL) in which animals succumb to metastasis of CTCL cells to multiple organs. However, administration of neutralizing CCL20 antibodies significantly prolonged the survival of xenografted mice (Oncotarget. 2016 Mar 22;7(12):13563-74. doi:10.18632 / oncotarget.6916.). Lee and colleagues described that administration of anti-CCL20 antibodies prevented the development of bone metastases (one of the primary sites of breast cancer metastasis in humans) in a mouse model of metastatic breast cancer (in which MDA-MB-231 cells were injected into the left ventricle of nude mice) (Sci Rep. 2017 Aug 29;7(1):9610. doi:10.1038 / s41598-017-09040-4.). In a humanized mouse model of nasopharyngeal carcinoma, Mrizak et al. observed that injection of anti-CCL20 monoclonal antibodies in mice significantly reduced the recruitment of regulatory T cells to tumors compared with sham-treated animals (J Natl Cancer Inst. 2015 Jan;107(1):363. doi:10.1093 / jnci / dju363.). Additionally, in a mouse model of hepatocellular carcinoma (Hepa1-6 cells), blocking CCL20 activity in immunocompetent mice using an anti-CCL20 antibody reduced tumor initiation and inhibited tumor growth and distant metastasis. Furthermore, the authors reported that CCL20 neutralization significantly inhibited tumor angiogenesis in this mouse model (He et al., PMID 28560063-Am J Cancer Res. 2017;7(5):1151-1163). Using the same mouse model, administration of an anti-CCL20 neutralizing antibody significantly reduced the infiltration of regulatory T cells, particularly CCR6-positive regulatory T cells, into tumors and significantly reduced tumor growth. Treatment of mice with the antibody in combination with an anti-PDL-1 antibody further enhanced the antitumor effect.Together, these data sets suggest that CCL20 blockade can inhibit the recruitment of regulatory T cells to tumors, thereby suppressing anti-PD-L1 resistance in mouse models of hepatocellular carcinoma (Hepatology. 2019 Jul;70(1):198-214. doi:10.1002 / hep.30593.).

[0021] Specifically, the potential role of the CCR6 / CCL20 system in tumor metastasis has been described in the literature. Dellacasagrande et al. reported that in a mouse model of plasmacytoma, tumor cells disseminated to the liver overexpressed functional CCR6 compared with tumor cells from the primary tumor (obtained by sc injection of mouse plasmacytoma (MOPC315)). The same authors found that CCR6 was overexpressed in small liver metastases of colon, thyroid, and ovarian cancer compared with normal liver (Scand J Immunol. 2003 Jun;57(6):534-44. doi:10.1046 / j.1365-3083.2003.01263.x.).

[0022] Furthermore, the CCR6 modulators of the present invention can be used alone or in combination to inhibit CCR6 and / or CCL These compounds may be useful in treating or preventing cancers in which CCR6 expression correlates with disease progression and resistance to standard treatments. Specifically, the correlation of CCR6 expression with disease progression has been documented in the literature for many cancer diseases. For example, in renal cell carcinoma, CCR6 expression is associated with poor overall survival (Cancers (Basel). 2019 Dec 30;12(1). doi:10.3390 / cancersl 2010089.). In colorectal cancer, tumor expression of CCR6 positively correlates with metastasis, and upregulation of CCR6 predicts poor overall survival, disease-free survival (PLoS One. 2014;9(6):e101137. doi:10.1371 / journal.pone.0101137.), and 5-year overall survival (Biochim Biophys Acta Mol Basis Dis. 2018 Feb;1864(2):387-397. doi:10.1016 / j.bbadis.2017.10.033.). In ovarian cancer, high CCR6 mRNA expression was also associated with poor prognosis (Cancer Lett. 2020 Mar 1;472:59-69. doi:10.1016 / j.canlet.2019.12.024.). CCR6 expression correlates with the aggressiveness of rectal cancer; indeed, high levels of CCR6 protein expression are more common in non-responders to radiation therapy than in responders (Cancer Res Treat. 2018 Oct;50(4):1203-1213. doi:10.4143 / crt.2017.538.). CCR6 expression levels in prostate cancer correlate with more aggressive and malignant clinical and pathological features of the disease (J Cancer Res Clin Oncol. 2008 Nov;134(11):1181-9. doi:10.1007 / s00432-008-0403-5.). In non-small cell lung cancer (NSCLC), high CCR6 expression is associated with shorter disease-free survival and a fivefold increased risk of disease recurrence, independent of disease stage (PLoS One. 2011;6(9):e24856. doi:10.1371 / journal.pone.0024856.).Hepatocellular carcinoma patients with increased numbers of infiltrating CCR6-positive immune cells in tumor tissue have a poor prognosis (Am J Cancer Res. 2017;7(5):1151-1163.).

[0023] Similar to CCR6, expression of its ligand, CCL20, has been reported to correlate with poor disease outcomes in several diseases. Specifically, in breast cancer, elevated CCL20 expression was significantly associated with poor overall disease-free survival, low percentage of metastasis-free survival (Sci Rep. 2017 Aug 29;7(1):9610. doi:10.1038 / s41598-017-09040-4.), high histological grade, high Ki67 index, and axillary lymph node metastasis. Furthermore, CCL20 expression in breast adenomas was positively correlated with expression of FOXP3, a marker of regulatory T cells. Patients with axillary lymph node metastases who also had elevated CCL20 expression and FOXP3-positive regulatory T cells had the poorest overall survival (Medicine (Baltimore). 2019 Dec;98(50):e18403. doi:10.1097 / MD.0000000000018403.). In NSCLC, high CCL20 expression correlated with poor overall survival (Biomed Pharmacother. 2015 Feb;69:242-8. doi:10.1016 / j.biopha.2014.12.008.) (Cancer Lett. 2015 Jul 10;363(1):60-70. doi:10.1016 / j.canlet.2015.04.005.). Similar to NSCLC, patients with hepatocellular carcinoma with high CCL20 expression had poor overall survival and shorter recurrence-free survival. The same authors noted that CCL20 expression was significantly correlated with tumor size, number of tumors, vascular invasion, tumor differentiation, and tumor recurrence rate (J Gastrointest Surg. 2012 Apr;16(4):828-36. doi:10.1007 / s11605-011-1775-4.). In addition to CCR6 or CCL20 alone, the correlation of CCR6 / CCL20 co-expression with disease progression has been described in the literature. In fact, overexpression of both CCL20 and CCR6 was detected in high-grade glioma tissues compared with low-grade tissues, and a World Health Organization (WHO) study on tumors (WMD) has shown that CCL20 expression correlates with tumor size, number of tumors, vascular invasion, tumor differentiation, and tumor recurrence rate (J Gastrointest Surg. 2012 Apr;16(4):828-36. doi:10.1007 / s11605-011-1775-4.). The incidence of CCL20 / CCR6 co-expression increased with increasing grade of tumor. In particular, patients with CCL20 / CCR6 co-expressing gliomas had the shortest overall survival (Med Oncol. 2012 Dec;29(5):3491-7. doi:10.1007 / s 12032-012-0314-9.).

[0024] Furthermore, CCR6 and / or CCL20 expression correlates with increased chemotherapy resistance and is associated with metastasis. Indeed, CCL20 expression can increase chemotherapy resistance in breast cancer cells (PLoS Biol. 2018 Jul;16(7):e2005869. doi:10.1371 / journal.pbio.2005869.). Rubie et al. describe that significant upregulation of CCL20 / CCR6 was detected (RT-PCR) in colorectal liver metastases (CRLM) and in human samples of hepatocellular carcinoma (HCC). Furthermore, CCL20 is significantly overexpressed in colorectal cancer liver metastases compared with primary HCC, indicating the involvement of the CCL20 / CCR6 ligand-receptor pair in the carcinogenesis and progression of liver malignancies (World J Gastroenterol. 2006 Nov 7;12(41):6627-33. doi:10.3748 / wjg.v12.i41.6627.).

[0025] The CCR6 modulators of the present invention, alone or in combination, may be useful in treating or preventing diseases or disorders in which CCR6 and / or CCL20 are expressed or overexpressed in patient samples or cancer cell lines. Specifically, the chemokine receptor CCR6 has been described in the literature as being expressed in several types of cancer or cancer cell lines. Lu and coworkers described that CCR6 expression was higher in laryngeal cancer tissues compared to their normal controls. The authors reported that CCR6 was also expressed in commonly used laryngeal cancer cells, such as TU212, M4E, M2E, and Hep-2 (Biomed Pharmacother. 2017 Jan;85:486-492. doi:10.1016 / j.biopha.2016.11.055.). Among the reported biological networks based on gene expression data in melanoma, the CCR6 gene was described and characterized as a potential factor involved in immune response and tumor growth (PLoS One. 2018;13(1):e0190447. doi:10.1371 / journal.pone.0190447.). Whole-exome analysis of 21 MALT lymphomas from the salivary gland and thyroid revealed CCR6 expression (Haematologica. 2018 Aug;103(8):1329-1336. doi:10.3324 / haematol.2018.191601.). CCR6 transcripts were detected in samples of adult human T-cell leukemia / lymphoma (ATLL), and CCR6 protein expression was also found using flow cytometry analysis (Leuk Lymphoma. 2006 Oct;47(10):2163-73. doi:10.1080 / 10428190600775599.). In patient-derived prostate cancer samples, CCR6 gene expression (mRNA) was significantly higher in tumor tissue compared with adjacent normal tissue (Cancer Res Treat. 2015 Apr;47(2):306-12. doi:10.4143 / crt.2014.015.). CCR6 expression has been detected in commonly used cancer cell lines, and indeed, according to Mays and colleagues, CCR6 expression was detected in salivary gland cystic carcinoma (salivary gland cystic carcinoma) using RT-PCR gene analysis. CCR6 was expressed along with other CC chemokine receptors in adenoid cystic carcinoma (SACC-83) cells (Anticancer Res. 2016 Aug;36(8):4013-8.) Moeller et al. reported that CCR6 was also expressed in multiple myeloma (MM) cell lines, including U266 1970, U-266 1984, U-1958, Karpas 707, LP-1,28 L-363, HL407E, and HL407L.3 (Leukemia. 2003 Jan;17(1):203-10. doi:10.1038 / sj.leu.2402717. ).

[0026] Similar to CCR6, the ligand CCL20 has been reported to be expressed in multiple tumor samples and tumor cell lines. For example, Zhang and colleagues used RT-PCR to demonstrate that CCL20 expression was higher in tumor samples than in adjacent tissue samples from NSCLC patients, a finding confirmed at the protein level using immunohistochemistry (Biomed Pharmacother. 2015 Feb;69:242-8. doi:10.1016 / j.biopha.2014.12.008.). Gene expression analysis of cholangiocarcinoma samples and matched normal tissues revealed that CCL20 was one of the most significantly overexpressed genes in malignant tissues compared with healthy tissues (EXCLI J. 2020;19:154-166. doi:10.17179 / excli2019-1893.). CCL20 expression has also been reported in human samples of multiple myeloma (MM) (Cancer Res. 2008 Aug 15;68(16):6840-50. doi:10.1158 / 0008-5472.CAN-08-0402.). Furthermore, Rubies et al. reported that CCL20 mRNA and protein were significantly upregulated (8-fold) in pancreatic cancers compared with the low expression of CCL20 in corresponding normal pancreases (J Transl Med. 2010 May 10;8:45. doi:10.1186 / 1479-5876-8-45.). CCL20 is also expressed in oral squamous cell carcinoma (IHC staining), and Lee et al. reported that its expression is enhanced in human CCR6+ regulatory T cells, which have excellent suppressive activity (J Immunol. 2017 Jul 15;199(2):467-476. doi:10.4049 / jimmunol.1601815.).

[0027] In addition to CCR6 or CCL20 alone, coexpression of both CCR6 and CCL20 has been reported in cancer patient samples and cancer cell lines. Both genes have been described as being expressed in adult T-cell leukemia / lymphoma patient samples (microarray and IHC protein staining) (Int J Oncol. 2014 Sep;45(3):1200-8. doi:10.3892 / ijo.2014.2524.) and CTCL. In the latter, CCL20 and CCR6 were detected at the mRNA and protein levels (Clin Cancer Res. 2011 Dec 15;17(24)7529-38. doi:10.1158 / 1078-0432.CCR-11-1192.). Transcriptome analysis (nanostrings) of hepatocellular carcinoma samples revealed CCR6 and CCL20 expression. Furthermore, a chemotactic gradient between non-tumor and tumor tissues was reported, suggesting a recruitment process of regulatory T cells, tumor-associated macrophages, and natural killer cells involving the CCR6 / CCL20 system (Proc Natl Acad Sci USA. 2017 Jul 18;114(29):E5900-E5909. doi:10.1073 / pnas.1706559114.). Similarly, Guo and colleagues reported upregulation of CCR6 and CCL20 in hepatocellular carcinoma lesions compared with healthy tissues, as well as CCR6 and CCL20 expression in hepatocellular carcinoma cell lines (L02, Li- / , Huh-7, SNU-387, Hep3B) (Oncol Rep. 2019 Sep;42(3):1075-1089. doi:10.3892 / or.2019.7221.). Nandi et al. reported that both CCL20 and CCR6 are expressed in human colorectal carcinoma (IHC protein staining). High expression of both CCR6 and CCL20 (protein and mRNA) was found in NSCLC samples (Oncol Lett. 2017 Dec;14(6):8183-8189. doi:10.3892 / ol.2017.7253). Using in situ hybridization, the mRNA portions of both CCL20 and CCR6 were strongly expressed in all pancreatic cancer samples analyzed.In contrast, expression of CCL20 and CCR6 was low in healthy pancreas (Int J Cancer. 1999 May 17;81(4):650-7. doi:10.1002 / (sici)1097-02. 15(19990517)81:4<650::aid-ijc23>3.0.co;2-#.). Jin and colleagues examined CCR6 and CCL20 expression in glioblastoma using publicly available datasets. The authors used the GEO dataset GSE2223 to compare CCL20 and CCR6 mRNA levels between normal brain and glioblastoma tissue. Again, CCR6 and CCL20 expression levels were significantly higher in glioblastoma tissue than in normal brain tissue (Oncogene. 2018 Jun;37(23):3070-3087. doi:10.1038 / s41388-018-0182-7.). In addition, Wallace et al. observed that expression of CCL20 and its receptor CCR6 was higher in endometrial adenocarcinoma explants and cell lines compared to non-malignant endometrium (mRNA, RT-PCR) (Mol Cell Endocrinol. 2011 Jan 1;331(1):129-35. doi:10.1016 / j.mce.2010.08.018.) The CCL20 / CCR6 axis may play a role in breast cancer, cholangiocarcinoma, and thyroid cancer. This is because expression of the CCR6 / CCL20 gene and / or protein has been reported in patient-derived breast cancer cells (Mol Carcinog. 2016 Jul;55(7):1175-86. doi:10.1002 / mc.22360.), HuCCTI and TFK-1 cholangiocarcinoma cell lines (Win et al., PMID 32194362) (EXCLI J. 2020;19:154-166. doi:10.17179 / excli2019-1893.), and thyroid cancer cell lines such as TPC-1, BCPAP, FTC-133, and SW1736 (Tumor Biol. 2016 Apr;37(4):5569-75. doi:10.1007 / s 13277-015-4418-7.). Furthermore, the CCR6 modulators of the present invention, alone or in combination, may be useful in treating or preventing cancers in which expression and / or evidence of CCR6 / CCL20 axis activity has been reported or in which CCR6+ regulatory T cells have been identified within the tumor microenvironment. Summary of the Invention

[0028] 1) One aspect of the present invention relates to compounds of formula (I): [ka]

[0029] wherein A represents a 6-membered heteroaryl having 1 to 3 ring nitrogen atoms (particularly 1 or 2 ring nitrogen atoms; especially 1 or 2 ring nitrogen atoms in the meta and / or para positions of A relative to the point of attachment of A to the remainder of the molecule), which 6-membered heteroaryl is independently unsubstituted or substituted with 1, 2 or 3 substituents (particularly 1 or 2 substituents in the meta and / or para positions of A relative to the point of attachment of A to the remainder of the molecule), and which substituents, if present, are - halogens (especially fluorine); - Cyano; - hydroxy-C optionally further substituted with 1 to 3 fluorine atoms 1-6 -alkyl (especially those in which the hydroxy group is separated from any fluorine atom by at least two carbon atoms; especially those in which the hydroxy-C 1-6 -Alkyl represents 3-hydroxypropyl, 4-hydroxybutyl, 3-hydroxybutyl, 3-hydroxy-3-methylbutyl, 3-hydroxy-4-methylpentyl, 3-hydroxy-3-trifluoromethylbutyl or 2,2-difluoro-3-hydroxyprop-1-yl; - C 1-5 alkyl (in particular methyl, ethyl, propyl, isopropyl, butyl or isobutyl), which is unsubstituted or which contains one -- C 1-3 -alkoxy (especially methoxy); -- C optionally fused to a pyridine ring (especially at positions 2 and 3 adjacent to the nitrogen atom of the pyridine ring) 3-6 -cycloalkyl, wherein the C 3-6 -cycloalkyl is unsubstituted or (especially as defined above in C 1-5 -C for alkyl 3-6 -substituted by one hydroxy at the point of attachment of the cycloalkyl, C 3-6 -cycloalkyl; -- -OR O1 (R O1 is C 3-6 -cycloalkyl (especially cyclopentyl) or pyrrolidinyl (especially pyrrolidin-2-yl), which are independently unsubstituted or have one C 1-3 -Alkyl (especially methyl) or C 1-4 -substituted by alkyl-carbonyl (especially acetyl), 3-6 -representing cycloalkyl (especially cyclopentyl) or pyrrolidinyl (especially pyrrolidin-2-yl); -- Phenyl-L 1 - (the phenyl is unsubstituted or substituted with one fluorine, C 1-4-alkoxy-carbonyl (especially methoxy-carbonyl) or hydroxy-C 1-4 -substituted by alkyl (especially hydroxy-methyl); -L 1 - represents a bond (i.e., the phenyl is directly bonded to the alkyl), oxygen (i.e., the phenyl is bonded to the alkyl through an oxygen), or the group -CH2-O- (the phenyl is bonded to the methylene group); -- C having 1 or 2 ring heteroatoms independently selected from nitrogen and oxygen 4-6 heterocyclyl (especially azetidinyl, imidazolidinyl, pyrrolidinyl, oxazolidinyl, piperidinyl or tetrahydropyranyl; especially azetidin-3-yl, tetrahydropyran-4-yl, imidazolidin-1-yl, pyrrolidin-1-yl, oxazolidin-3-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-4-yl), in which C 4-6 heterocyclyl is unsubstituted or has one or two oxo, hydroxy, C 1-3 -Alkyl (especially methyl), C 1-4 -Alkyl-carbonyl (especially acetyl) or C 1-4 -substituted by alkoxy-carbonyl (especially tert-butoxy-carbonyl), 4-6 -heterocyclyl; [Especially, such C 4-6 -heterocyclyl represents 1-(tert-butoxy-carbonyl)-3-hydroxy-azetidin-3-yl, tetrahydropyran-4-yl, 4-hydroxy-tetrahydropyran-4-yl, 2-oxo-imidazolidin-1-yl, 2-oxo-3-methyl-imidazolidin-1-yl, 2-oxo-pyrrolidin-1-yl, 2-oxo-oxazolidin-3-yl, 2-oxo-oxazolidin-3-yl, N-acetyl-2-methyl-pyrrolidin-2-yl, N-(tert-butoxy-carbonyl)-3-hydroxy-pyrrolidin-3-yl, N-acetyl-piperidin-4-yl or N-(tert-butoxy-carbonyl)-piperidin-4-yl. 5-membered heteroaryl (especially pyrazolyl; especially pyrazol-4-yl) having 1 or 2 ring nitrogen atoms, the 5-membered heteroaryl being unsubstituted or containing one C 1-3 -5-membered heteroaryl substituted by alkyl (especially methyl); --NR N1 R N2 (R N1 represents hydrogen, and R N2 is C 1-3 -Alkyl-carbonyl (especially acetyl) or hydroxy-C 1-3 -Alkyl-carbonyl (especially hydroxy ) [particularly, such -NR N1 R N2 represents acetyl-amino or hydroxymethyl-carbonyl-amino. ]; -- indolyl (especially indol-2-yl); -- pyrrolopyridinyl (especially 1H-pyrrolo[2,3-b]pyridin-2-yl)); -- N-(C 1-3 -alkyl)-amino-carbonyl-oxy; or -- 1-hydroxy-1-C 3-5 -cycloalkyl-1-(pyridinyl)-methyl (especially 1-hydroxy-1-cyclopropyl-1-(pyridin-2-yl)-methyl); C replaced by 1-5 - alkyl; [Especially, such C 1-5-Alkyl is methyl, ethyl, isopropyl, cyclopentyl-oxy-methyl, 2-(1-hydroxy-cyclopropyl)-ethyl, 2-(1-hydroxy-cyclobutyl)-ethyl, 2-(1-hydroxy-cyclopentyl)-ethyl, 3-methoxy-propyl, 4-fluoro-phenoxy-methyl, 2-(2-(methoxy-carbonyl)-phenyl)-ethyl, benzyl-oxy-methyl, N-(isopropyl)-amino-carbonyl-oxy-methyl, 2-(1-(tert-butyl)- 2-(N-(tert-butoxy-carbonyl)-3-hydroxyazetidin-3-yl)-ethyl, 3-methyl-3-(2-oxo-imidazolidin-1-yl)-butyl, 3-methyl-3-(2-oxo-3-methyl-imidazolidin-1-yl)-butyl, 3-methyl-3-(2-oxo-pyrrolidin-1-yl)-butyl, 2-(N-(tert-butoxy-carbonyl)-3-hydroxy-pyrrolidin-3-yl)-ethyl, 3-methyl-3-(2-oxo-oxazolidin-3-yl)-butyl, 2-(N-(tert-butoxy-carbonyl)-3-hydroxy-pyrrolidin-3-yl)-ethyl, 3-methyl-3-(2-oxo-oxazolidin-3-yl)-butyl, 2-( 1-Methyl-1H-pyrazol-4-yl)-ethyl, 2-(2-hydroxymethyl-phenyl)-ethyl, 2-(tetrahydropyran-4-yl)-ethyl, 2-(4-hydroxy-tetrahydropyran-4-yl)-ethyl, 2-(indol-2-yl)-ethyl, 2-(8-hydroxy-5,6,7,8-tetrahydroquinolin-8-yl)-ethyl, 2-(7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)-ethyl, 2-(N-acetyl-pyridin-4-yl)-ethyl 2-(N-(tert-butoxy-carbonyl)-piperidin-4-yl)-ethyl, N-acetyl-2-methyl-pyrrolidin-2-yl-oxy-methyl, acetyl-amino-isopropyl, N-(hydroxymethyl-carbonyl)-amino-methyl, 3-hydroxy-3-cyclopropyl-3-(pyridin-2-yl)-propyl, 2-(indol-2-yl)-ethyl or 2-(1H-pyrrolo[2,3-b]pyridin-2-yl)-ethyl. - C 3-5 - alkyl (especially n-propyl, n-butyl or n-pentyl), and hydroxy and R A1 and any of the substituents is substituted by the C3-5 - in the 3-position relative to the point of attachment of the alkyl; -- R A1 but, --- tetrahydropyranyl (especially tetrahydropyran-4-yl); --- unsubstituted or containing one fluorine (especially 3-fluoro-phenyl) or C 1-3 phenyl substituted by alkoxy (in particular 2-methoxy-phenyl or 4-methoxy-phenyl); 5- or 6-membered heteroaryl having 1 or 2 ring heteroatoms independently selected from nitrogen and sulfur (especially thiazolyl, pyrazolyl, pyridinyl, pyrazinyl or pyrimidinyl; especially thiazol-4-yl, thiazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, pyridin-2-yl, pyridin-3-yl, pyrimidin-2-yl, pyrazin-2-yl or pyrimidin-4-yl), which 5- or 6-membered heteroaryl is independently unsubstituted or substituted by 1 or 2 substituents, if present, which are selected from the group consisting of C 1-3 -Alkyl (especially methyl), C 3-5 -cycloalkyl (especially cyclopropyl) or C 1-3 - a 5- or 6-membered heteroaryl independently selected from alkoxy (especially methoxy); or --- indazolyl (especially indazol-3-yl); C represents 3-5 - alkyl; [Especially, such C 3-5-Alkyl is 3-hydroxy-3-(tetrahydropyran-4-yl)-propyl, 3-hydroxy-3-phenyl-propyl, 3-hydroxy-3-phenyl-butyl, 3-hydroxy-3-(3-fluoro-phenyl)-butyl, 3-hydroxy-3-(2-methoxy-phenyl)-butyl, 3-hydroxy-3-(4-methoxy-phenyl)-butyl, 3-hydroxy-3-(1,5-dimethyl-pyrazol-3-yl)-butyl, 3-hydroxy- 3-(1-methyl-pyrazol-3-yl)-butyl, 3-hydroxy-3-(1-cyclopropyl-1H-pyrazol-3-yl)-butyl, 3-hydroxy-3-(1,5-dimethyl-pyrazol-3-yl)-propyl, 3-hydroxy-3-(2-methyl-thiazol-4-yl)-butyl, 3-hydroxy-3-(2-methyl-thiazol-5-yl)-butyl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-butyl, 3-hydroxy hydroxy-3-(5-methyl-pyridin-3-yl)-butyl, 3-hydroxy-3-(pyridin-2-yl)-butyl, 3-hydroxy-3-(6-methyl-pyridin-2-yl)-butyl, 3-hydroxy-3-(pyrimidin-2-yl)-butyl, 3-hydroxy-3-(6-methoxy-pyrimidin-4-yl)-butyl, 3-hydroxy-3-(6-methyl-pyrimidin-4-yl)-pentyl, 3-hydroxy-3-(2-methyl-pyrimidin-4-yl)-butyl 3-hydroxy-3-(5-methyl-pyrazin-2-yl)-butyl, 3-hydroxy-3-(1H-indazol-3-yl)-butyl, 3-hydroxy-3-(1,3-dimethyl-pyrazol-4-yl)-propyl, 3-hydroxy-3-(2-methyl-thiazol-4-yl)-propyl, 3-hydroxy-3-(pyridin-2-yl)-pentyl or 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-pentyl. - C 3-5 -alkenyl, unsubstituted (especially isopropenyl) or substituted by one hydroxy (especially 4-hydroxy-but-1-en-2-yl), C 3-5 -alkenyl; - C 4-6-cycloalkenyl (especially cyclopentenyl; especially cyclopent-1-en-1-yl), unsubstituted or containing one or two C 1-3 -substituted by alkyl, oxo or hydroxy; 4-6 -cycloalkenyl, one ring carbon atom of which is optionally replaced by an oxygen atom, C 4-6 -cycloalkenyl; [Especially, such C 4-6 -Cycloalkenyl represents cyclopent-1-en-1-yl, 3-oxo-cyclopent-1-en-1-yl, 3-hydroxy-cyclopent-1-en-1-yl, 3-hydroxy-3-methyl-cyclopent-1-en-1-yl or 2,3-dihydro-furan-3-yl. - unsubstituted or 1 or 2 C 1-3 -Alkyl (especially methyl, ethyl, isopropyl), hydroxy or hydroxy-C 1-3 -substituted by alkyl (especially 1-hydroxy-1-methyl-ethyl) 3-6 -cycloalkyl, wherein the C 3-6 -cycloalkyl, one ring carbon atom of which is optionally replaced by an oxygen atom, C 3-6 -cycloalkyl; [Especially, such C 3-6 -Cycloalkyl represents cyclopropyl, cyclopentyl, 3-hydroxy-cyclopentyl, 3-hydroxy-3-methyl-cyclopentyl, 3-hydroxy-3-ethyl-cyclopentyl, 3-hydroxy-3-isopropyl-cyclopentyl, 2-(2-hydroxy-isopropyl)-cyclopropyl, 4-hydroxy-cyclohexyl, 4-hydroxy-4-methyl-cyclohexyl, oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydrofuran-2-yl, tetrahydropyran-4-yl, 5-methyl-tetrahydrofuran-2-yl or 5,5-dimethyl-tetrahydrofuran-2-yl. - -OR O2 (-- R O2 teeth, --- C 1-4- alkyl (in particular methyl, ethyl, isopropyl, sec-butyl or isobutyl); --- C 2-5 -alkyl, with one hydroxy or C 1-3 -Alkoxy (especially C substituted by (methoxy) 2-5 - alkyl; [Especially, such C 2-5 -Alkyl represents 2-hydroxy-ethyl, 3-hydroxy-propyl, 2-hydroxy-2-methyl-propyl, 3-hydroxy-3-methyl-butyl or 2-methoxy-ethyl. --- -L 2 -CY 2 (---- -L 2 - independently represents a bond (i.e., CY 2 is directly attached to the rest of the molecule; represents -CH2- or -CH2-CH2-; ---- CY 2 are, independently, ----- unsubstituted or one hydroxy-C 1-3 -phenyl substituted by alkyl (especially 2-hydroxyethyl); ----- benzyl-oxy; ----- 5- to 6-membered heteroaryl having 1 to 3 ring heteroatoms independently selected from nitrogen, oxygen, or sulfur (especially pyridinyl, oxadiazolyl, or triazolyl); especially pyridin-2-yl, 1,2,4-oxadiazol-5-yl, or 1,2,4-triazol-1-yl), wherein the 5- or 6-membered heteroaryl is independently unsubstituted or substituted by 1 or 2 substituents; if such substituents are present, they are selected from the group consisting of C 1-3 -Alkyl (especially methyl) or C 1-3 - 5-6 membered heteroaryl independently selected from cycloalkyl (especially cyclopropyl); ----- C 3-6-cycloalkyl in which one carbon ring atom is optionally replaced by one heteroatom selected from oxygen and nitrogen (in particular oxetanyl, cyclopentyl or cyclohexyl); 3-6 -cycloalkyl is unsubstituted or substituted by 1 or 2 substituents, said substituents being C 1-3 -Alkyl (especially methyl), hydroxy, fluoro, oxo, C 1-3 -Alkyl-carbonyl (especially acetyl) and C 1-3 -alkoxy (especially methoxy), C 3-6 -cycloalkyl; ----- Benzoxazolonyl (especially 3H-benzoxazol-2-on-6-yl); ----- Chromanil (especially chroman-6-yl); represents. ); [Especially, the -L 2 -CY 2 represents phenyl, 4-(2-hydroxy-ethyl)-phenyl, 2-(2-hydroxy-ethyl)-phenyl, benzyl, 2-(benzyl-oxy)-ethyl, 2-(pyridin-2-yl)-ethyl, 3-cyclopropyl-1,2,4-oxadiazol-5-yl-methyl, 2-(3,5-dimethyl-1,2,4-triazol-1-yl)-ethyl, oxetan-3-yl-methyl, 2,2-dimethyl-cyclopentyl, 3,3-difluoro-cyclopentyl, 3-methoxy-cyclopentyl, cyclohexyl, 4-hydroxy-cyclohexyl, 4-methyl-4-hydroxy-cyclohexyl, 4-oxo-cyclohexyl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl, tetrahydropyran-4-yl-methyl, N-acetyl-piperidin-4-yl-methyl, 3H-benzoxazol-2-one-6-yl or chroman-6-yl. ]; represents. ); [Especially, such -OR O2are methoxy, ethoxy, isopropoxy, isobutoxy, sec-butoxy, phenoxy, 4-(2-hydroxy-ethyl)-phenoxy, 2-(2-hydroxy-ethyl)-phenoxy, benzyl-oxy, 2-(benzyl-oxy)-ethoxy, 2-methoxy-ethoxy, 3-hydroxy-propoxy, 2-hydroxy-2-methyl-propoxy, 2-hydroxy-ethoxy, 3-hydroxy-3-methyl-butoxy, 2,2-dimethyl-cyclopentyl-oxy, 3,3-difluoro-cyclopentyl-oxy, cyclohexyl-oxy, 4-hydroxy-cyclohexyl-oxy, 4-methyl-4-hydroxy-cyclohexyl-oxy, 4-oxo-cyclohexyl-oxy, tetrahydrofuran-3-yl-oxy, tetrahydropyran-4-yl-oxy, tetrahydropyran-4-yl-methoxy, 3-methoxy-cyclopentyl-oxy , oxetan-3-yl-methoxy, 2-(pyridin-2-yl)-ethyl-oxy, (3-cyclopropyl-1,2,4-oxadiazol-5-yl)-methoxy, 2-(3,5-dimethyl-1,2,4-triazol-1-yl)-ethoxy, N-acetyl-piperidin-4-yl-methyl-oxy, 3H-benzoxazol-2-one-6-yl or chroman-6-yl-oxy. - -C≡CR T1 (-- R T1 teeth, --- C 1-4 - alkyl (in particular methyl, ethyl, isopropyl or isobutyl), 1-4 -alkyl is independently one ---- hydroxy; [In particular, the C 1-4 -alkyl represents hydroxy-methyl, 1-hydroxy-ethyl, 2-hydroxy-ethyl, 1-hydroxy-2-methyl-propyl, 1-hydroxy-1-methyl-ethyl or 1-hydroxy-1-trifluoromethyl-ethyl; ---- C 1-3 -alkoxy (especially methoxy); ---- -S(=O)2-R SOT (RSOT is C 1-3 -Alkyl, C 1-3 -Alkyl-amino or C 3-5 -cycloalkyl.) (In particular, such -S(=O)2-R SOT represents methyl-sulfonyl, methyl-amino-sulfonyl or cyclopropyl-sulfonyl; ---- -NR NT1 R NT2 (R NT1 represents hydrogen, and R NT2 is C 1-3 -Alkyl-carbonyl, C 1-3 -Alkoxy-C 1-3 -Alkyl-carbonyl or C 3-5 -cycloalkyl-carbonyl.) (In particular, such -NR NT1 R NT2 represents acetyl-amino, isopropyl-carbonyl-amino, methoxy-methyl-carbonyl-amino or cyclopropyl-carbonyl-amino; ---- C having 1 or 2 ring heteroatoms independently selected from nitrogen and oxygen 4-6 -heterocyclyl (especially oxazolidinyl, imidazolidinyl or pyrrolidinyl; especially oxazolidin-3-yl, imidazolidin-3-yl or pyrrolidin-1-yl); 4-6 -heterocyclyl is substituted by one oxo; or oxo and C 1-3 -substituted by two alkyl (especially methyl) substituents, C 4-6 -heterocyclyl; (especially those C 4-6 -heterocyclyl represents oxazolidin-2-one-3-yl, imidazolidin-2-one-3-yl, 1-methyl-imidazolidin-2-one-3-yl or pyrrolidin-2-one-1-yl; or ---- N-(C 1-3 -Alkyl-carbonyl)-piperidinyl-C 1-3 - alkyl (especially N-acetyl-piperidin-4-yl-methyl); C replaced by 1-4 - alkyl; --- C 3-6 -cycloalkyl (especially cyclopropyl) (especially the above C to the rest of the molecule) 3-6 -at the point of attachment of the cycloalkyl) one ---- hydroxy; ----amino-sulfonyl optionally substituted with two methyls; ---- phenyl substituted by one halogen (especially 4-fluorophenyl);---- pyridinyl (especially pyridin-2-yl); ---- 1 C 1-3 -pyrimidinyl substituted by alkyl (especially 6-methyl-pyrimidin-4-yl); ---- oxazolidinonyl (especially oxazolidin-2-one-3-yl); C replaced by 3-6 -cycloalkyl; [Especially, such C 3-6 -cycloalkyl is 1-hydroxy-cyclopropyl, 1-hydroxy-cyclobutyl, 1-hydroxy-cyclopentyl, 1-(amino-sulfonyl)-cyclopropyl, 1-(dimethyl-amino-sulfonyl)-cyclopropyl, 1-(6-methyl-pyrimidin-4-yl)-cyclopropyl, 1-(pyridin-2-yl)-cyclopropyl, 1-(4-fluoro-phenyl)-cyclopropyl, 1-(pyridin-2-yl)-cyclopropyl or 1-(oxazolidin-2-one-3-yl)-cyclopropyl. represents propyl.]; --- C fused to a pyridine ring (especially at the 2- and 3-positions of the pyridine ring) 3-6 -cycloalkyl (especially cyclopentyl or cyclohexyl), 3-6 -cycloalkyl (especially the above C 3-6 - substituted by one hydroxyl at position 1 of the cycloalkyl ring; 3-6 - one ring carbon atom in the cycloalkyl is optionally replaced by one oxygen atom, C 3-6 -cycloalkyl; [Especially, such C 3-6-cycloalkyl represents 8-hydroxy-5,6,7,8-tetrahydroquinolin-8-yl, 7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl or 4-hydroxy-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl; --- C with one ring heteroatom independently selected from nitrogen and oxygen 4-6 heterocyclyl (especially azetidinyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl; especially azetidin-3-yl, piperidin-4-yl, pyrrolidin-3-yl, pyrrolidin-2-yl, pyrrolidin-1-yl or tetrahydropyran-4-yl); 4-6 -heterocyclyl is substituted by 1, 2 or 3 substituents (in particular 1 or 2 substituents), said substituents being selected from the group consisting of C 1-3 -Alkyl (especially methyl), hydroxy, oxo, C 1-3 -Alkyl-carbonyl (especially acetyl), C 1-3 -alkoxy-carbonyl (especially tert-butoxy-carbonyl), C 1-3 -Alkyl-sulfonyl (especially methyl-sulfonyl) and C 1-3 -alkyl-amino-sulfonyl (particularly methyl-amino-sulfonyl), C 4-6 -heterocyclyl; [Especially, such C 4-6-heterocyclyl is N-(isopropyl-carbonyl)-3-hydroxy-azetidin-3-yl, N-(tert-butoxy-carbonyl)-3-hydroxy-azetidin-3-yl, N-methyl-3-hydroxy-pyrrolidin-2-one-3-yl, N-acetyl-2-methyl-pyrrolidin-2-yl, 3-hydroxy-N-(tert-butoxy-carbonyl)-pyrrolidin-3-yl, 2-oxo-pyrrolidin-1-yl, N-acetyl-piperidin-1-yl, N-acetyl-4-methyl-piperidin-4-yl, N-(methyl-amino-sulfonyl)-4-methyl-piperidin-4-yl, N-acetyl-4-hydroxy-piperidin-4-yl, N-(methyl-sulfonyl)-piperidin-4-yl, N-(tert-butoxy-carbonyl)-piperidin-4-yl, 3-hydroxy-2-oxo-1-methyl-pyrrolidin-2-yl or 4-hydroxy-tetrahydropyran-4-yl; --- Pyrazolyl (especially 1H-pyrazol-4-yl) N-substituted by methyl; --- indolyl (especially indol-2-yl); --- 3-hydroxy-1-methyl-1,3-dihydro-indol-2-on-3-yl; or --- 4-Hydroxy-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl; represents. ); [In particular, such -C≡CR T1are 3-hydroxy-3-trifluoromethyl-but-1-yn-1-yl, 3-hydroxy-prop-1-yn-1-yl, 4-hydroxy-but-1-yn-1-yl, 3-hydroxy-but-1-yn-1-yl, 3-hydroxy-3-methyl-but-1-yn-1-yl, 3-methyl-3-(pyrrolidin-2-one-1-yl)-but-1-yn-1-yl, 3-methyl-3-(cyclopropyl-sulfonyl)-but- 1-yn-1-yl, 3-methyl-3-(acetyl-amino)-but-1-yn-1-yl, 3-methyl-3-(oxazolidin-2-one-3-yl)-but-1-yn-1-yl, 3-methyl-3-(imidazolidin-2-one-3-yl)-but-1-yn-1-yl, 3-methyl-3-(1-methyl-imidazolidin-2-one-3-yl)-but-1-yn-1-yl, 3-methyl-3-(2-oxo-pyrrolidine- 1-yl)-but-1-yn-1-yl, 3-methyl-3-(methyl-sulfonyl)-but-1-yn-1-yl, 3-methyl-3-(cyclopropyl-carbonyl-amino)-but-1-yn-1-yl, 3-methyl-3-(isopropyl-carbonyl-amino)-but-1-yn-1-yl, 3-methyl-3-(methoxy-methyl-carbonyl-amino)-but-1-yn-1-yl, 3-hydroxy-4-methyl- Pent-1-yn-1-yl, 3-methoxy-prop-1-yn-1-yl, 3-(N-acetyl-piperidin-4-yl)-prop-1-yn-1-yl, (1-hydroxy-cyclopropyl)-ethynyl, (1-hydroxy-cyclobutyl)-ethynyl, (1-hydroxy-cyclopentyl)-ethynyl, (8-hydroxy-5,6,7,8-tetrahydroquinolin-8-yl)-ethynyl, (7-hydroxy-6,7-Dihydro-5H-cyclopenta[b]pyridin-7-yl)-ethynyl, (1-methyl-pyrazol-4-yl)-ethynyl, (tetrahydropyran-4-yl)-ethynyl, (4-hydroxy-tetrahydropyran-4-yl)-ethynyl, indol-2-yl-ethynyl, (1-(isopropyl-carbonyl)-3-hydroxy-azetidin-3-yl)-ethynyl, (1-(tert-butoxy-carbonyl)-3-hydroxy-azetidin-3 -yl)-ethynyl, (1-(6-methyl-pyrimidin-4-yl)-cyclopropyl)-ethynyl, (N-acetyl-4-methyl-piperidin-4-yl)-ethynyl, (N-acetyl-4-hydroxy-piperidin-4-yl)-ethynyl, (1-(4-fluoro-phenyl)-cyclopropyl)-ethynyl, (N-acetyl-piperidin-4-yl)-ethynyl, (N-(methyl-sulfonyl)-piperidin-4-yl)-ethynyl, (1-(dimethyl -amino-sulfonyl)-cyclopropyl)-ethynyl, (1-(amino-sulfonyl)-cyclopropyl)-ethynyl, (N-(methyl-amino-sulfonyl)-4-methyl-piperidin-4-yl)-ethynyl, (1-(pyridin-2-yl)-cyclopropyl)-ethynyl, (3-hydroxy-N-(tert-butoxy-carbonyl)-pyrrolidin-3-yl)-ethynyl, (1-(oxazolidin-2-one-3-yl)-cyclopropyl)-ethynyl nyl, (3-hydroxy-1-methyl-1,3-dihydro-indol-2-one-3-yl)-ethynyl, (4-hydroxy-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-ethynyl, (N-(tert-butoxy-carbonyl)-piperidin-4-yl)-ethynyl, (N-acetyl-2-methyl-pyrrolidin-2-yl)-ethynyl or (3-hydroxy-2-oxo-1-methyl-pyrrolidin-3-yl)-ethynyl. - -C≡CC(OH)(R T2 )(R T3 ) (-- R T2 is hydrogen or C 1-3 - alkyl (especially methyl or ethyl; especially methyl); -- R T3 teeth, --- phenyl, unsubstituted or substituted by one substituent, said substituent, if present, being selected from the group consisting of C 1-3 phenyl selected from alkoxy (especially methoxy) or halogen (especially fluorine); [In particular, such phenyl, unsubstituted or substituted by one substituent, is 2-fluoro-phenyl, 4-methoxy-phenyl or 2-methoxy-phenyl.] 5-6-membered heteroaryl having 1 or 2 ring heteroatoms independently selected from nitrogen, oxygen or sulfur (in particular thiophenyl, thiazolyl, pyrrolyl, pyrazolyl, isoxazolyl, pyridinyl, pyrazinyl or pyrimidinyl; especially thiophen-2-yl, thiazol-4-yl, thiazol-5-yl, pyrrol-2-yl, pyrazol-3-yl, pyrazol-4-yl, isoxazol-5-yl, pyridin-2-yl, pyrimidin-2-yl, pyrazin-2-yl or pyrimidin-4-yl), which 5- or 6-membered heteroaryl are independently unsubstituted or substituted by 1 or 2 substituents, if any, which are selected from C 1-3 -Alkyl (especially methyl), C 1-3 -cycloalkyl (especially cyclopropyl), C 1-3 -fluoroalkyl (especially C1-fluoroalkyl; especially difluoromethyl or trifluoromethyl) L) and C 1-3 - 5-6 membered heteroaryl independently selected from alkoxy (especially methoxy); [In particular, such 5- to 6-membered heteroaryls include 5-methyl-thiophen-2-yl, 2-methyl-thiazol-5-yl, 1-methyl-1H-pyrrol-2-yl, 1-cyclopropyl-1H-pyrazol-3-yl, 1-methyl-1H-pyrazol-3-yl, 1,3-dimethyl-pyrazol-4-yl, 1,5-dimethyl-1H-pyrazol-3-yl, 2-methyl-thiazol-4-yl, 3-methyl-isoxazol-5-yl, 1-methyl-1H-imidazol-2-yl, pyridin-2-yl, 6-methoxy-pyridin-2-yl, 6-methyl-pyridin-2-yl, pyrimidin-2-yl, 2-methoxy-pyrimidin-4-yl, 6-methoxy-pyridin-2-yl, 2-methyl-pyrimidin-4 ... pyrimidin-4-yl, pyrimidin-4-yl, 2-methyl-pyrimidin-4-yl, 6-methyl-pyrimidin-4-yl, 2,6-dimethyl-pyrimidin-4-yl, 2,6-dimethoxy-pyrimidin-4-yl, 2-methyl-6-methoxy-pyrimidin-4-yl, 2-methoxy-6-methyl-pyrimidin-4-yl, 5-methyl-pyrazin-2-yl, 1-cyclopropyl-1H-pyrazol-3-yl, 6-cyclopropyl-pyrimidin-4-yl, 6-difluoromethyl-pyrimidin-4-yl, 2-trifluoromethyl-pyrimidin-4-yl, 6-trifluoromethyl-pyrimidin-4-yl or 1,5-dimethyl-1H-pyrazol-3-yl. --- C with one ring heteroatom selected from nitrogen and oxygen 4-7 -heterocyclyl; 4-7 -heterocyclyl is unsubstituted or substituted by 1 or 2 substituents, if such substituents are present, and 1-3 -Alkyl (especially methyl) or C 1-3 -alkyl-carbonyl (especially acetyl), C 4-7 -heterocyclyl; or [Especially, such C 4-7 -heterocyclyl represents N-acetyl-piperidin-4-yl, N-acetyl-4-methyl-piperidin-4-yl or tetrahydropyran-4-yl. --- indazolyl (especially indazol-3-yl)); represents. ); [In particular, such -C≡CC(OH)(R T2 )(R T3 ) is 3-hydroxy-3-(5-methyl-thiophen-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methyl-thiazol-5-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-1H-pyrrol-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(3-methyl-isoxazol-5-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-1H-pyrrol-2-yl)-but-1-yn-1-yl 3-hydroxy-3-(1-methyl-1H-imidazol-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(5-methyl-pyrazin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(tetrahydropyran-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-(N-acetyl-piperidin-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-(N-acetyl-4-methyl-piperidin-4-yl)-prop-1-yn-1-yl )-but-1-yn-1-yl, 3-hydroxy-3-phenyl-prop-1-yn-1-yl, 3-hydroxy-3-(2-methyl-thiazol-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-(1,3-dimethyl-pyrazol-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-phenyl-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-1H-pyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy -3-(1-cyclopropyl-1H-pyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1,5-dimethyl-1H-pyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-pyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(pyrimidin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-pyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-pyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy hydroxy-3-(3-fluoro-phenyl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methoxy-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methoxy-6-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2,6-dimethoxy-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(pyridin-2-yl)-pent-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methyl-pyridin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methyl-pyridin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methyl-pyridin-2-yl)-but-1-yn-1-yl, 3-hydroxy 3-hydroxy-3-(6-methyl-pyridin-2-yl)-pent-1-yn-1-yl, 3-hydroxy-3-(2,6-dimethyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-pent-1-yn-1-yl, 3-hydroxy-3-(1H-indazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-cyclopropyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-difluoromethyl-pyridin-2-yl)-but-1-yn-1-yl 3-hydroxy-3-(indazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(4-methoxy-phenyl)-but-1-yn-1-yl, 3-hydroxy-3-(4-methoxy-phenyl)-but-1-yn-1-yl, 3-hydroxy-3-(2-trifluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-trifluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(indazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(4-methoxy-phenyl)-but-1-yn-1-yl, or 3-hydroxy-3-(2-methoxy-phenyl)-but-1-yn-1-yl. -NR N3 R N4 (-- R N3 is C 1-3 - represents alkyl (especially methyl); and R N4 is hydroxy-C 1-3 -alkyl (especially 2-hydroxyethyl) or 2-(benzyloxy)-C 1-3 -alkyl (especially 2-(benzyl-oxy)-ethyl); or -- R N3 and R N4 together with the nitrogen to which they are attached form a 4- to 6-membered (particularly 5- to 6-membered) heterocycle, and the ring members necessary to complete the heterocycle are -CH2-, -O-, -(C=O)-, -CHR X - and -C(R Y )2-; the heterocycle has no more than one ring member independently selected from the group consisting of -O- and -(C=O)-; the heterocycle is -CHR X -; the heterocycle has no more than two ring members selected from the group consisting of -C(R Y )2-; R X are independently fluorine, methyl, isopropyl, isobutyl, tert-butyl, hydroxy, trifluoromethyl, hydroxymethyl, 1-hydroxyethyl, 1-hydroxy-1-methylethyl, cyclopropyl, 2-methoxyethyl, 2-methylthiazol-5-yl, 4-methylthiazol-2-yl, phenyl, benzyl, tetrahydropyran-4-yl, N-acetyl-piperidin-4-yl, 1,2,4-oxadiazolyl, 3-methyl-1,2,4 -oxadiazol-5-yl, 2-methyl-2H-[1,2,3]triazol-4-yl, 1-methyl-1H-pyrazol-4-yl, 1-difluoromethyl-1H-pyrazol-4-yl, 1,3-dimethyl-1H-pyrazol-4-yl, pyridin-2-yl, 6-methyl-pyridin-3-yl, 6-isopropyl-pyridin-2-yl, 6-trifluoromethyl-pyridin-3-yl, 2-isopropyl-pyrimidin-4-yl or 1-methoxy-methyl; R Yindependently represent fluorine, hydroxy, cyclopropyl, methyl, hydroxy-methyl or trifluoromethyl; in particular, such -NR N3 R N4 is pyrrolidinyl; 2-pyrrolidonyl; oxazolidinonyl (especially 1,3-oxazolidin-2-one-3-yl); piperidinyl; or R X and R Y and one or two substituents independently selected from the group consisting of and independently optionally substituted morpholinyl. [Especially, such -NR N3 R N4are pyrrolidin-1-yl, 3-fluoro-pyrrolidin-1-yl, 3,3-difluoro-pyrrolidin-1-yl, 3,4-difluoro-pyrrolidin-1-yl, 3-isopropyl-pyrrolidin-1-yl, 3,3-dimethyl-pyrrolidin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 2-methyl-pyrrolidin-1-yl, 3-hydroxy-3-methyl-pyrrolidin-1-yl, 3-(hydroxy-methyl)-pyrrolidin-1-yl, 2-(hydroxy-methyl)-pyrrolidin-1-yl, 3-(1-hydroxy-ethyl)-pyrrolidin-1-yl, 3-hydroxy-3-cyclopropyl-pyrrolidin-1-yl, 3-hydroxy-3-trifluoromethyl-pyrrolidin-1-yl, 3-Trifluoromethyl-pyrrolidin-1-yl, 3-(1-hydroxy-1-methyl-ethyl)-pyrrolidin-1-yl, 3-(1-hydroxy-ethyl)-pyrrolidin-1-yl, 3-(hydroxy-methyl)-3-methyl-pyrrolidin-1-yl, 1,3-oxazolidin-2-one-3-yl, 5-(tert-butyl)-1,3-oxazolidin-2-one-3-yl, 5-phenyl-1,3-oxazolidin-2-one-3-yl, 5-benzyl-1,3-oxazolidin-2-one-3-yl, 5-isopropyl-1,3-oxazolidin-2-one-3-yl, 5-(tetrahydropyran-4-yl)-1,3-oxazolidin-2-one-3-yl, 5,5-dimethyl-1,3-Oxazolidin-2-one-3-yl, morpholin-4-yl, piperidin-1-yl, 4-hydroxy-piperidin-1-yl, 3-hydroxy-piperidin-1-yl, 3-(tetrahydropyran-4-yl)-pyrrolid-2-one-1-yl, N-methyl-N-(2-(benzyl-oxy)-ethyl)-amino, N-methyl-N-(2-hydroxy-ethyl)-amino, pyrrolidin-2-one-1-yl, 4-phenyl-pyrrolidin-2-one-1-yl, 4-(N-acetyl-piperidin-4-yl)-pyrrolidine -2-one-1-yl, 4-(pyridin-2-yl)-pyrrolidin-2-one-1-yl, 4-(6-methyl-pyridin-3-yl)-pyrrolidin-2-one-1-yl, 4-(2-isopropyl-pyrimidin-4-yl)-pyrrolidin-2-one-1-yl, 4-(6-isopropyl-pyridin-2-yl)-pyrrolidin-2-one-1-yl, 4-(6-trifluoromethyl-pyridin-3-yl)-pyrrolidin-2-one-1-yl, 4-methyl-pyrrolidin-2-one-1-yl, 4-isopropyl-pyrrolidin-2-one-1-yl, 3- Isopropyl-pyrrolidin-2-one-1-yl, 3,3-dimethyl-pyrrolidin-2-one-1-yl, 4,4-dimethyl-pyrrolidin-2-one-1-yl, 3-(piperidin-4-yl)-pyrrolidin-2-one-1-yl, 4-(1-methyl-1H-pyrazol-4-yl)-pyrrolidin-2-one-1-yl, 4-(1-difluoromethyl-1H-pyrazol-4-yl)-pyrrolidin-2-one-1-yl, 4-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrrolidin-2-one-1-yl, 4-(6-isopropyl-pyridin-4-yl)-pyrrolidin-2-one-1-yl 4-(2-methoxy-ethyl)-pyrrolidin-2-one-1-yl, 2,2,6,6-tetrafluoro-morpholin-4-yl, 2,6-dimethyl-morpholin-4-yl, 2-(methoxy-methyl)-morpholin-4-yl, 3-(3-methyl-1,2,4-oxadiazol-5-yl)-pyrrolidin-1-yl, 4-(2-methyl-thiazol-5-yl)-pyrrolidin-2-one-1-yl, 4-(2-methyl-2H-[1,2,3]triazol-4-yl)-pyrrolidin-2-one-1-yl, 3-(4-methyl-thiazol-2-yl)-pyrrolidin-1-yl or 3-(phenyl)-pyrrolidin-1-yl. - -(C=O)-N(R N5 )(R N6 ) (-- R N5 represents hydrogen; and R N6 is C 3-6 -cycloalkyl (especially cyclopentyl) or tetrahydropyranyl (especially tetrahydropyran-4-yl); or -- R N5 and R N6 form pyrrolidinyl together with the nitrogen to which they are attached; [In particular, such -(C=O)-N(R N5 )(R N6 ) represents N-cyclopentyl-amino-carbonyl, N-(tetrahydropyran-4-yl)-amino-carbonyl or pyrrolidinyl-carbonyl. piperidin-4-yl or pyrrolidin-3-yl substituted at the nitrogen ring atom by one substituent, said substituent being C 1-4 - piperidin-4-yl or pyrrolidin-3-yl independently selected from alkoxy-carbonyl (especially tert-butoxy-carbonyl), pyridinyl (especially pyridin-2-yl), phenyl and (4-methylphenyl)-sulfonyl; [In particular, such piperidin-4-yl or pyrrolidin-3-yl is N-(tert-butoxy-carbonyl)-piperidin-4-yl, N-(tert-butoxy-carbonyl)-pyrrolidin-3-yl, N-(pyridin-2-yl)-piperidin-4-yl, N-(phenyl)-piperidin-4-yl or N-((4-methylphenyl)-sulfonyl)-piperidin-4-yl.] - 5- or 6-membered heteroaryl having 1 to 3 (particularly 2 or 3; more particularly 3) ring heteroatoms independently selected from nitrogen, oxygen and sulfur (particularly pyrazolyl, triazolyl, oxazolyl, thiazolyl, oxadiazolyl, pyrimidinyl or pyridinyl; especially pyrazol-1-yl, 1H-1,2,3-triazol-1-yl, oxazol-2-yl, thiazol-2-yl, 1,2,4-oxadiazol-5-yl, 1,2,4-oxadiazol-3-yl, pyrimidin-2-yl or pyridin-2-yl), which 5- or 6-membered heteroaryl is independently unsubstituted or substituted by 1, 2 or 3 substituents (particularly substituted by 1 substituent; especially substituted by 1 substituent at the 3-position relative to the point of attachment of the 5- or 6-membered heteroaryl to A), if present, -- C 1-4 - alkyl (in particular methyl, ethyl, propyl, isopropyl or tert-butyl), --- unsubstituted; or --- 1 piece, ---- hydroxy; ---- C 1-4 alkoxy (especially methoxy and tert-butoxy); or ---- -N(R N7 )(R N8 )(R N7 is hydrogen or C 1-3 - represents alkyl (especially methyl); R N8 are independently, C 3-5 -cycloalkyl-carbonyl (especially cyclopropyl-carbonyl), C 1-3 -Alkyl (especially methyl), C 1-3 -Alkyl-carbonyl (deuterated C 1-3 -alkyl-carbonyl) (especially acetyl, ethyl-carbonyl, isopropyl-carbonyl or acetyl-2,2,2-d3), C 1-3 -Alkoxy-C 1-3-alkyl-carbonyl (especially methoxy-methyl-carbonyl), tetrahydropyranyl-carbonyl (especially tetrahydropyran-4-yl-carbonyl) or hydroxy-C 1-3 -alkyl-carbonyl (especially hydroxy-methyl-carbonyl); is replaced by; - substituted with two substituents, one of which is hydroxy and the other of which is trifluoromethyl; or both of which are hydroxy; or --- substituted with two or three substituents, two of which are fluorine, and if a further substituent is present, said further substituent is hydroxy (particularly, said hydroxy group is separated from any of the fluorine substituents by at least two carbon atoms); C 1-4 - alkyl; [Especially, such C 1-4 -Alkyl is methyl, isopropyl, hydroxy-methyl, 1-Hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, 2-hydroxy-1,1-dimethyl-ethyl, methoxy-methyl, 2-methoxy-ethyl, 1-methoxy-1-methyl-ethyl, 2-methoxy-2-methyl-propyl, 2-methoxy-1,1-dimethyl-ethyl, tert-butoxy-methyl; 1,2-dihydroxy-ethyl, N-acetyl-2-amino-ethyl, N-(acetyl-2,2,2-d3)-2-amino-ethyl, 2-(methylcarboxamido)-2-methyl-propyl, 2-(ethylcarboxamido)-2-methyl-propyl, 2-(cyclopropyl-carboxamido)-2-methyl-propyl, 2-(tetrahydropyran-4-yl-carboxamido)-4-methyl-propyl, 2-(methyl-d3-carboxamido)-2-methyl-propyl, 2-(methoxy-methyl-carboxamido)-2-methyl-propyl, 2-(ethyl-carboxamido)-2-methyl-propyl, 2-(isopropyl-carboxamido)-2-methyl-propyl, 2-(methyl-d3-carboxamido)-2-methyl-propyl, N-methyl-N-(hydroxy-methyl-carbonyl)-2-amino-ethyl, N-methyl-N-acetyl-2-amino-ethyl, 2,2,2-trifluoro-1-hydroxy-1-methyl-ethyl, 1,1-difluoro-2-hydroxy-ethyl, 1,1-difluoro-ethyl or N-methyl-N-(acetyl-2,2,2-d3)-2-amino-ethyl; in particular, such C 1-4 -alkyl group is 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl or 2-hydroxy-1,1-dimethyl-ethyl. -- -L 3 -CY 3 (--- -L 3 - independently represents a bond (i.e., CY 3 is directly attached to the remainder of the molecule; -CH2-, -CH2-CH2-, -C(CH3)2-, -CH(OH)-, or -O-CH2-; -L 3 When - is -O-CH2-, the CY 3 is attached to the oxygen atom of the -O-CH2-; --- CY 3 are independently, C 3-6-cycloalkyl or C 4-6 -heterocyclyl, 4-6 -heterocyclyl has 1 or 2 ring heteroatoms independently selected from nitrogen and oxygen (especially CY 3 represents cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl, morpholinyl, imidazolidinyl, piperidinyl, or piperazinyl; 3 is independently unsubstituted or substituted with 1, 2 or 3 substituents, the substituents being ---- halogens (especially fluorine); ---- oxo; ---- hydroxy; ---- 1 C 1-3 -C optionally substituted with alkoxy 1-3 -alkyl (especially such C 1-3 -Alkyl represents methyl, ethyl, isopropyl or methoxy-methyl; ---- C 1-3 -alkoxy (especially methoxy); ---- -(C=O)-R CO (R CO teeth, ----- 1 hydroxy or C 1-3 -C optionally substituted with alkoxy 1-3 - alkyl (in particular methyl, ethyl, n-propyl, isopropyl, tert-butyl, hydroxymethyl, methoxymethyl, benzyloxy or 2-methoxyethyl); ----- C 1-3 -fluoroalkyl (especially 2,2,2-trifluoro-ethyl);----- C 1-3 -alkoxy, wherein the C 1-3 -C with one alkoxy 1-3 C optionally substituted with -alkoxy 1-3 -alkoxy (especially methoxy, ethoxy or 2-methoxy-ethoxy); ----- C in which one or two carbon ring atoms are optionally replaced by one or two oxygen ring atoms 3-6-Cycloalkyl-(CH2) n - (n represents an integer of 0, 1 or 2) (particularly, such C 3-5 -Cycloalkyl-(CH2) n - represents cyclopropyl, cyclopentyl, oxetan-3-yl, oxetan-3-yl-methyl, 1,4-dioxan-2-yl or tetrahydropyran-4-yl; or ----- phenyl; represents. ); [In particular, such -(C=O)-R CO represents acetyl, ethyl-carbonyl, n-propyl-carbonyl, isopropyl-carbonyl, tert-butyl-carbonyl, hydroxymethyl-carbonyl, 2,2,2-trifluoro-ethyl-carbonyl, methoxy-methyl-carbonyl, 2-methoxy-ethyl-carbonyl, methoxy-carbonyl, ethoxy-carbonyl, 2-methoxy-ethoxy-carbonyl, cyclopropyl-carbonyl, cyclopentyl-carbonyl, oxetan-3-yl-carbonyl, oxetan-3-yl-methyl-carbonyl, phenyl-carbonyl or tetrahydropyran-4-yl-carbonyl, methoxy-methyl-carbonyl or 1,4-dioxan-2-yl-carbonyl. ---- -N(R N9 )(R N10 )(R N9 is hydrogen or C 1-3 - represents alkyl (especially methyl); R N10 is C 1-3 -Alkyl (especially methyl), C 1-3 -Alkyl-carbonyl (especially acetyl), C 1-3 -Alkyl-sulfonyl (especially methyl-sulfonyl), C 1-3 -alkoxy-carbonyl (especially ethoxy-carbonyl), C 1-3 -Alkoxy-C 1-3 -alkyl-carbonyl (especially methoxy-methyl-carbonyl) or tetrahydropyranyl-carbonyl (especially tetrahydropyran-4-yl-carbonyl); ---- -S(=O)2-R SO (R SO teeth, ----- 1 hydroxy, C 1-3 -C optionally substituted by alkoxy or amino 1-3 -alkyl (especially such C 1-3 -Alkyl is methyl, n-propyl, isopropyl, 2-hydroxyethyl, 2-methoxyethyl or methylamino; or ----- C with one carbon ring atom optionally replaced by one oxygen ring atom 3-5 cycloalkyl (especially cyclopropyl, cyclopentyl or tetrahydropyranyl); represents. ); [In particular, such -S(=O)2-R SO represents methyl-sulfonyl, n-propyl-sulfonyl, isopropyl-sulfonyl, 2-hydroxyethyl-sulfonyl, cyclopropyl-sulfonyl, cyclopentyl-sulfonyl, 2-methoxy-ethyl-sulfonyl, methyl-amino-sulfonyl or tetrahydropyran-4-yl-sulfonyl. ---- 5-membered heteroaryl having one ring heteroatom (especially oxygen) selected from nitrogen, oxygen and sulfur; 5-membered heteroaryl (especially furanyl; especially furan-2-yl), wherein the 5-membered heteroaryl is unsubstituted; and ---- Phenyl-(CH2) p -(p represents an integer 0, 1 or 2) (particularly such phenyl-(CH2) p - represents phenyl or benzyl; Selected from.) [Especially, the -L 3 -CY 3are 1-hydroxy-cyclopropyl, 1-(methyl-amino)-cyclopropyl, 1-(acetyl-amino)-cycloprop-1-yl-methyl, 1-(N-acetyl-N-methyl-amino)-cycloprop-1-yl-methyl, 1-(N-(methoxy-methyl-carbonyl)-amino)-cycloprop-1-yl-methyl, 1-(N-(ethoxy-carbonyl)-N-methyl-amino)-cycloprop-1-yl, 1-(N-methylacetamido)-cycloprop-1-yl (including 1-(N-methylacetamido)-cycloprop-1-yl). yl), 1-(1-(methoxy-methyl)-cyclopropyl)-methyl, 1-(tetrahydropyran-4-yl-carbonyl-amino)-cyclopropyl-methyl, cyclobutyl-oxy-methyl, 1-hydroxy-cyclobutyl, 3-hydroxy-cyclobutyl, 1-methoxy-cyclobutyl, 1-hydroxy-cyclopentyl, 3-hydroxy-3-methyl-cyclopentyl, 1-hydroxy-cyclohexyl, 4-hydroxy-cyclohexyl, (1-hydroxy-cyclohexyl)-methyl, (1-hydroxy-cyclobutyl)-methyl, 1-hydroxy- 1-Cyclohexyl-methyl, 1-methoxy-cyclopentyl, oxetan-3-yl, tetrahydrofuran-2-yl-methyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, 4-hydroxy-tetrahydropyran-4-yl, 4-hydroxy-tetrahydropyran-4-yl-methyl, 4-methyl-tetrahydropyran-4-yl-methyl, 4-methyl-tetrahydropyran-4-yl, 2,6-dimethyl-tetrahydropyran-4-yl, 4-methoxy -tetrahydropyran-4-yl, 4-fluoro-tetrahydropyran-4-yl, tetrahydropyran-4-yl-methyl, 2-(tetrahydropyran-4-yl)-ethyl, 1-(tetrahydropyran-4-yl)-1-methyl-ethyl, tetrahydropyran-4-yl-oxy-methyl, (4-methyl-tetrahydropyran-4-yl)-oxy-methyl, N-acetyl-3-fluoro-azetidin-3-yl (including N-acetyl-d3-3-fluoro-azetidin-3-yl), N-acetyl-3-methyl-azetidin-3-yl N-acetyl-3-methyl-azetidin-3-yl, 2-oxo-azetidin-3-yl, 2-oxo-azetidin-4-yl, N-acetyl-azetidin-3-yl, 5-oxo-pyrrolidin-2-yl, N-phenyl-5-oxo-pyrrolidin-2-yl, N-phenyl-5-oxo-pyrrolidin-3-yl, N-benzyl-5-oxo-pyrrolidin-3-yl, N-benzyl-2-oxo-pyrrolidin-3-yl, 5-oxo-pyrrolidin-3-yl, N-(furan-2-yl-methyl)-5-oxo-pyrrolidin-3-yl N-3-yl, 3-methyl-5-oxo-pyrrolidin-3-yl, 1-methyl-5-oxo-pyrrolidin-3-yl, 1-isopropyl-5-oxo-pyrrolidin-3-yl, 1,3-dimethyl-2-oxo-pyrrolidin-3-yl, 2-oxo-pyrrolidin-1-yl-methyl, 2-oxo-pyrrolidin-1-yl-methyl, 1-ethyl-5-oxo-pyrrolidin-3-yl, 1-isobutyl-5-oxo-pyrrolidin-3-yl, N-acetyl-pyrrolidin-3-yl, N-acetyl-pyrrolidin-3-yl-methyl, 2,5-dioxo-3,3-dimethyl-pyrrolidin-1-yl-methyl, 2-oxo-imidazolidin-1-yl-methyl, 2-oxo-oxazolidin-3-yl-methyl, piperidin-4-yl, 1-methyl-2,6-dioxo-piperidin-4-yl, 4-methyl-piperidin-4-yl, 4-fluoro-piperidin-4-yl, 2-oxo-piperidin-4-yl, 6-oxo-piperidin-2-yl, 6-oxo-piperidin-3-yl, 1-methyl-6-oxo-piperidin-3-yl, 3-methyl-6-oxo-piperidin-3-yl, N-acetyl-piperidin-4-yl, N-acetyl-piperidin-4-yl-methyl, N-acetyl-2-methyl-piperidin-4-yl, N-acetyl-4-fluoro-piperidine -4-yl, N-acetyl-3-methyl-piperidin-4-yl, N-acetyl-4-methyl-piperidin-4-yl, N-acetyl-4-hydroxy-piperidin-4-yl, N-acetyl-4-methoxy-piperidin-4-yl, N-acetyl-piperidin-3-yl, N-acetyl-piperidin-3-yl-methyl, N-acetyl-3-methyl-piperidin-3-yl, N-acetyl-3-hydroxy-piperidin-3-yl, N-(isopropyl-carbonyl)-4-hydroxy-piperidin-4-yl, N- (tert-Butyl-carbonyl)-piperidin-4-yl, N-(2-methoxy-ethoxy-carbonyl)-piperidin-4-yl, N-(hydroxymethyl-carbonyl)-piperidin-4-yl, N-(cyclopropyl-sulfonyl)-piperidin-4-yl, N-(methyl-sulfonyl)-piperidin-4-yl, N-(n-propyl-sulfonyl)-piperidin-4-yl, N-(isopropyl-sulfonyl)-piperidin-4-yl, N-(2-hydroxy-ethyl-sulfonyl)-piperidin-4-yl , N-(cyclopentyl-sulfonyl)-piperidin-4-yl, N-(methoxy-carbonyl)-piperidin-4-yl, N-(cyclopropyl-carbonyl)-piperidin-4-yl, N-(cyclopentyl-carbonyl)-piperidin-4-yl, N-(methyl-amino-sulfonyl)-piperidin-4-yl, N-(2-methoxy-ethyl-sulfonyl)-piperidin-4-yl, N-(ethyl-carbonyl)-4-hydroxy-piperidin-4-yl, N-(methoxy-methyl-carbonyl)-piperidine-, 4-yl, N-(ethoxy-carbonyl)-piperidin-4-yl, N-acetyl-4-ethyl-piperidin-4-yl, N-(n-propyl-carbonyl)-piperidin-4-yl, N-(2-methoxy-ethyl-carbonyl)-piperidin-4-yl, N-(oxetan-3-yl-carbonyl)-piperidin-4-yl, N-(oxetan-3-yl-methyl-carbonyl)-piperidin-4-yl, N- (2,2,2-trifluoro-ethyl-carbonyl)-piperidin-4-yl, N-(tetrahydropyran-4-yl-carbonyl)-piperidin-4-yl, N-(phenyl-carbonyl)-piperidin-4-yl, N-(tetrahydropyran-4-yl-sulfonyl)-piperidin-4-yl, N-(benzyl-oxy-carbonyl)-piperidin-4-yl, N-(methoxy-methyl-carbonyl)-4-yl isopropyl-piperidin-4-yl, N-(1,4-dioxan-2-yl-carbonyl)-piperidin-4-yl, morpholin-4-yl, morpholin-4-yl-methyl, 1-methyl-1-(morpholin-4-yl)-ethyl, (2,6-dimethyl-morpholin-4-yl)-methyl, 2,4-dioxo-imidazolidin-1-yl-methyl, 2,5-dioxo-imidazolidin-1-yl-methyl, 2,5- dioxo-3-methyl-imidazolidin-1-yl-methyl, 2,4-dioxo-3-methyl-imidazolidin-1-yl-methyl, 2-oxo-3-methyl-imidazolidin-1-yl-methyl, 2-oxo-3-cyclopropyl-imidazolidin-1-yl-methyl, 2,5-dioxo-pyrrolidin-1-yl-methyl, N-acetyl-pyrrolidin-3-yl or 4-acetyl-piperazin-1-yl; phenyl or 6-membered heteroaryl having 1 or 2 ring nitrogen atoms (especially pyridinyl or pyrimidinyl; especially pyridin-3-yl or pyrimidin-4-yl); the phenyl or 6-membered heteroaryl is independently unsubstituted or contains one C 1-3 -Alkyl (especially methyl) or C 1-3 -Alkoxy (especially meth phenyl or 6-membered heteroaryl having 1 or 2 ring nitrogen atoms, substituted by (oxy); [In particular, the phenyl or 6-membered heteroaryl is 3-methoxy-phenyl, pyridin-3-yl or 6-methyl-pyrimidin-4-yl.] -- Pyrazolyl-C 1-3 - alkyl (especially 2-(pyrazol-1-yl)-ethyl); -- C 1-3 -Alkyl-sulfonyl-C 1-3 - alkyl (especially methyl-sulfonyl-methyl); -- 3-hydroxymethyl-bicyclo[1.1.1]pent-1-yl; 7-oxa-bicyclo[2.2.1]hept-2-yl; and -- 6-oxa-spiro[2.5]oct-1-yl; a 5- or 6-membered heteroaryl independently selected from 5-oxo-4-oxa-6-azaspiro[2.4]hept-6-yl, 5-aza-spiro[2.4]heptan-6-one-5yl, 2,2-dimethyl-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl, 2-cyclopropyl-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl, 2-oxo-1-oxa-3-azaspiro[4.4]non-3-yl, 8,8-difluoro-2-oxo-1-oxa-3-azaspiro[4.5]dec-3-yl or 8-oxo-7-oxa-9-azadispiro[3.1.4.1]undec-9-yl; 7-aza-bicyclo[2.2.1]hept-7-yl, 2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl, 6-oxa-3-aza-bicyclo[3.1.1]hept-3-yl or 8-oxa-3-azabicyclo[3.2.1]oct-3-yl; 5-oxo-6-azaspiro[3.4]oct-6-yl, 3-oxo-2-azaspiro[4.4]non-2-yl, 1-oxo-3-aza-spiro[4.5]decan-2-on-3-yl, 1-oxo-2-azaspiro[4.5]dec-2-yl, 1-oxo-8-oxa-2-azaspiro[4.5]dec-2-yl, 3-oxo-8-oxa-2-azaspiro[4.5]dec-2-yl or 4-oxo-hexahydro-5H-furo[2, 3-c]pyrrol-5-yl; - 3-(7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)propyl or 3-(8-hydroxy-5,6,7,8-tetrahydroquinolin-8-yl)propyl); - 6-acetyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-2-yl; - 6-acetyl-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl;- 2-(6,7-dihydro-5H-[1]pyridin(pyrindin)-7-ol)-ethyl; - 2-(8-hydroxy-5,6,7,8-tetrahydro-quinolin-8-yl)-ethyl; - 7,8-dihydro-5H-[1,6]naphthyridin-6-yl; - 2,3-dihydro-isoindol-1-on-2-yl; 7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl; and - 6-acetyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-2-yl; are independently selected from; B represents phenyl unsubstituted or substituted with 1, 2 or 3 substituents, and if a first substituent is present (particularly at the para position relative to the point of attachment of B to the remainder of the molecule), said first substituent is - halogens (especially bromine); - C 1-5 - alkyl (especially methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, 1-ethylpropyl, 2,2-dimethylpropyl, 1,1-dimethylpropyl; especially methyl, ethyl or isopropyl; especially isopropyl); - C 2-4 -alkenyl (especially prop-1-en-2-yl); - C 1-3 alkoxy (especially methoxy, ethoxy or isopropoxy); - C 1-3 -Alkoxy-C 1-4- alkyl (especially 3-methoxy-propyl); - C 1-4 -fluoroalkyl (in particular trifluoromethyl, 1-methyl-1-fluoro-ethyl, 1,1-difluoro-ethyl, 2,2,2-trifluoro-ethyl, 1,1-dimethyl-1-trifluoromethyl-methyl, 1,1,2,2,2-pentafluoro-ethyl or 1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl); - C 3-5 -cycloalkyl (especially cyclopropyl or cyclobutyl), which are independently unsubstituted or (especially those C 3-5 -One C at the attachment point of the cycloalkyl 1-3 -Alkyl (especially methyl) or C 1-3 -substituted by fluoroalkyl (especially trifluoromethyl), 3-5 -cycloalkyl;- -SF5; - bicyclo[1.1.1]pent-1-yl; - C 3-5 -cycloalkoxy (especially cyclopropoxy or cyclobutoxy); and - C 1-3 - fluoroalkoxy (especially trifluoromethoxy); Selected from; The remaining substituents of B, if present, are selected from halogen (especially fluorine or chlorine; especially, the remaining substituent is meta to the point of attachment of B to the remainder of the molecule) and C 1-3 - independently selected from alkyl (especially methyl); or B represents benzothiophenyl (especially 1-benzothiophenyl; especially 1-benzothiophen-5-yl) or naphthalenyl (especially naphthalen-2-yl); [In particular, such B may be phenyl, 4-bromo-phenyl, 4-methyl-phenyl, 4-ethyl-phenyl, 4-propyl-phenyl, 4-isopropyl-phenyl, 4-butyl-phenyl, 4-isobutyl-phenyl, 4-tert-butyl-phenyl, 4-(1-ethyl-propyl)-phenyl, 4-(1,1-dimethyl-propyl)-phenyl, 4- (2,2-dimethyl-propyl)-phenyl, 3-chloro-4-isopropyl-phenyl, 3-fluoro-4-isopropyl-phenyl, 3,5-difluoro-4-isopropyl-phenyl, 3-methyl-4-isopropyl-phenyl, 4-(prop-1-en-2-yl)-phenyl, 4-cyclopropyl-phenyl, 4-methoxy-phenyl, 4-ethoxy-phenyl, 4-isopropoxy-phenyl, 4-trifluoromethyl-phenyl, 4-(1-methyl-1-fluoro-ethyl)-phenyl, 4-(1,1-difluoro-ethyl)-phenyl, 4-(2,2,2-trifluoro-ethyl)-phenyl, 4-(1,1-dimethyl-1-trifluoromethyl-methyl)-phenyl, 4-( 1,1,2,2,2-pentafluoro-ethyl)-phenyl, 4-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-phenyl, 4-trifluoromethoxy-phenyl, 4-(1-methyl-cyclopropyl)-phenyl, 4-cyclobutyl-phenyl, 4-(pentafluoro-16-sulfanyl)-phenyl, 4-(bicyclo[1.1.1]pent-1-yl)-phenyl, 4-cyclopropoxy-phenyl, 4-cyclobutoxy-phenyl, 4-(trifluoromethoxy)-phenyl, 4-(3-methoxy-propyl)-phenyl, 4-(1-trifluoromethyl-cyclopropyl)-phenyl, naphthalen-2-yl or 1-benzothiophen-5-yl. R 1 is C 1-3 - represents alkyl (especially methyl or ethyl), cyano or halogen (especially fluorine); R 2 is C 1-4 - alkyl (especially methyl, ethyl, n-propyl, isopropyl, tert-butyl or isobutyl), C 3-5 -cycloalkyl (especially cyclopropyl or cyclobutyl), C 3-5 -Cycloalkyl-C 1-3 -Alkyl (especially cyclopropyl-methyl), hydroxy-C 1-3 -Alkyl (especially 2-hydroxy-ethyl), C 1-3 -Alkoxy-C 1-3 -alkyl (especially 2-methoxy-ethyl) or C1-3 -fluoroalkyl (in particular 2,2-difluoro-ethyl, 3,3,3-trifluoro-propyl or 2-fluoroethyl).

[0030] The definitions set forth herein are uniformly applied to compounds of formula (I) defined in any one of embodiments 1) to 53) and apply mutatis mutandis throughout the specification and claims unless a broader or narrower definition is provided by a specific definition. It is understood that any definition or preferred definition of a term may independently (and together with) define and replace each term in any or all other terms or preferred definitions defined herein. Unless expressly defined otherwise in each embodiment or claim, groups defined herein are unsubstituted.

[0031] The term "halogen", used alone or in combination, means fluorine, chlorine, bromine or iodine; especially fluorine or chlorine; especially fluorine.

[0032] The term "cyano," used alone or in combination, refers to the group --CN.

[0033] The term "oxy", used alone or in combination, refers to the group --O--.

[0034] The term "oxo", used alone or in combination, refers to the group =0.

[0035] The term "amino", used alone or in combination, refers to the group -NH2.

[0036] The term "amino-carbonyl," used alone or in combination, refers to the group -C(=O)-NH2.

[0037] The term "amino-carbonyl-oxy", used alone or in combination, refers to the group -OC(=O)-NH, where the substituents on the amino group may be further defined. For example, N-(C 1-3 -alkyl)-amino-carbonyl-oxy is an amino-carbonyl-oxy group in which the amino group is C 1-3 -alkyl group This means that the C 1-3 -Alkyl groups are defined below. N-(C 1-3 An example of an N-(isopropyl)-amino-carbonyl-oxy is N-(isopropyl)-amino-carbonyl-oxy.

[0038] The term "alkyl," used alone or in combination, means a straight or branched saturated hydrocarbon chain radical having from 1 to 6 carbon atoms. x-y The term "alkyl" (x and y are each integers) refers to an alkyl group as defined above having x to y carbon atoms. x-y When an -alkyl group is used in combination with another substituent, the term also applies when that substituent is C x-y -means that the group is attached to the rest of the molecule through an alkyl group. For example, C 1-6 -Alkyl groups have 1 to 6 carbon atoms. 1-6 Examples of alkyl groups are C 1-4 The alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl and isobutyl, as well as n-pentyl and isopentyl. 1 C used in 1-3 A preferred example of -alkyl is methyl. 2 C used in 1-4 Preferred examples of -alkyl are ethyl or methyl; most preferably methyl. 1-5 A particularly preferred example of -alkyl is isopropyl.

[0039] The term "amino-alkyl", used alone or in combination, refers to an alkyl group as defined above in which one hydrogen atom has been replaced by an amino group. x-y The term "amino-alkyl" (x and y are each integers), used alone or in combination, refers to an amino-alkyl group as defined above, where the alkyl group has x to y carbon atoms. For example, amino-C 1-4 -alkyl is an amino-alkyl group having 1 to 4 carbon atoms. 1-4 Examples of -alkyl groups are amino-methyl, 1-amino-ethyl, 2-amino-ethyl and 2-amino-2,2-dimethyl-ethyl.

[0040] The term "hydroxyalkyl," used alone or in combination, refers to an alkyl group, as defined above, in which one hydrogen atom has been replaced with a hydroxy group. x-y The term "hydroxy-alkyl" (x and y are each integers), used alone or in combination, refers to a hydroxyalkyl group as defined above, where the alkyl group has x to y carbon atoms. For example, hydroxy-C 1-6 -Alkyl groups are hydroxyalkyl groups as defined above having 1 to 6 carbon atoms.

[0041] The term "hydroxy-alkyl" means an alkyl group as defined above in which one hydrogen atom has been replaced with a hydroxy group.

[0042] The term "oxetanyl-alkyl", used alone or in combination, means an alkyl group as defined above in which one hydrogen atom has been replaced by an oxetanyl group; in particular, such an oxetanyl group is oxetan-3-yl. x-yThe term "oxetanyl-alkyl" (x and y are each integers), used alone or in combination, refers to an oxetanyl-alkyl group as defined above, where the alkyl group has x to y carbon atoms. For example, oxetanyl-C 1-3 The -alkyl group is an oxetanyl-alkyl group as defined above having 1 to 3 carbon atoms.

[0043] The term "pyridinyl-alkyl", used alone or in combination, refers to an alkyl group as defined above in which one hydrogen atom has been replaced by a pyridinyl group; in particular, such a pyridinyl group is pyridin-2-yl. x-y The term "-alkyl" (x and y are each integers) is used alone. Used alone or in combination, refers to a pyridinyl-alkyl group as defined above, where the alkyl group has x to y carbon atoms. For example, pyridinyl-C 1-3 -alkyl group is a pyridinyl-alkyl group as defined above having 1 to 3 carbon atoms.

[0044] The term "pyrazolyl-alkyl", used alone or in combination, means an alkyl group as defined above in which one hydrogen atom has been replaced by a pyrazolyl group; in particular, such a pyrazolyl group is pyrazol-1-yl. x-y The term "pyrazolyl-alkyl" (x and y are each integers), used alone or in combination, refers to a pyrazolyl-alkyl group as defined above, wherein the alkyl group has x to y carbon atoms. For example, pyrazolyl-C 1-3 -alkyl group is a pyrazolyl-alkyl group as defined above having 1 to 3 carbon atoms.

[0045] The term "benzyl-oxy-alkyl", used alone or in combination, means an alkyl group as defined above in which one hydrogen atom has been replaced by the group C6H5-CH2-O-. x-y The term "benzyl-oxy-alkyl" (x and y are each integers), used alone or in combination, refers to a benzyl-oxy-alkyl group as defined above, wherein the alkyl group has x to y carbon atoms. For example, benzyl-oxy-C 1-3 -alkyl group is a benzyl-oxy-alkyl group as defined above having 1 to 3 carbon atoms.

[0046] The term "alkyl-carbonyl," used alone or in combination, refers to an alkyl group as defined above in which one hydrogen atom has been replaced by the group -C(=O)-. x-y The term "-alkyl-carbonyl" (x and y are each integers), used alone or in combination, refers to an alkyl-carbonyl group as defined above, where the alkyl group has x to y carbon atoms. For example, C 1-3 -Alkyl-carbonyl group is an alkyl-carbonyl group as defined above having 1 to 3 carbon atoms.

[0047] The term "amino-carbonyl-oxy," used alone or in combination, refers to the group H2N-C(=O)-O-, where the substituents on the amino group may be further defined.

[0048] The term "(hydroxy-alkyl)-carbonyl", used alone or in combination, refers to a hydroxy-alkyl group as defined above, in which one hydrogen atom of the alkyl has been replaced by a group -C(=O)-. x-yThe term (hydroxy-C alkyl)-carbonyl (x and y are each integers), used alone or in combination, refers to a (hydroxy-C alkyl)-carbonyl group as defined above, wherein the alkyl group has x to y carbon atoms. For example, (hydroxy-C alkyl)-carbonyl 1-3 A (hydroxy-alkyl)-carbonyl group is a (hydroxy-alkyl)-carbonyl group as defined above having 1 to 3 carbon atoms.

[0049] The term "alkyl-sulfonyl-alkyl", used alone or in combination, means an alkyl group as defined above in which one hydrogen atom is replaced by an alkyl-sulfonyl group, and the alkyl portion of the alkyl-sulfonyl is as defined above. x1-y1 -Alkyl-sulfonyl-C x2-y2 The term "-alkyl" (x1, x2, y1 and y2 are each an integer), used alone or in combination, denotes an alkyl-sulfonyl-alkyl group as defined above, wherein the alkyl groups have, independently of one another, from x1 to y1 and from x2 to y2 carbon atoms. For example, C 1-3 -Alkyl-sulfonyl-C 1-3 -Alkyl is an alkyl-sulfonyl-alkyl group as defined above wherein both alkyl portions independently have from 1 to 3 carbon atoms.

[0050] The term "fluoroalkyl", used alone or in combination, refers to an alkyl group as defined above in which one or more, and in some cases all, hydrogen atoms have been replaced by fluorine. x-y The term "fluoroalkyl" (x and y are each integers) refers to a fluoroalkyl group as defined above having x to y carbon atoms. For example, C 1-3 -Fluoroalkyl groups have 1 to 3 carbon atoms and 1 to 7 hydrogen atoms are replaced by fluorine. 1-3Examples of 2-fluoroalkyl groups are trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl and 2,2,2-trifluoroethyl.

[0051] The term "alkenyl," used alone or in combination, refers to a straight or branched hydrocarbon chain alkyl group, as defined above, wherein the chain contains one double bond. x-y The term "-alkenyl" (x and y are each integers), used alone or in combination, refers to an alkenyl group as defined above having x to y carbon atoms. For example, C 3-5 The term -alkenyl, used alone or in combination, refers to an alkenyl group as defined above having 3 to 5 carbon atoms. 3-5 Examples of alkenyl groups are -CH=CH2, -CH=CH2-CH3, -CH2-CH=CH2 and -C(CH3)=CH2.

[0052] The term "alkylene," used alone or in combination, means a saturated, branched, or straight-chain divalent aliphatic hydrocarbon group deemed to be derived from an alkane by the removal of two hydrogen atoms. x-y The term "-alkylene" (x and y are each integers), used alone or in combination, refers to an alkylene group as defined above having x to y carbon atoms. For example, C 1-2 -Alkylene is an alkylene group as defined above having 1 or 2 carbon atoms. 1-2 Examples of alkylene groups are -CH2-, -(CH2)2- and -CH(CH3)-.

[0053] The term "hydroxy-alkylene," used alone or in combination, means an alkylene group as defined above in which one hydrogen atom has been replaced with a hydroxy group. x-yThe term "hydroxy-alkylene" (x and y are each integers), used alone or in combination, refers to a hydroxy-alkylene group as defined above having x to y carbon atoms. For example, hydroxy-C 1-2 -Alkylene is a hydroxy-alkylene group as defined above having 1 or 2 carbon atoms. 1-2 Examples of alkylene groups are -CH(OH)-, -CH(OH)-CH2- and -C(OH)(CH3)-; preferably -CH(OH)-.

[0054] Oxy-C 1-2 The term -alkylene, when used alone or in combination, refers to C 1-2 - alkylene is as defined above, the group -OC 1-2 -alkylene. Preferably, oxy-C 1-2 -Alkylene is the group -O-CH2-.

[0055] The term "alkoxy", used alone or in combination, refers to an alkyl group as defined above in which one hydrogen atom has been replaced with -O-. x-y The term "-alkoxy" (x and y are each integers) may be used alone. When used alone or in combination, the alkoxy group refers to an alkoxy group as defined above having x to y carbon atoms. For example, C 1-3 -alkoxy group is an alkoxy group as defined above having 1 to 3 carbon atoms. 1-3 Examples of -alkoxy groups are methoxy, ethoxy, n-propoxy or isopropoxy; in particular methoxy.

[0056] The term "alkoxy-alkyl", used alone or in combination, refers to an alkyl group as defined above in which one hydrogen atom is replaced by an alkoxy group as defined above. x1-y1 -Alkoxy-C x2-y2The term "-alkyl" (x1, x2, y1 and y2 are each an integer), used alone or in combination, refers to an alkoxy-alkyl group as defined above, in which the two hydrocarbon moieties of said group have, independently of each other, from x1 to y1 and from x2 to y2 carbon atoms. For example, C 1-3 -Alkoxy-C 1-3 -Alkyl is an alkoxy-alkyl group as defined above having 1 to 3 carbon atoms in each of the two hydrocarbon portions of said group independently. 1-3 -Alkoxy-C 1-3 Examples of -alkyl groups are methoxy-methyl or ethoxy-ethyl.

[0057] The term "fluoroalkoxy", used alone or in combination, means an alkoxy group, as defined above, having 1 to 3 carbon atoms in which one or more (and in some cases all) hydrogen atoms have been replaced by fluorine. x-y The term "fluoroalkoxy" (x and y are each integers) refers to a fluoroalkoxy group as defined above having x to y carbon atoms. For example, C 1-3 -Fluoroalkoxy groups have 1 to 3 carbon atoms and 1 to 7 hydrogen atoms are replaced by fluorine. 1-3 Examples of -fluoroalkoxy groups include trifluoromethoxy, difluoromethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy and 2,2,2-trifluoroethoxy.

[0058] "C 1-4 The term "-alkoxy-carbonyl" means an alkoxy group, as defined above, attached to a carbonyl group (i.e., C 1-4 -alkoxy-C(=O)-).

[0059] The term "cycloalkyl," used alone or in combination, means a saturated monocyclic hydrocarbon ring having 3 to 7 carbon atoms (preferably 3 to 6 carbon atoms). x-yThe term "-cycloalkyl" (x and y are each integers) means a saturated monocyclic hydrocarbon ring having x to y carbon atoms. For example, C 3-6 -Cycloalkyl groups have 3 to 6 carbon atoms. 3-6 Examples of cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

[0060] Similarly, "C x-y The term "-heterocyclyl" means a cycloalkyl group as defined above having x to y ring atoms, in which one or more ring carbon atoms in the group are replaced by a heteroatom as expressly defined.

[0061] The term "cycloalkenyl," whether used alone or in combination, refers to an unsaturated monocyclic hydrocarbon ring having one ring carbon-carbon double bond and having 4 to 6 (preferably 5) carbon atoms. x-y The term "-cycloalkenyl" (x and y are each integers) refers to a cycloalkenyl ring as defined above having x to y carbon atoms. For example, C 4-6 -Cycloalkenyl groups have 4 to 6 carbon atoms. 4-6 Examples of -cycloalkenyl groups are cyclobutenyl, cyclopentenyl and cyclohexenyl; in particular cyclopentenyl; and especially cyclopent-1-en-1-yl.

[0062] The term "cycloalkoxy", used alone or in combination, refers to a cycloalkyl group as defined above in which one hydrogen atom has been replaced with -O-. x-y The term "-cycloalkoxy" (x and y are each integers), used alone or in combination, refers to a cycloalkoxy group as defined above having x to y carbon atoms. For example, C 3-5 -Cycloalkoxy group is a cycloalkoxy group as defined above having 3 to 5 carbon atoms.3-5 Examples of cycloalkoxy groups are cyclopropoxy, cyclobutoxy or cyclopentoxy.

[0063] The term "cycloalkyl-sulfonyl," used alone or in combination, refers to a cycloalkyl group as defined above in which one hydrogen atom has been replaced with a sulfonyl group (i.e., -S(=O)2-). x-y The term "-cycloalkyl-sulfonyl" (x and y are each integers) refers to a cycloalkyl group having x to y carbon atoms. For example, C 3-5 -Cycloalkyl-sulfonyl groups are 3 to 5 C 3-5 Examples of -cycloalkyl-sulfonyl groups are cyclopropyl-sulfonyl, cyclobutyl-sulfonyl and cyclopentyl-sulfonyl.

[0064] The term "cycloalkyl-alkyl", used alone or in combination, refers to an alkyl group as defined above in which one hydrogen atom is replaced by a cycloalkyl group as defined above. x1-y1 -Cycloalkyl-C x2-y2 The term "cycloalkyl" (x1, x2, y1 and y2 are each an integer), used alone or in combination, refers to a cycloalkyl-alkyl group as defined above, in which the two hydrocarbon moieties of said group independently have from x1 to y1 and from x2 to y2 carbon atoms. For example, C 3-5 -Cycloalkyl-C 1-3 -Alkyl is a cycloalkyl-alkyl group as defined above having 3 to 5 carbon atoms inclusively in the cycloalkyl portion and 1 to 3 carbon atoms inclusively in the alkyl portion. 3-5 -Cycloalkyl-C 1-3 Examples of -alkyl groups are cyclopropyl-methyl or cyclopropyl-ethyl.

[0065] "C fused with pyridine ring 3-6The term "-cycloalkyl", used alone or in combination, refers to a C-cycloalkyl group, as defined above, fused to a pyridine ring. 3-6 -cycloalkyl group. C fused with a pyridine ring 3-6 Examples of -cycloalkyl are the following groups:

[0066] [ka]

[0067] Preferably, from left to right, it is the last two groups. 3-6 -cycloalkyl" the point of attachment of the substituent to the rest of the molecule is the C 3-6 - in the cycloalkyl moiety and fused pyrimidine It is assumed that this is not present in the gin ring.

[0068] The term "hydroxy-azetidinyl," used alone or in combination, refers to an azetidinyl group substituted with a hydroxy group. Preferably, the term hydroxy-azetidinyl refers to 3-hydroxy-azetidin-3-yl.

[0069] The term "heteroaryl," used alone or in combination, refers to a 5- to 10-membered monocyclic or bicyclic aromatic ring having from 1 to a maximum of 4 heteroatoms (particularly from 1 to a maximum of 3 heteroatoms), each independently selected from oxygen, nitrogen, and sulfur. Examples of such heteroaryl groups are furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzoxadiazolyl, benzothiadiazolyl, quinolinyl, isoquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyrrolopyridinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyrrolopyrazinyl, imidazopyridinyl, imidazopyridazinyl and imidazothiazolyl. The above heteroaryl / heteroarylene groups are unsubstituted or substituted as explicitly defined.

[0070] The term "5- to 6-membered heteroaryl," whether used alone or in combination, means a 5- to 6-membered monocyclic aromatic ring having from 1 to a maximum of 4 ring heteroatoms (preferably from 1 to a maximum of 3 ring heteroatoms), each ring heteroatom independently selected from oxygen, nitrogen, and sulfur. Examples of 5-membered groups are 5-membered heteroaryl groups such as furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, etc.; in particular, pyrazolyl, triazolyl, oxazolyl, thiazolyl, oxadiazolyl; especially, pyrazol-1-yl, 1,2,3-triazol-1-yl, oxazol-2-yl, thiazol-2-yl, 1,2,4-oxadiazol-5-yl, or 1,2,4-oxadiazol-3-yl; most preferably, 1,2,4-oxadiazol-5-yl, or 1,2,4-oxadiazol-3-yl. Examples of 6-membered heteroaryl groups are pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, etc. The above heteroaryl groups are unsubstituted or substituted as explicitly defined.

[0071] With respect to a 5-membered heteroaryl group substituted with one substituent, substitution at the 3-position of the 5-membered heteroaryl relative to the point of attachment to A is intended to mean that said substituent at the 3-position and the point of attachment to A are in a 1,3-configuration relative to each other. Preferred examples of such 5-membered heteroaryl groups substituted with one substituent at the 3-position of the 5-membered heteroaryl relative to the point of attachment to A are selected from the group consisting of:

[0072] [ka]

[0073] In the formula, one asterisk ( * ) indicates the point of attachment to the substituent, and two asterisks ( **) indicates the point of attachment to A. Particularly preferred are the last two 5-membered heteroaryl groups (from left to right).

[0074] Further aspects of the present invention are described below: 2) One embodiment relates to compounds according to embodiment 1), in which A represents pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl (particularly pyridazinyl or pyridinyl; especially pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl, pyrazin-2-yl or pyridazin-4-yl), and A is independently unsubstituted or substituted by 1, 2 or 3 substituents (particularly substituted by 1 or 2 substituents in the meta and / or para position of A relative to the point of attachment of A to the rest of the molecule; especially substituted by 1 substituent in the meta position of A relative to the point of attachment of A to the rest of the molecule), said substituents, if present, being as defined in embodiment 1).

[0075] 3) Another embodiment relates to compounds according to embodiment 1), in which A represents pyridin-3-yl, pyridin-4-yl or pyridazin-4-yl (particularly pyridin-3-yl or pyridazin-4-yl), and A is independently unsubstituted or substituted by 1, 2 or 3 substituents (particularly substituted by 1 or 2 substituents in the meta and / or para position of A relative to the point of attachment of A to the rest of the molecule; especially substituted by 1 substituent in the meta position of A relative to the point of attachment of A to the rest of the molecule), said substituents, if present, being as defined in embodiment 1).

[0076] In a subembodiment, A is independently - unsubstituted; - substituted by one substituent (especially in the meta position of A relative to the point of attachment of A to the rest of the molecule), said substituent being as defined in embodiment 1); or - is substituted by two substituents, the first substituent (particularly in the meta position of A relative to the point of attachment of A to the rest of the molecule) being selected from the substituents defined in embodiment 1) (particularly excluding halogen (especially fluorine) or cyano); and the second substituent (particularly in the para position of A relative to the point of attachment of A to the rest of the molecule) being selected from halogen (especially fluorine) and cyano.

[0077] 4) Another embodiment relates to compounds according to embodiment 1), in which A represents pyridin-3-yl, pyridin-4-yl or pyridazin-4-yl (in particular pyridin-3-yl or pyridazin-4-yl; especially pyridin-3-yl), and A is substituted (in particular in the meta position of A relative to the point of attachment of A to the rest of the molecule) by one substituent, said substituent being as defined in embodiment 1).

[0078] 5) Another embodiment is that at least one of the substituents of A / A is - as defined in aspect 1) - OR O2 ; The present invention relates to a compound according to any one of embodiments 1) to 4), wherein

[0079] 6) Another embodiment is that at least one of the substituents of A / A is - -OR O2 (-- R O2 teeth, --- C 1-4 - alkyl (especially isopropyl, sec-butyl or isobutyl); --- C 2-5 -alkyl, with one hydroxy or C 1-3 -C substituted by alkoxy (especially methoxy) 2-5 - alkyl; [Especially, such C 2-5 -Alkyl represents 2-hydroxy-ethyl, 3-hydroxy-propyl, 2-hydroxy-2-methyl-propyl, 3-hydroxy-3-methyl-butyl or 2-methoxy-ethyl. --- -L 2 -CY 2 (---- -L 2 - independently represents a bond (i.e., CY 2 is directly bonded to the rest of the molecule; ---- CY 2 are, independently, ----- C 3-6 - cycloalkyl (in particular oxetanyl, cyclopentyl or cyclohexyl) in which one carbon ring atom is optionally replaced by one oxygen atom; 3-6 -cycloalkyl is unsubstituted or substituted by 1 or 2 substituents, said substituents being C 1-3 -Alkyl (especially methyl), hydroxy, fluoro, oxo, C 1-3 -Alkyl-carbonyl (especially acetyl) and C 1-3 -alkoxy (especially methoxy), C 3-6 -cycloalkyl; ----- represents chromanyl (especially chroman-6-yl); ) wherein R represents an integer of 1 to 3.

[0080] [Especially, the -L 2 -CY 2 represents 2-(benzyl-oxy)-ethyl, 2,2-dimethyl-cyclopentyl, 3,3-difluoro-cyclopentyl, 3-methoxy-cyclopentyl, cyclohexyl, 4-hydroxy-cyclohexyl, 4-methyl-4-hydroxy-cyclohexyl, 4-oxo-cyclohexyl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl, tetrahydropyran-4-yl-methyl or chroman-6-yl. [Especially, such -OR O2represents isopropoxy, isobutoxy, sec-butoxy, 2-(benzyloxy)-ethoxy, 2-methoxy-ethoxy, 3-hydroxy-propoxy, 2-hydroxy-2-methyl-propoxy, 2-hydroxy-ethoxy, 3-hydroxy-3-methyl-butoxy, 2,2-dimethyl-cyclopentyl-oxy, 3,3-difluoro-cyclopentyl-oxy, cyclohexyl-oxy, 4-hydroxy-cyclohexyl-oxy, 4-methyl-4-hydroxy-cyclohexyl-oxy, 4-oxo-cyclohexyl-oxy, tetrahydrofuran-3-yl-oxy, tetrahydropyran-4-yl-oxy, tetrahydropyran-4-yl-methoxy, 3-methoxy-cyclopentyl-oxy or chroman-6-yl-oxy.

[0081] 7) Another embodiment is that at least one of the substituents of A / A is - C as defined in aspect 1) 3-5 - alkyl; The present invention relates to a compound according to any one of embodiments 1) to 4), wherein

[0082] 8) Another embodiment is that at least one of the substituents of A / A is - C 3-5 - alkyl (especially n-propyl, n-butyl or n-pentyl), and hydroxy and R A1 and any of the substituents is substituted by the C 3-5 - in the 3-position relative to the point of attachment of the alkyl; -- R A1 but, --- unsubstituted or containing one fluorine (especially 3-fluoro-phenyl) or C1 -3 -phenyl substituted by alkoxy (in particular 2-methoxy-phenyl or 4-methoxy-phenyl); --- 6-membered heteroaryl having 1 or 2 ring nitrogen heteroatoms (especially pyridin-2-yl, pyridin-3-yl, pyrimidin-2-yl, pyrazin-2-yl or pyrimidin-4-yl), wherein the 5- or 6-membered heteroaryl is independently unsubstituted or substituted by 1 or 2 substituents, if present, which are selected from the group consisting of C 1-3 -Alkyl (especially methyl), C 3-5 -cycloalkyl (especially cyclopropyl) or C 1-3 -6-membered heteroaryl independently selected from alkoxy (especially methoxy); C represents 3-5 - alkyl; or [Especially, such C 3-5 -alkyl is 3-hydroxy-3-phenyl-propyl, 3-hydroxy-3-phenyl-butyl, 3-hydroxy-3-(3-fluoro-phenyl)-butyl, 3-hydroxy-3-(2-methoxy-phenyl)-butyl, 3-hydroxy-3-(4-methoxy-phenyl)-butyl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-butyl, 3-hydroxy-3-(5-methyl-pyridin-3-yl)-butyl, 3-hydroxy-3-(pyridin-2-yl)-butyl, 3-hydroxy-3-(6-methyl-pyridin-2-yl)-butyl, 3-hydroxy-3-(pyrimidin-2-yl)-butyl, 3-hydroxy-3-(6-methoxy-pyrimidin-4-yl)-butyl, 3-hydroxy-3-(6-methyl-pyrimidin-4-yl)-pentyl, 3-hydroxy-3-(2-methyl-pyrimidin-4-yl)-butyl, 3-hydroxy-3-(5-methyl-pyrazin-2-yl)-butyl, 3-hydroxy-3-(pyridin-2-yl)-pentyl or 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-pentyl. It relates to compounds according to embodiment 7).

[0083] 9) Another embodiment is that at least one of the substituents of A / A is -NR N3 R N4 (RN3 and R N4 together with the nitrogen to which they are attached form a heterocycle as defined in embodiment 1); The present invention relates to a compound according to any one of embodiments 1) to 4), wherein

[0084] 10) Another embodiment is where at least one of the substituents of A / A is: -NR N3 R N4 (-- R N3 and R N4 together with the nitrogen to which they are attached form a 4- to 6-membered (particularly 5- to 6-membered) heterocycle, and the ring members necessary to complete the heterocycle are -CH2-, -O-, -(C=O)-, -CHR X - and -C(R Y )2-; the heterocycle has no more than one ring member independently selected from the group consisting of -O- and -(C=O)-; the heterocycle is -CHR X -; the heterocycle has no more than two ring members selected from the group consisting of -C(R Y )2-; R X each independently represents fluorine, methyl, isopropyl, hydroxy, trifluoromethyl, cyclopropyl, phenyl, or 3-methyl-1,2,4-oxadiazol-5-yl; R Y independently represent fluorine, hydroxy, cyclopropyl, methyl or trifluoromethyl. The compound according to embodiment 9) is

[0085] [Especially, such -NR N3 R N4 is pyrrolidinyl; 2-pyrrolidonyl; oxazolidinonyl (especially 1,3-oxazolidin-2-one-3-yl); piperidinyl; or R X and R Y and morpholinyl optionally substituted independently with 1 or 2 substituents independently selected from the group consisting of:

[0086] [Especially, such -NRN3 R N4 are pyrrolidin-1-yl, 3-fluoro-pyrrolidin-1-yl, 3,3-difluoro-pyrrolidin-1-yl, 3,4-difluoro-pyrrolidin-1-yl, 3-isopropyl-pyrrolidin-1-yl, 3,3-dimethyl-pyrrolidin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 2-methyl-pyrrolidin-1-yl, 3-hydroxy-3-methyl-pyrrolidin-1-yl, 3-hydroxy-3-trifluoromethyl-pyrrolidin-1-yl, 3-trifluoromethyl-pyrrolidin-1-yl pyridin-1-yl, morpholin-4-yl, 3-(tetrahydropyran-4-yl)-pyrrolidin-2-one-1-yl, pyrrolidin-2-one-1-yl, 4-phenyl-pyrrolidin-2-one-1-yl, 4-(pyridin-2-yl)-pyrrolidin-2-one-1-yl, 4-(6-methyl-pyridin-3-yl)-pyrrolidin-2-one-1-yl, 4-(2-isopropyl-pyrimidin-4-yl)-pyrrolidin-2-one-1-yl, 4-(6-isopropyl-pyridin-2-yl) -pyrrolidin-2-one-1-yl, 4-(6-trifluoromethyl-pyridin-3-yl)-pyrrolidin-2-one-1-yl, 4-methyl-pyrrolidin-2-one-1-yl, 4-isopropyl-pyrrolidin-2-one-1-yl, 3-isopropyl-pyrrolidin-2-one-1-yl, 3,3-dimethyl-pyrrolidin-2-one-1-yl, 4,4-dimethyl-pyrrolidin-2-one-1-yl, 3-(piperidin-4-yl)-pyrrolidin-2-one-1-yl, 4-(6-isopropyl)-pyrrolidin-2-one-1-yl, 4-(3-methyl-1,2,4-oxadiazol-5-yl)-pyrrolidin-1-yl or 3-(phenyl)-pyrrolidin-1-yl. 11) Another embodiment is where at least one of the substituents of A / A is: - a 5- or 6-membered heteroaryl as defined in embodiment 1), in which the above-mentioned substituents of said 5- or 6-membered heteroaryl, if present, are -- C as defined in aspect 1) 1-4 - alkyl; The present invention relates to a compound according to any one of embodiments 1) to 4), which is independently selected from:

[0087] 12) Another embodiment is where at least one of the substituents of A / A is: - 5- or 6-membered heteroaryl having 1 to 3 (especially 2 or 3; especially 3) ring heteroatoms independently selected from nitrogen, oxygen and sulfur (especially pyrazolyl, oxazolyl, thiazolyl, oxadiazolyl, pyrimidinyl or pyridinyl; especially pyrazol-1-yl, 1H-1,2,3-triazol-1-yl, oxazol-2-yl, thiazol-2-yl, 1,2,4-oxadiazol-5-yl, 1,2,4-oxadiazol-3-yl, pyrimidin-2-yl or pyridinyl). lysin-2-yl; especially 1,2,4-oxadiazol-5-yl or 1,2,4-oxadiazol-3-yl; especially 1,2,4-oxadiazol-3-yl); wherein the 5- or 6-membered heteroaryl is independently unsubstituted or substituted with 1, 2 or 3 substituents (particularly substituted with 1 substituent; especially substituted with 1 substituent at the 3-position relative to the point of attachment of the 5- or 6-membered heteroaryl to A), and wherein the substituent, if present, is -- C 1-4 - alkyl (in particular methyl, ethyl, propyl, isopropyl or tert-butyl), --- Is it unsubstituted; --- 1 piece, ---- Hydroxy; or ---- C 1-4 -substituted by alkoxy (especially methoxy and tert-butoxy); or [Especially, such C 1-4 -Alkyl is methyl, isopropyl, hydroxymethyl, 1 -hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, 2-hydroxy-1,1-dimethyl-ethyl, methoxy-methyl, 2-methoxy-ethyl, 1-methoxy-1-methyl-ethyl, 2-methoxy-2-methyl-propyl, 2-methoxy-1,1-dimethyl-ethyl or tert-butoxy-methyl; in particular, such C 1-4 -Alkyl represents 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl or 2-hydroxy-1,1-dimethyl-ethyl. --- substituted by two substituents, one of which is hydroxy and the other of which is trifluoromethyl; or two of which are hydroxy; --- substituted with two or three substituents, two of which are fluorine and, if present, one of which is hydroxy, wherein the hydroxy group is separated from any of the fluorine substituents by at least two carbon atoms; C 1-4 - alkyl; The compound according to embodiment 11) is independently selected from:

[0088] [Especially, such C 1-4-Alkyl is methyl, isopropyl, hydroxymethyl, 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, 2-hydroxy-1,1-dimethyl-ethyl, methoxymethyl, 2-methoxy-ethyl, 1-methoxy-1-methyl-ethyl, 2-methoxy-2-methyl-propyl, 2-methoxy-1,1-dimethyl-ethyl, tert-butoxy-methyl; 1,2-dihydroxy-ethyl, N-acetyl-2-amino-ethyl, N-(acetyl-2,2,2-d3)-2-amino-ethyl, 2-(methylcarboxamido)-2-methyl-propyl, 2-(ethylcarboxamido)-2-methyl-propyl, 2-(cyclopropyl-carboxamido)-2-methyl-propyl, 2-(tetrahydroxy- hydropyran-4-yl-carboxamido)-2-methyl-propyl, 2-(methoxy-methyl-carboxamido)-2-methyl-propyl, 2-(ethyl-carboxamido)-2-methyl-propyl, 2-(isopropyl-carboxamido)-2-methyl-propyl, 2-(methyl-d3-carboxamido)-2-methyl-propyl, N-methyl-N-(hydroxy-methyl-carbonyl)-2-amino-ethyl, N-methyl-N-acetyl-2-amino-ethyl, 2,2,2-trifluoro-1-hydroxy-1-methyl-ethyl, 1,1-difluoro-2-hydroxy-ethyl, 1,1-difluoro-ethyl or N-methyl-N-(acetyl-2,2,2-d3)-2-amino-ethyl; in particular such C 1-4 -alkyl group is 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl or 2-hydroxy-1,1-dimethyl-ethyl. 13) Another embodiment is where at least one of the substituents of A / A is: - 1,2,4-oxadiazol-5-yl or 1,2,4-oxadiazol-3-yl (in particular 1,2,4-oxadiazol-3-yl), in which the oxadiazolyl group is substituted by one substituent, which is -- C 1-4 - alkyl (in particular methyl, ethyl, propyl, isopropyl or tert-butyl), --- 1 piece, ---- Hydroxy; or ---- C 1-4 -alkoxy (especially methoxy and tert-butoxy) C replaced by 1-4 -alkyl.

[0089] [Especially, such C 1-4 -Alkyl represents hydroxymethyl, 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, 2-hydroxy-1,1-dimethyl-ethyl, methoxy-methyl, 2-methoxy-ethyl, 1-methoxy-1-methyl-ethyl, 2-methoxy-2-methyl-propyl, 2-methoxy-1,1-dimethyl-ethyl or tert-butoxy-methyl; in particular such C 1-4 -Alkyl is 1 2-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl or 2-hydroxy-1,1-dimethyl-ethyl. 14) Another embodiment is where at least one of the substituents of A / A is: - 1,2,4-oxadiazol-3-yl, which is substituted (in particular at the 3-position relative to the point of attachment of the oxadiazolyl to A) by one substituent, which is -- C 1-4 - alkyl (in particular methyl, ethyl, propyl, isopropyl or tert-butyl), --- 1 piece, ---- hydroxy; C replaced by 1-4 -alkyl.

[0090] [Especially, such C 1-4 -Alkyl represents hydroxymethyl, 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, 2-hydroxy-1,1-dimethyl-ethyl, in particular such C 1-4-Alkyl represents 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl or 2-hydroxy-1,1-dimethyl-ethyl. 15) Another embodiment is when A represents pyridin-3-yl, which is substituted with one substituent at the meta position relative to the point of attachment of the pyridin-3-yl to the remainder of the molecule, and said substituent is - 1,2,4-oxadiazol-3-yl, substituted by one substituent (in particular in the 3-position relative to the point of attachment of the oxadiazolyl to A), which substituent is hydroxymethyl, 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl or 2-hydroxy-1,1-dimethyl-ethyl; The compound according to embodiment 11) is

[0091] [In particular, such 1,2,4-oxadiazol-3-yl represents 5-(hydroxymethyl)-1,2,4-oxadiazol-3-yl, 5-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazol-3-yl, 5-(2-hydroxy-2-methyl-propyl)-1,2,4-oxadiazol-3-yl or 5-(2-hydroxy-1,1-dimethyl-ethyl)-1,2,4-oxadiazol-3-yl.] 16) Another embodiment is where at least one of the substituents of A / A is: - a 5- or 6-membered heteroaryl as defined in embodiment 1), in which the substituents of said 5- or 6-membered heteroaryl, if present, are ---L as defined in aspect 1) 3 -CY 3 ; The present invention relates to a compound according to any one of embodiments 1) to 4), which is independently selected from:

[0092] 17) Another embodiment is where at least one of the substituents of A / A is: - 5- or 6-membered heteroaryl having 1 to 3 (especially 2 or 3; especially 3) ring heteroatoms independently selected from nitrogen, oxygen and sulfur (especially pyrazolyl, oxazolyl, thiazolyl, oxadiazolyl, pyrimidinyl or pyridinyl; especially pyrazol-1-yl, 1H-1,2,3-triazol-1-yl, oxazol-2-yl, thiazol-2-yl, 1,2,4-oxadiazol-5-yl, 1,2,4-oxadiazol-3-yl, pyrimidin-2-yl or pyridin-2-yl; especially 1,2,4-oxadiazol-5-yl or 1,2,4-oxadiazol-3-yl; especially 1,2,4-oxadiazol-3-yl); wherein the 5- or 6-membered heteroaryl is independently unsubstituted or substituted with 1, 2, or 3 substituents (particularly substituted with 1 substituent; especially substituted with 1 substituent at the 3-position relative to the point of attachment of the 5- or 6-membered heteroaryl to A), and when such substituents are present, The base is -- -L 3 -CY 3 (--- -L 3 - independently represents a bond (i.e., CY 3 is directly attached to the remainder of the molecule; -CH2-, -CH2-CH2-, -C(CH3)2-, -CH(OH)-, or -O-CH2-; -L 3 When - is -O-CH2-, the CY 3 is attached to the oxygen atom of the -O-CH2-; --- CY 3 represents piperidinyl; said piperidinyl is independently unsubstituted or substituted by 1, 2 or 3 substituents as defined in embodiment 1).

[0093] 18) Another embodiment is where at least one of the substituents of A / A is: - 1,2,4-oxadiazol-5-yl or 1,2,4-oxadiazol-3-yl (in particular 1,2,4-oxadiazol-3-yl), in which the oxadiazolyl group is substituted by one substituent, which is -- -L 3 -CY 3 (--- -L 3 - independently represents a bond (i.e., CY 3 is directly attached to the remainder of the molecule; -CH2-, -CH2-CH2-, -C(CH3)2-, -CH(OH)-, or -O-CH2-; -L 3 When - is -O-CH2-, the CY 3 is attached to the oxygen atom of the -O-CH2-; --- CY 3 independently represent piperidinyl (particularly piperidin-2-yl, piperidin-3-yl or piperidin-4-yl; especially piperidin-4-yl), which piperidinyl is independently unsubstituted or has one, two or three (particularly unsubstituted or has one or two) ---- halogens (especially fluorine); ---- oxo; ---- hydroxy; ---- 1 C 1-3 -C optionally substituted with alkoxy 1-3 -alkyl (especially such C 1-3 -Alkyl represents methyl, ethyl, propyl, isopropyl or methoxy-methyl; ---- C 1-3 -alkoxy (especially methoxy); ---- -(C=O)-R CO (R CO teeth, ----- 1 hydroxy or C 1-3 -C optionally substituted with alkoxy 1-3 - alkyl (especially methyl, ethyl, n-propyl, isopropyl, tert-butyl, hydroxymethyl, methoxymethyl, benzyloxy or 2-methoxyethyl; especially the -(C=O)-R COis acetyl); ----- C 1-3 -fluoroalkyl (especially 2,2,2-trifluoro-ethyl);----- C 1-3 -alkoxy (especially methoxy); ----- C in which one or two carbon ring atoms are optionally replaced by one or two oxygen ring atoms 3-6 -Cycloalkyl-(CH2) n - (n represents an integer of 0 or 1) (especially, such C 3-6 -Cycloalkyl-(CH2) n - represents cyclopropyl, cyclopentyl, oxetan-3-yl, oxetan-3-yl-methyl, 1,4-dioxan-2-yl or tetrahydropyran-4-yl; or ----- phenyl; represents.) [In particular, such -(C=O)-R CO represents acetyl, ethyl-carbonyl, n-propyl-carbonyl, isopropyl-carbonyl, tert-butyl-carbonyl, hydroxymethyl-carbonyl, 2,2,2-trifluoro-ethyl-carbonyl, methoxy-methyl-carbonyl, 2-methoxy-ethyl-carbonyl, methoxy-carbonyl, ethoxy-carbonyl, 2-methoxy-ethoxy-carbonyl, cyclopropyl-carbonyl, cyclopentyl-carbonyl, oxetan-3-yl-carbonyl, oxetan-3-yl-methyl-carbonyl, phenyl-carbonyl or tetrahydropyran-4-yl-carbonyl, methoxy-methyl-carbonyl or 1,4-dioxan-2-yl-carbonyl. ---- -S(=O)2-R SO (R SO teeth, ----- 1 hydroxy, C 1-3 -C optionally substituted by alkoxy or amino 1-3 -alkyl (in particular methyl, n-propyl, isopropyl, 2-hydroxyethyl, 2-methoxyethyl or methylamino); or ----- C with one carbon ring atom optionally replaced by one oxygen ring atom3-5 cycloalkyl (especially cyclopropyl, cyclopentyl or tetrahydropyran-4-yl); represents. ); [In particular, such -S(=O)2-R SO represents methyl-sulfonyl, n-propyl-sulfonyl, isopropyl-sulfonyl, 2-hydroxyethyl-sulfonyl, cyclopropyl-sulfonyl, cyclopentyl-sulfonyl, 2-methoxy-ethyl-sulfonyl, methyl-amino-sulfonyl or tetrahydropyran-4-yl-sulfonyl. is replaced by ); The compound according to embodiment 16) is independently selected from:

[0094] [Especially, the -L 3 -CY 3are piperidin-4-yl, 1-methyl-2,6-dioxo-piperidin-4-yl, 4-methyl-piperidin-4-yl, 4-fluoro-piperidin-4-yl, 2-oxo-piperidin-4-yl, 6-oxo-piperidin-2-yl, 6-oxo-piperidin-3-yl, 1-methyl-6-oxo-piperidin-3-yl, 3-methyl-6-oxo-piperidin-3-yl, N-acetyl-piperidin-4-yl, N-acetyl-piperidin-4-yl-methyl, N-acetyl-2-methyl-piperidin-4-yl, N-acetyl-4-fluoro- Oro-piperidin-4-yl, N-acetyl-3-methyl-piperidin-4-yl, N-acetyl-4-methyl-piperidin-4-yl, N-acetyl-4-hydroxy-piperidin-4-yl, N-acetyl-4-methoxy-piperidin-4-yl, N-acetyl-piperidin-3-yl, N-acetyl-piperidin-3-yl-methyl, N-acetyl-3-methyl-piperidin-3-yl, N-acetyl-3-hydroxy-piperidin-3-yl, N-(isopropyl-carbonyl)-4-hydroxy-piperidin-4-yl, N-(tert -butyl-carbonyl)-piperidin-4-yl, N-(2-methoxy-ethoxy-carbonyl)-piperidin-4-yl, N-(hydroxymethyl-carbonyl)-piperidin-4-yl, N-(cyclopropyl-sulfonyl)-piperidin-4-yl, N-(methyl-sulfonyl)-piperidin-4-yl, N-(n-propyl-sulfonyl)-piperidin-4-yl, N-(isopropyl-sulfonyl)-piperidin-4-yl, N-(2-hydroxy-ethyl-sulfonyl)-piperidin-4-yl, N-(cyclopentyl-sulfonyl) -piperidin-4-yl, N-(methoxy-carbonyl)-piperidin-4-yl, N-(cyclopropyl-carbonyl)-piperidin-4-yl, N-(cyclopentyl-carbonyl)-piperidin-4-yl, N-(methyl-amino-sulfonyl)-piperidin-4-yl, N-(2-methoxy-ethyl-sulfonyl)-piperidin-4-yl, N-(ethyl-carbonyl)-4-hydroxy-piperidin-4-yl, N-(methoxy-methyl-carbonyl)-piperidin-4-yl, N-(ethoxy-carbonyl)-piperidin-4-yl,N-acetyl-4-ethyl-piperidin-4-yl, N-(n-propyl-carbonyl)-piperidin-4-yl, N-(2-methoxy-ethyl-carbonyl)-piperidin-4-yl, N-(oxetan-3-yl-carbonyl)-piperidin-4-yl, N-(oxetan-3-yl-methyl-carbonyl)-piperidin-4-yl, N-(2,2,2-trifluoro-ethyl-carbonyl)-piperidin-4-yl, N-(tetrahydropyran-4-yl-carbonyl)-piperidin-4-yl, N-(phenyl-carbonyl)-piperidin-4-yl, N-(tetrahydropyran-4-yl-sulfonyl)-piperidin, N-(1,4-dioxan-2-yl-carbonyl)-piperidin-4-yl, N-(benzyl-oxy-carbonyl)-piperidin-4-yl, N-(methoxy-methyl-carbonyl)-4-isopropyl-piperidin-4-yl, N-(1,4-dioxan-2-yl-carbonyl)-piperidin-4-yl.

[0095] 19) Another embodiment is where at least one of the substituents of A / A is: - 1,2,4-oxadiazol-3-yl, in which the oxadiazolyl group is substituted by one substituent, said substituent being - -L 3 -CY 3 (-- -L 3 - is a bond (i.e., CY 3 is directly attached to the rest of the molecule; -- CY 3 represents independently unsubstituted or substituted piperidin-4-yl by one or two substituents; --- one of the substituents is attached to the nitrogen atom of the piperidine ring, and the substituent is -(C=O)-R CO (R CO teeth, ---- C optionally substituted with one substituent 1-3 -alkyl, wherein the substituent is C 1-3 -representing alkoxy or hydroxy, C 1-3 -alkyl (especially such C 1-3-Alkyl is methyl, ethyl, n-propyl, isopropyl, tert-butyl, hydroxymethyl, methoxymethyl or 2-methoxyethyl; in particular, the -(C=O)-R CO is acetyl); ---- C 1-3 - fluoroalkyl (especially 2,2,2-trifluoro-ethyl); ---- C 1-3 -alkoxy (especially methoxy); ---- C optionally having one or two carbon ring atoms replaced by one or two oxygen ring atoms 3-6 -Cycloalkyl-(CH2) n - (n represents an integer of 0 or 1) (especially, such C 3-6 -Cycloalkyl-(CH2) n - represents cyclopropyl, cyclopentyl, oxetan-3-yl, oxetan-3-yl-methyl, 1,4-dioxan-2-yl or tetrahydropyran-4-yl; ); or [In particular, such -(C=O)-R CO represents acetyl, ethyl-carbonyl, n-propyl-carbonyl, isopropyl-carbonyl, tert-butyl-carbonyl, hydroxymethyl-carbonyl, 2,2,2-trifluoro-ethyl-carbonyl, methoxy-methyl-carbonyl, 2-methoxy-ethyl-carbonyl, methoxy-carbonyl, ethoxy-carbonyl, 2-methoxy-ethoxy-carbonyl, cyclopropyl-carbonyl, cyclopentyl-carbonyl, oxetan-3-yl-carbonyl, oxetan-3-yl-methyl-carbonyl, tetrahydropyran-4-yl-carbonyl, methoxy-methyl-carbonyl or 1,4-dioxan-2-yl-carbonyl. --- and / or one of the substituents is attached to a carbon atom of the piperidine ring and the substituent is C 1-3 -Alkyl (especially methyl), halogen (especially fluorine), hydroxy or C 1-3 -alkoxy (especially methoxy); The compound according to embodiment 16) is independently selected from:

[0096] 20) Another embodiment is where at least one of the substituents of A / A is independently -C≡CR T1 or - -C≡CC(OH)(R T2 )(R T3 ); and the groups are as defined in embodiment 1); relates to compounds according to any one of embodiments 1) to 4).

[0097] 21) Another embodiment is where at least one of the substituents of A / A is: - -C≡CR T1 (-- R T1 teeth, --- C 1-4 - alkyl (especially methyl, ethyl, isopropyl or isobutyl) And the C 1-4 -alkyl is independently one ---- hydroxy; [Especially, such C 1-4 -alkyl represents hydroxy-methyl, 1-hydroxy-ethyl, 2-hydroxy-ethyl, 1-hydroxy-2-methyl-propyl or 1-hydroxy-1-methyl-ethyl; ---- C 1-3 -alkoxy (especially methoxy); ---- -S(=O)2-R SOT (R SOT is C 1-3 -Alkyl, C 1-3 -Alkyl-amino or C 3-5 -cycloalkyl.) (In particular, such -S(=O)2-R SOT represents methyl-sulfonyl, methyl-amino-sulfonyl or cyclopropyl-sulfonyl; ---- C having 1 or 2 ring heteroatoms independently selected from nitrogen and oxygen 4-6-heterocyclyl (especially oxazolidinyl, imidazolidinyl or pyrrolidinyl; especially oxazolidin-3-yl, imidazolidin-3-yl or pyrrolidin-1-yl); 4-6 -heterocyclyl is substituted by one oxo; or oxo and one C 1-3 -C substituted by two alkyl (especially methyl) substituents 4-6 -heterocyclyl; (especially those C 4-6 -heterocyclyl represents oxazolidin-2-one-3-yl, imidazolidin-2-one-3-yl, 1-methyl-imidazolidin-2-one-3-yl or pyrrolidin-2-one-1-yl; C replaced by 1-4 - alkyl; --- C 1-4 - alkyl (especially methyl, ethyl, isopropyl or isobutyl) independently substituted by two substituents, one of which is hydroxy and the second is trifluoromethyl; C 1-4 - alkyl (especially 1-hydroxy-1-trifluoromethyl-ethyl); --- C 3-6 -cycloalkyl (especially cyclopropyl), (especially those having the above C to the rest of the molecule) 3-6 -at the point of attachment of the cycloalkyl) one ---- hydroxy; ----amino-sulfonyl optionally substituted with two methyls; ---- phenyl substituted by one halogen (especially 4-fluorophenyl);---- pyridinyl (especially pyridin-2-yl); ---- 1 C 1-3 -pyrimidinyl substituted by alkyl (especially 6-methyl-pyrimidin-4-yl); ---- oxazolidinonyl (especially oxazolidin-2-one-3-yl); C replaced by 3-6 -cycloalkyl; [Especially, such C 3-6-cycloalkyl represents 1-hydroxy-cyclopropyl, 1-hydroxy-cyclobutyl, 1-hydroxy-cyclopentyl, 1-(amino-sulfonyl)-cyclopropyl, 1-(dimethyl-amino-sulfonyl)-cyclopropyl, 1-(6-methyl-pyrimidin-4-yl)-cyclopropyl, 1-(pyridin-2-yl)-cyclopropyl, 1-(4-fluoro-phenyl)-cyclopropyl, 1-(pyridin-2-yl)-cyclopropyl or 1-(oxazolidin-2-one-3-yl)-cyclopropyl; --- C with one ring heteroatom independently selected from nitrogen and oxygen 4-6 heterocyclyl (especially azetidinyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl; especially azetidin-3-yl, piperidin-4-yl, pyrrolidin-3-yl, pyrrolidin-2-yl, pyrrolidin-1-yl or tetrahydropyran-4-yl); 4-6 -heterocyclyl is substituted by 1, 2 or 3 substituents (in particular 1 or 2 substituents), said substituents being selected from the group consisting of C 1-3 -Alkyl (especially methyl), hydroxy, oxo, C 1-3 -Alkyl-carbonyl (especially acetyl), C 1-3 -alkoxy-carbonyl (especially tert-butoxy-carbonyl), C 1-3 -Alkyl-sulfonyl (especially methyl-sulfonyl) and C 1-3 -alkyl-amino-sulfonyl (particularly methyl-amino-sulfonyl), C 4-6 -Heterocycly Le; [Especially, such C 4-6-heterocyclyl is N-(isopropyl-carbonyl)-3-hydroxy-azetidin-3-yl, N-(tert-butoxy-carbonyl)-3-hydroxy-azetidin-3-yl, N-methyl-3-hydroxy-pyrrolidin-2-one-3-yl, N-acetyl-2-methyl-pyrrolidin-2-yl, 3-hydroxy-N-(tert-butoxy-carbonyl)-pyrrolidin-3-yl, 2-oxo-pyrrolidin-1-yl, N-acetyl-piperidin-1-yl, N-acetyl-4-methyl-piperidin-4-yl, N-(methyl-amino-sulfonyl)-4-methyl-piperidin-4-yl, N-acetyl-4-hydroxy-piperidin-4-yl, N-(methyl-sulfonyl)-piperidin-4-yl, N-(tert-butoxy-carbonyl)-piperidin-4-yl, 3-hydroxy-2-oxo-1-methyl-pyrrolidin-2-yl or 4-hydroxy-tetrahydropyran-4-yl; --- indolyl (especially indol-2-yl); --- 3-hydroxy-1-methyl-1,3-dihydro-indol-2-on-3-yl; ); or [In particular, such -C≡CR T1are 3-hydroxy-3-trifluoromethyl-but-1-yn-1-yl, 3-hydroxy-prop-1-yn-1-yl, 4-hydroxy-but-1-yn-1-yl, 3-hydroxy-but-1-yn-1-yl, 3-hydroxy-3-methyl-but-1-yn-1-yl, 3-hydroxy-4-methyl-pent-1-yn-1-yl, (1-hydroxy-cyclopropyl)-ethynyl, (1-hydroxy-cyclobutyl)-ethynyl, (1-hydroxy-cyclopentyl)-ethynyl, (8-hydroxy-5,6,7,8-tetrahydroquinolin-8-yl)-ethynyl, (7-hydroxy-6,7-dihydro-5H-cyclopenta[b] pyridin-7-yl)-ethynyl, (4-hydroxy-tetrahydropyran-4-yl)-ethynyl, (1-(isopropyl-carbonyl)-3-hydroxy-azetidin-3-yl)-ethynyl, (1-(tert-butoxy-carbonyl)-3-hydroxy-azetidin-3-yl)-ethynyl, (N-acetyl-4-hydroxy-piperidine-(3-hydroxy-N-(tert-butoxy-carbonyl)-pyrrolidin-3-yl)-ethynyl, (3-hydroxy-1-methyl-1,3-dihydro-indol-2-one-3-yl)-ethynyl or (3-hydroxy-2-oxo-1-methyl-pyrrolidin-3-yl)-ethynyl. -C≡CC(OH)(R T2 )(R T3 ); The compound according to embodiment 20) is

[0098] 22) Another embodiment is where at least one of the substituents of A / A is: - -C≡CC(OH)(R T2 )(R T3 ) (-- R T2 is hydrogen or C 1-3 - alkyl (especially methyl or ethyl; especially methyl); -- R T3 teeth, 6-membered heteroaryl having 1 or 2 ring nitrogen atoms (especially pyridinyl, pyrazinyl or pyrimidinyl; more particularly pyridin-2-yl, pyrimidin-2-yl, pyrazin-2-yl or pyrimidin-4-yl; especially pyrimidin-4-yl), which 6-membered heteroaryl is independently unsubstituted or substituted by 1 or 2 substituents, if present, which are selected from the group consisting of C 1-3 -Alkyl (especially methyl), C 1-3 -cycloalkyl (especially cyclopropyl), C 1-3 -fluoroalkyl (especially C1-fluoroalkyl; especially difluoromethyl or trifluoromethyl) and C 1-3 - a 6-membered heteroaryl independently selected from alkoxy (especially methoxy); [In particular, such 6-membered heteroaryls include pyridin-2-yl, 6-methoxy-pyridin-2-yl, 6-methyl-pyridin-2-yl, pyrimidin-2-yl, 2-methoxy-pyridin-2-yl, 2-methyl ... -pyrimidin-4-yl, 6-methoxy-pyrimidin-4-yl, pyrimidin-4-yl, 2-methyl-pyrimidin-4-yl, 6-methyl-pyrimidin-4-yl, 2,6-dimethyl-pyrimidin-4-yl, 2,6-dimethoxy-pyrimidin-4-yl, 2-methyl-6-methoxy-pyrimidin-4-yl, 2-methoxy-6-methyl-pyrimidin-4-yl, 5-methyl-pyrazin-2-yl, 6-cyclopropyl-pyrimidin-4-yl, 6-difluoromethyl-pyrimidin-4-yl, 2-trifluoromethyl-pyrimidin-4-yl or 6-trifluoromethyl-pyrimidin-4-yl. [In particular, such -C≡CC(OH)(R T2 )(R T3) is 3-hydroxy-3-(pyrimidin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methoxy-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methoxy-6-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyrimidin-4 -yl)-but-1-yn-1-yl, 3-hydroxy-3-(2,6-dimethoxy-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(pyridin-2-yl)-pent-1-yn-1-yl, 3-hydroxy- 3-(6-Methoxy-pyridin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methyl-pyridin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methyl-pyridin-2-yl)-pent-1-yn-1-yl, 3-hydroxy-3-(2,6-dimethyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-pent-1-yn -1-yl, 3-hydroxy-3-(6-cyclopropyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-difluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-trifluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl or 3-hydroxy-3-(6-trifluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl; The compound according to embodiment 20) is

[0099] 23) Another embodiment is where B is phenyl and is substituted with 1, 2, or 3 substituents, the first of which is attached at the para position relative to the point of attachment of B to the remainder of the molecule, and the substituent is: - C 1-5- alkyl (especially methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, 1-ethylpropyl, 2,2-dimethylpropyl, 1,1-dimethylpropyl; more particularly methyl, ethyl or isopropyl; especially isopropyl); - C 1-3 -Alkoxy-C 1-4 - alkyl (especially 3-methoxy-propyl); - C 1-2 - fluoroalkyl (especially trifluoromethyl or 2,2,2-trifluoro-ethyl); - C 3-5 -cycloalkyl (especially cyclopropyl or cyclobutyl), which are independently unsubstituted or (especially those C 3-5 -One C at the attachment point of the cycloalkyl 1-3 -Alkyl (especially methyl) or C 1-3 -substituted by fluoroalkyl (especially trifluoromethyl), 3-5 -cycloalkyl; and - C1-fluoroalkoxy (especially trifluoromethoxy); represents phenyl, selected from: Any remaining substituents of B (particularly those that are attached meta to the point of attachment of B to the remainder of the molecule), if present, are independently selected from halogen (particularly fluorine or chlorine; especially fluorine); The compound according to any one of embodiments 1) to 22).

[0100] [In particular, such group B represents 4-methyl-phenyl, 4-ethyl-phenyl, 4-propyl-phenyl, 4-isopropyl-phenyl, 4-butyl-phenyl, 4-isobutyl-phenyl, 4-tert-butyl-phenyl, 4-(1-ethyl-propyl)-phenyl, 4-(1,1-dimethyl-propyl)-phenyl, 4-(2,2-dimethyl-propyl)-phenyl, 3-chloro-4-isopropyl-phenyl, 3-fluoro-4-isopropyl-phenyl, 3,5-difluoro-4-isopropyl-phenyl, 4-cyclopropyl-phenyl, 4-trifluoromethyl-phenyl, 4-(2,2,2-trifluoro-ethyl)-phenyl, 4-trifluoromethoxy-phenyl, 4-(1-methyl-cyclopropyl)-phenyl, 4-cyclobutyl-phenyl, 4-(3-methoxy-propyl)-phenyl or 4-(1-trifluoromethyl-cyclopropyl)-phenyl.]

[0101] 24) Another embodiment is where B is phenyl and is substituted with 1, 2, or 3 substituents, the first of which is attached at the para position relative to the point of attachment of B to the remainder of the molecule, and the substituent is: - C 2-4 - alkyl (especially n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl; especially isopropyl); - trifluoromethyl or 2,2,2-trifluoro-ethyl; - C 3-5 -cycloalkyl (especially cyclopropyl or cyclobutyl), which are independently unsubstituted or (especially those C 3-5 -One C at the attachment point of the cycloalkyl 1-3 -Alkyl (especially methyl) or C 1-3 -substituted by fluoroalkyl (especially trifluoromethyl), 3-5 -cycloalkyl; and - C1-fluoroalkoxy (especially trifluoromethoxy); represents phenyl, selected from: Any remaining substituents of B (particularly those that are attached meta to the point of attachment of B to the remainder of the molecule), if present, are independently selected from halogen (particularly fluorine or chlorine; especially fluorine); The compound according to any one of embodiments 1) to 22).

[0102] [In particular, such group B represents 4-propyl-phenyl, 4-isopropyl-phenyl, 4-butyl-phenyl, 4-isobutyl-phenyl, 4-tert-butyl-phenyl, 3-chloro-4-isopropyl-phenyl, 3-fluoro-4-isopropyl-phenyl, 3,5-difluoro-4-isopropyl-phenyl, 4-cyclopropyl-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 4-(2,2,2-trifluoro-ethyl)-phenyl, 4-(1-methyl-cyclopropyl)-phenyl, 4-cyclobutyl-phenyl or 4-(1-trifluoromethyl-cyclopropyl)-phenyl.]

[0103] 25) Another embodiment relates to compounds according to any one of embodiments 1) to 22), wherein B represents phenyl substituted with one substituent, said substituent being attached in the para position relative to the point of attachment of B to the rest of the molecule, and said substituent being selected from isopropyl (preferred), trifluoromethyl, trifluoromethoxy, trifluoromethyl, cyclopropyl, cyclobutyl, 1-methyl-cyclopropyl, and 1-trifluoromethyl-cyclopropyl.

[0104] [In particular, such group B represents 4-isopropyl-phenyl, 4-cyclopropyl-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 4-(1-methyl-cyclopropyl)-phenyl, 4-cyclobutyl-phenyl or 4-(1-trifluoromethyl-cyclopropyl)-phenyl.]

[0105] 26) Another aspect is R 1 C 1-3- alkyl (in particular methyl or ethyl; especially methyl).

[0106] 27) Another aspect is R 2 But C 1-4 - alkyl (especially methyl (preferred), ethyl, n-propyl, isopropyl, tert-butyl or isobutyl), C 3-5 -cycloalkyl (especially cyclopropyl or cyclobutyl), C 3-5 -Cycloalkyl-C 1-3 -alkyl (especially cyclopropyl-methyl) or C 1-3 -fluoroalkyl (in particular 2,2-difluoro-ethyl or 2-fluoroethyl).

[0107] 28) Another aspect is R 2 represents methyl (preferred), ethyl, n-propyl, isopropyl, cyclopropyl or cyclobutyl.

[0108] 29) Another embodiment is when A represents pyridin-3-yl substituted with one substituent at the meta position relative to the point of attachment of the pyridin-3-yl to the remainder of the molecule, said substituent being 5-(hydroxymethyl)-1,2,4-oxadiazol-3-yl, 5-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazol-3-yl, 5-(2-hydroxy-2-methyl-propyl)-1,2,4-oxadiazol-3-yl, or 5-(2-hydroxy-1,1-dimethyl-ethyl)-1,2,4-oxadiazol-3-yl; B represents 4-propyl-phenyl, 4-isopropyl-phenyl, 4-isobutyl-phenyl, 4-tert-butyl-phenyl, 3-fluoro-4-isopropyl-phenyl, 3,5-difluoro-4-isopropyl-phenyl, 4-cyclopropyl-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 4-(2,2,2-trifluoro-ethyl)-phenyl, 4-cyclobutyl-phenyl or 4-(1-trifluoromethyl-cyclopropyl)-phenyl; R 1 represents methyl; R 2 represents methyl; It relates to compounds according to embodiment 1).

[0109] 30) Another embodiment is when A represents pyridin-3-yl, which is substituted with one substituent at the meta position relative to the point of attachment of the pyridin-3-yl to the remainder of the molecule, and said substituent is - 1,2,4-oxadiazol-3-yl, wherein the oxadiazolyl group is substituted by one substituent, and the substituent is piperidin-4-yl, which is unsubstituted or substituted by one or two substituents, one of which is attached to the nitrogen atom of the piperidine ring, and the substituent is -- acetyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, tert-butylcarbonyl, hydroxymethylcarbonyl, 2,2,2-trifluoroethylcarbonyl, methoxymethylcarbonyl, 2-methoxyethylcarbonyl, methoxycarbonyl, ethoxycarbonyl, 2-methoxyethoxycarbonyl, cyclopropylcarbonyl, cyclopentylcarbonyl, oxetan-3-ylcarbonyl, oxetan-3-ylmethylcarbonyl, tetrahydropyran-4-ylcarbonyl, methoxymethylcarbonyl or 1,4-dioxan-2-ylcarbonyl; and; and / or one of the substituents is bonded to a carbon atom of the piperidine ring and the substituent is C 1-3-Alkyl (especially methyl), halogen (especially fluorine), hydroxy or C 1-3 -alkoxy (especially methoxy); piperidin-4-yl; B represents 4-propyl-phenyl, 4-isopropyl-phenyl, 4-isobutyl-phenyl, 4-tert-butyl-phenyl, 3-fluoro-4-isopropyl-phenyl, 3,5-difluoro-4-isopropyl-phenyl, 4-cyclopropyl-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 4-(2,2,2-trifluoro-ethyl)-phenyl, 4-cyclobutyl-phenyl or 4-(1-trifluoromethyl-cyclopropyl)-phenyl; R 1 represents methyl; R 2 represents methyl; It relates to compounds according to embodiment 1).

[0110] 31) Another embodiment is when A represents pyridin-3-yl substituted with one substituent at the meta position relative to the point of attachment of the pyridin-3-yl to the remainder of the molecule, and the substituent is selected from the group consisting of 3-hydroxy-3-(pyrimidin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methoxy-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methoxy-6-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2,6-dimethoxy-pyrimidin-4-yl)-but-1-yn-1-yl, -1-yn-1-yl, 3-hydroxy-3-(2-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2,6-dimethyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-cyclopropyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-difluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-trifluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl or 3-hydroxy-3-(6-trifluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl; B represents 4-propyl-phenyl, 4-isopropyl-phenyl, 4-isobutyl-phenyl, 4-tert-butyl-phenyl, 3-fluoro-4-isopropyl-phenyl, 3,5-difluoro-4-isopropyl-phenyl, 4-cyclopropyl-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 4-(2,2,2-trifluoro-ethyl)-phenyl, 4-cyclobutyl-phenyl or 4-(1-trifluoromethyl-cyclopropyl)-phenyl; R 1 represents methyl; R 2 represents methyl; It relates to compounds according to embodiment 1).

[0111] 32) Another embodiment relates to a compound according to any one of embodiments 1) to 31), which is also a compound of formula (II) (i.e., the asymmetric carbon atom to which A and B are attached has the absolute configuration shown in formula (II)):

[0112] [ka]

[0113] 33) Another embodiment relates to a compound according to embodiment 1), selected from the group consisting of the following compounds: (3-fluoro-1-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; 3-[hydroxy-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methyl]-1-methyl-azetidine-3-carbonitrile; (R)-(1-Ethyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(3-methyl-1-propyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-Isopropyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-cyclopropylmethyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-Cyclobutyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-Isobutyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-cyclopropyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-[1-(2-fluoro-ethyl)-3-methyl-azetidin-3-yl]-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-[1-(2,2-difluoro-ethyl)-3-methyl-azetidin-3-yl]-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-tert-butyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-methoxy-prop-1-ynyl)-pyridin-3-yl]-methanol 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-prop-1-yne-1 -Oar; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-methyl-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopentanol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopropanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-azetidine-1-carboxylic acid tert-butyl ester; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclobutanol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-1-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(1-methyl-1H-pyrazol-4-ylethynyl)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-phenyl-prop-2-yn-1-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-phenyl-but-3-yn-2-ol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-methyl-pent-1-yn-3-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-tetrahydro-pyran-4-ol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(tetrahydro-pyran-4-yl)-prop-2-yn-1-ol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(1,3-dimethyl-1H-pyrazol-4-yl)-prop-2-yn-1-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-pyran-4-ylethynyl)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4 -isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(2-methyl-thiazol-4-yl)-prop-2-yn-1-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(3-fluoro-phenyl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(4-methoxy-phenyl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-phenyl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazol-4-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-pyrimidin-2-yl-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(1,5-dimethyl-1H-pyrazol-3-yl)-prop-2-yn-1-ol; 8-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-5,6,7,8-tetrahydro-quinolin-8-ol; 7-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-6,7-dihydro-5H-[1]pyrindin-7-ol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-pyridin-2-yl-pent-1-yn-3-ol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methoxy-pyridin-2-yl)-pent-1-yn-3-ol; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-azetidin-1-yl)-2-methyl-propan-1-one; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-(1H-indol-2-ylethynyl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-methoxy-propyl)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-propan-1-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-methyl-butan-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-butan-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-butan-2-ol; 1-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-cyclopentanol; 1-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-cyclopropanol; 3-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-3-hydroxy-azetidine-1-carboxylic acid tert-butyl ester; 1-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-cyclobutanol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-butan-1-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[2-(1-methyl-1H-pyrazol-4-yl)-ethyl]-pyridin-3-yl}-methanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-phenyl-propan-1-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-phenyl-butan-2-ol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-methyl-pentan-3-ol; 4-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-tetrahydro-pyran-4-ol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(tetrahydro-pyran-4-yl)-propan-1-ol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(1,3-dimethyl-1H-pyrazol-4-yl)-propan-1-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl )-{5-[2-(tetrahydro-pyran-4-yl)-ethyl]-pyridin-3-yl}-methanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(2-methyl-thiazol-4-yl)-propan-1-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(3-fluoro-phenyl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(4-methoxy-phenyl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-phenyl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazol-4-yl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyridin-2-yl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-pyrimidin-2-yl-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl)-butan-2-ol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(1,5-dimethyl-1H-pyrazol-3-yl)-propan-1-ol; 8-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-5,6,7,8-tetrahydro-quinolin-8-ol; 7-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-6,7-dihydro-5H-[1]pyrindin-7-ol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-pyridin-2-yl-pentan-3-ol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methoxy-pyridin-2-yl)-pentan-3-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-{5-[2-(1H-indol-2-yl)-ethyl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (R)-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-{5-[3-(tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-{5-[3-(2-methoxy-1,1-dimethyl-ethyl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-[5-(3-cyclobutoxymethyl-[1,2,4]oxadiazol-5-yl)-pyridin-3-yl]-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-propyl-phenyl)-{5-[3-(tetrahydro-pyran-4-yloxymethyl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-propyl-phenyl)-{5-[3-(tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-[5-(3-cyclobutoxymethyl-[1,2,4]oxadiazol-5-yl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-propyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-morpholin-4-ylmethyl-[1,2,4]oxadiazol-5-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-{5-[3-(2,6-dimethyl-morpholin-4-ylmethyl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(4-methyl-tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[(1S,2S,4R)-3-(7-oxa-bicyclo[2.2.1]hept-2-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(tetrahydro-pyran-4-yloxymethyl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-morpholin-4-yl-[1,2,4]oxadiazol-5-yl)-pyridin-3-yl]-methanol; (R)-(4-Cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-{5-[3-(4-methoxy-tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(4-Cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-{5-[3-(3-hydroxymethyl-bicyclo[1.1.1]pent-1-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-{5-[3-(3-hydroxymethyl-bicyclo[1.1.1]pent-1-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 2-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-2-methyl-propan-1-ol; 2-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-propan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(1-methoxy-1-methyl-ethyl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(1-methoxy-cyclobutyl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; 1-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-2-methyl-propan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-methanesulfonylmethyl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(2-methoxy-ethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-methoxymethyl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-furan-3-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-cyclohexanol; (R)-[5-(5-tert-butoxymethyl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-pyran-4-ylmethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-cyclohexanol; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-cyclohexanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methoxy-cyclobutyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(6-oxa-spiro[2.5]oct-1-yl)-[1,2,4] oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-pyran-3-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(tetrahydro-furan-2-yl)methyl]-[1,2,4]oxadiazol-3-yl}-pyridin-3-yl)-methanol; (R)-2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1,1,1-trifluoro-propan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methoxy-1-methyl-ethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-{5-[5-((R)-cyclohexyl-hydroxy-methyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-cyclopropanol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-cyclopentanol; 3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-cyclobutanol; (R)-(1,3-dimethyl-azetidin-3-yl)-{5-[5-(4-fluoro-tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-{5-[5-((2R,4R,6S)-2,6-dimethyl-tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-pyran-4-yloxymethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-methyl-1-(tetrahydro-pyran-4-yl)-ethyl]-[1,2,4]oxadiazol-3-yl}-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{5-[2-(tetrahydro-pyran-4-yl)-ethyl]-[1,2,4]oxadiazol-3-yl}-pyridin-3-yl)-methanol; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-cyclobutanol; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4] Oxadiazol-5-yl)-2-methyl-propan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(7-oxa-bicyclo[2.2.1]hept-2-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(4-methyl-tetrahydro-pyran-4-yloxymethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-oxetan-3-yl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(2-methoxy-1,1-dimethyl-ethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-2-methyl-propan-1-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(2-methoxy-2-methyl-propyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-cyclobutanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methoxymethyl-cyclopropylmethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(2-pyrazol-1-yl-ethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-N-(2-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)ethyl)acetamide-2,2,2-d3; (R)-N-(1-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)-2-methylpropan-2-yl)acetamide-2,2,2-d3; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-2-hydroxy-ethanone; (R)-1-(4-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethan-1-one-2,2,2-d3; N-[2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-ethyl]-2-hydroxy-N-methyl-acetamide; (R)-N-(2-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)ethyl)-N-methylacetamide-d3; (1,3-dimethyl-azetidin-3-yl)-(6-methoxy-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(6-phenoxy-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(6-ethoxy-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(5-methyl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-propyl-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-methoxy-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-ethyl-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1,3-dimethyl-azetidin-3-yl)-phenyl-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (4-Cyclobutyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (4-Cyclobutoxy-phenyl)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-ethoxy-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (4-tert-butyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropoxy-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methanol; (1,3-dimethyl-azetidin-3-yl)-[4-(1-methyl-cyclopropyl)-phenyl]-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (4-Cyclopropoxy-phenyl)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (S)-[2-(3,3-difluoro-pyrrolidin-1-yl)-pyridin-4-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (S)-[2-((3R,4S)-3,4-difluoro-pyrrolidin-1-yl)-pyridin-4-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (S)-(1,3-dimethyl-azetidin-3-yl)-(2-isobutoxy-pyridin-4-yl)-(4-isopropyl-phenyl)-methanol; 4-{4-[(S)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-2-yl}-2-methyl-butan-2-ol; (R)-[6-(3,3-difluoro-pyrrolidin-1-yl)-pyridazin-4-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (S)-5-tert-butyl-3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-oxazolidin-2-one; (R)-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-ol; (S)-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-((S)-3-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (S)-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-methyl-pyrrolidin-3-ol; 3-Cyclopropyl-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-ol; 2-((S)-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-yl)-propan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-morpholin-4-yl-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-5'-yl)-methanol; (R)-[5-(7-Aza-bicyclo[2.2.1]hept-7-yl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-((S)-2-methyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-trifluoromethyl-pyrrolidin-3-ol; (R)-[5-(3,3-difluoro-pyrrolidin-1-yl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 5'-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-4-ol; 5'-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-3-ol: (R)-{5-[(2-benzyloxy-ethyl)-methyl-amino]-pyridin-3-yl}-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[4-(1-methyl-cyclopropyl)-phenyl]-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (R)-[5-((3R,4S)-3,4-difluoro-pyrrolidin-1-yl)-pyrrolidine azetidin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methanol; 2-[(S)-1-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-pyrrolidin-3-yl]-propan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methanol; (R)-(4-tert-butyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-(3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-5'-yl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-{5-[5-(1-cyclopropanesulfonyl-piperidin-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 2-({5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-methyl-amino)-ethanol; (R)-1-((S)-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-yl)-ethanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-oxazolidin-2-one; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5-phenyl-oxazolidin-2-one; 5-benzyl-3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-oxazolidin-2-one; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5-isopropyl-oxazolidin-2-one; 6-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-oxa-6-aza-spiro[2.4]heptan-5-one; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-oxa-3-aza-spiro[4.4]nonan-2-one; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5-(tetrahydro-pyran-4-yl)-oxazolidin-2-one; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5,5-dimethyl-oxazolidin-2-one; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-8,8-difluoro-1-oxa-3-aza-spiro[4.5]decan-2-one; 9-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4 -isopropyl-phenyl)-methyl]-pyridin-3-yl}-7-oxa-9-aza-dispiro[3.1.4.1]undecan-8-one; 2-Cyclopropyl-7-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5-oxa-7-aza-spiro[3.4]octan-6-one; 7-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2,2-dimethyl-5-oxa-7-aza-spiro[3.4]octan-6-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-phenyl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-isopropyl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-isopropyl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4,4-dimethyl-pyrrolidin-2-one; 5-(5-((R)-(1,3-dimethyl-azetidin-3-yl)(hydroxy)(4-isopropyl-phenyl)methyl)pyridin-3-yl)hexahydro-4H-furo[2,3-c]pyrrol-4-one; 2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-aza-spiro[4.4]nonan-3-one; 6-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-6-aza-spiro[3.4]octan-5-one; 2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-8-oxa-2-aza-spiro[4.5]decan-3-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(tetrahydro-pyran-4-yl)-pyrrolidin-2-one; 2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-aza-spiro[4.5]decan-1-one; 2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-8-oxa-2-aza-spiro[4.5]decan-1-one; (S)-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-isobutyl-pyrrolidin-2-one; 4-Cyclopropyl-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-trifluoromethyl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(2-methoxy-ethyl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(2-methoxy-ethyl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-pyrrolidin-2-one; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-((R)-3-isopropyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-((2R,6S)-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(6-oxa-3-aza-bicyclo[3.1.1]hept-3-yl)-pyridin-3-yl]-methanol; (R)-[5-((3R,4S)-3,4-difluoro-pyrrolidin-1-yl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-[5-((3S,4S)-3,4-difluoro-pyrrolidin-1-yl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-((2S,6S)-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-((2R,6R)-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrrolidin-1-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(4-methyl-thiazol-2-yl)-pyrrolidin-1-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-phenyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-(3,3-dimethyl-pyrrolidin-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[(1S,4S)-5-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-pyridin-3-yl]-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(2,2,6,6-tetrafluoro-morpholin-4-yl)-pyridine-3 -yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-((R)-2-methoxymethyl-morpholin-4-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-((S)-2-methoxymethyl-morpholin-4-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-trifluoromethyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[(1R,4R)-5-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[(1S,5R)-5-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-pyridin-3-yl]-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-[(1S,4S)-5-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-pyridin-3-yl]-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-ethyl-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-ethyl-phenyl)-[5-(6-oxa-3-aza-bicyclo[3.1.1]hept-3-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-ethyl-phenyl)-[(1S,4S)-5-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-pyridin-3-yl]-methanol; (R)-(5-benzyloxy-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(2-pyridin-2-yl-ethoxy)-pyridin-3-yl]-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(2-methoxy-ethoxy)-pyridin-3-yl]-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(oxetan-3-ylmethoxy)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-propan-1-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(5-isopropoxy-pyridin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(5-cyclohexyloxy-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-2-methyl-propan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-methoxy-cyclopentyloxy)-pyridin-3-yl]-methanol; (R)-[5-(3-cyclopropyl-[1,2,4]oxadiazol-5-ylmethoxy)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4- isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-{5-[2-(3,5-dimethyl-[1,2,4]triazol-1-yl)-ethoxy]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-2-methyl-butan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-methoxy-pyridin-3-yl)-methanol; (R)-[5-(2-benzyloxy-ethoxy)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-pyran-4-yloxy)-pyridin-3-yl]-methanol; 2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-ethanol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-cyclohexanol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-1-methyl-cyclohexanol; (1,3-dimethyl-azetidin-3-yl)-(2-phenoxy-pyrimidin-5-yl)-(4-trifluoromethoxy-phenyl)-methanol; (6-benzyloxy-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(5-pyrazol-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-Dimethyl-azetidin-3-yl)-(6-fluoro-5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; 5-[(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-trifluoromethoxy-phenyl)-methyl]-3-pyrrolidin-1-yl-pyridine-2-carbonitrile; (1,3-dimethyl-azetidin-3-yl)-[6-(tetrahydro-pyran-4-yloxy)-pyridin-3-yl]-(4-trifluoromethoxy-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-[6-(oxetan-3-ylmethoxy)-pyridin-3-yl]-(4-trifluoromethoxy-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(4-methyl-thiazol-2-yl)-pyridin-3-yl]-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-methyl-thiazol-2-yl)-pyridin-3-yl]-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(2-methoxy-pyrimidin-5-yl)-methanol; (S)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(2-pyrrolidin-1-yl-pyridin-4-yl)-methanol; (1,3-dimethyl-azetidin-3-yl)-[2-((R)-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-4-yl]-(4-isopropyl-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(3 ,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4'-yl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(2-morpholin-4-yl-pyridin-4-yl)-methanol; (S)-(1,3-dimethyl-azetidin-3-yl)-(2-ethyl-pyridin-4-yl)-(4-isopropyl-phenyl)-methanol; (S)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[2-(tetrahydro-pyran-4-ylmethoxy)-pyridin-4-yl]-methanol; (S)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[2-(2-methoxy-ethoxy)-pyridin-4-yl]-methanol; (S)-(2-Cyclopentyl-pyridin-4-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-((R)-3-hydroxymethyl-3-methyl-pyrrolidin-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-((S)-3-fluoro-pyrrolidin-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[4-(tetrahydro-pyran-4-yl)-[1,2,3]triazol-1-yl]-pyridin-3-yl}-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-methyl-pyridin-3-yl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(5-isopropenyl-pyridin-3-yl)-(4-isopropyl-phenyl)-methanol; (5-cyclopropyl-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (5-cyclopent-1-enyl-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 3-{5-[(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclopent-2-enol;(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-isopropyl-pyridin-3-yl)-methanol; (5-Cyclopentyl-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 3-{5-[(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclopentanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-pyridin-3-yl-methanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclopent-2-enone; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-methyl-cyclopent-2-enol; (3S)-3-(5-((R)-(1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1-methylcyclopentadiene pentane-1-ol; (3R)-3-(5-((R)-(1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1-methylcyclopentan-1-ol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-ethyl-cyclopentanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-isopropyl-cyclopentanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(4-methyl-oxazol-2-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(5-ethyl-pyridin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-methyl-pyridin-3-yl)-methanol; (R)-[5-(4,5-dihydro-furan-3-yl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-furan-3-yl)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-en-1-ol; N-Cyclopentyl-5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-nicotinamide; {5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-1-yl-methanone; 5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-N-(tetrahydro-pyran-4-yl)-nicotinamide; (1,3-dimethyl-azetidin-3-yl)-[4-(3-methoxy-propyl)-phenyl]-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (R)-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-p-tolyl-methanol; 5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-carboxylic acid tert-butyl ester; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidine-1-carboxylic acid tert-butyl ester; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-pyran-4-yl)-pyridin-3-yl]-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(3',4',5',6'-tetrahydro-2'H-[2,1';4',3'']terpyridin-5''-yl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(1'-phenyl-1',2',3',4',5',6'-hexahydro-[3,4']bipyridinyl-5-yl)-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[1'-(toluene-4-sulfonyl)-1',2',3',4',5',6'-hexahydro-[3,4']bipyridinyl-5-yl]-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-furan-2-yl)-pyridin-3-yl]-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-methyl-tetrahydro-furan-2-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-(5,5-dimethyl-tetrahydro-furan-2-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2,2-difluoro-propan-1-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-methyl-oxazol-2-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-pyran-4-yl)-oxazol-2-yl]-pyridin-3-yl}-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-[5-(4-fluoro-phenoxymethyl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol;Isopropyl-carbamic acid 5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylmethyl ester; (R)-[5-(2-benzyloxy-ethyl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-methyl-cyclohexanol; 2-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclopropyl)-propan-2-ol; (S)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{2-[5-(tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-4-yl}-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(2-pyrrolidin-1-yl-pyrimidin-5-yl)-methanol; and (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(6-pyrrolidin-1-yl-pyrazin-2-yl)-methanol.

[0114] 34) Another embodiment relates to a compound according to embodiment 1), selected from the group consisting of the following compounds: (R)-N-(1-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)cyclopropyl)acetamide-2,2,2-d3; (R)-N-(1-(3-(5-((1,3-dimethylazetidin-3-yl)(hydrogen) oxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)cyclopropyl)-N-methylacetamide-d3; (R)-N-((3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)methyl)-N-methylacetamide-d3; N-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-2-hydroxy-acetamide; (R)-N-((3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)methyl)acetamide-2,2,2-d3; 1-(3-{5-[(R)-hydroxy-(1-isopropyl-3-methyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-2-methyl-propan-2-ol; 1-(3-{5-[(R)-(1-ethyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-2-methyl-propan-2-ol; 2-(3-{5-[(R)-hydroxy-(1-isopropyl-3-methyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(1-ethyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 4-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-piperidine-1-carboxylic acid benzyl ester; 1-[4-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-ethanone; (R)-1-(3-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)azetidin-1-yl)ethan-1-one-2,2,2-d3; (R)-1-(3-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)-3-methylazetidin-1-yl)ethan-1-one-2,2,2-d3; (R)-1-(3-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)-3-fluoroazetidin-1-yl)ethan-1-one-2,2,2-d3; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methyl-1-morpholin-4-yl-ethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-methyl-piperidin-2-one; 1-[(S)-3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-pyrrolidin-1-yl]-ethanone; 1-[(R)-3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-pyrrolidin-1-yl]-ethanone; N-[1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-methyl-ethyl]-acetamide; 1-benzyl-3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-pyrrolidin-2-one; 3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1,3-dimethyl-pyrrolidin-2-one; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-isobutyl-pyrrolidin-2-one; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-furan-2-ylmethyl-pyrrolidin-2-one; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-phenyl-pyrrolidin-2-one; 1-benzyl-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-pyrrolidin-2-one; 5-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-phenyl-pyrrolidin-2-one; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-pyrrolidin-2-one; (S)-5-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-pyrrolidin-2-one; (R)-5-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-pyrrolidin-2-one; (S)-6-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-2-one; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-2-one; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-azetidin-2-one; (S)-3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-azetidin-2-one; (S)-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2, 4]Oxadiazol-5-yl)-1,4-dimethyl-pyrrolidin-2-one; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1,4-dimethyl-pyrrolidin-2-one; (R) or (S)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1,4-dimethyl-pyrrolidin-2-one; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-piperidin-4-yl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(4-methyl-piperidin-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-{5-[5-(4-fluoro-piperidin-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-butan-1-one; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-2,2-dimethyl-propan-1-one; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-2-methoxy-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-3-methoxy-propan-1-one; Cyclopropyl-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone; Cyclopentyl-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone; [4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-(tetrahydro-pyran-4-yl)-methanone; [4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-phenyl-methanone; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidine-1-carboxylic acid methyl ester; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidine-1-carboxylic acid ethyl ester; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidine-1-carboxylic acid 2-methoxy-ethyl ester; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methanesulfonyl-piperidin-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(propane-2-sulfonyl)-piperidin-4-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(propane-1-sulfonyl)-piperidin-4-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-3-yl)-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(2-methoxy-ethanesulfonyl)-piperidin-4-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-3-yl)-methanol; 2-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidine-1-sulfonyl]-ethanol; (R)-{5-[5-(1-cyclopentanesulfonyl-piperidin-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(tetrahydro-pyran-4-sulfonyl)-piperidin-4-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-3-yl)-methanol; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidine-1-sulfonic acid methylamide; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methylamino-cyclopropyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; [1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-cyclopropyl]-methyl-carbamic acid ethyl ester; N-[1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-cyclopropyl]-N-methyl-methanesulfonamide; (R)-(1,3-dimethyl-azetidin-3-yl)-[6-(2,2-dimethyl-cyclopentyloxy)-pyridazin-4-yl]-(4-isopropyl-phenyl)-methanol; (R)-[6-(3,3-difluoro-cyclopentyloxy)-pyridazin-4-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 2-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy -(4-isopropyl-phenyl)-methyl]-pyridazin-3-yloxy}-phenyl)-ethanol; 2-(4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yloxy}-phenyl)-ethanol; (R)-[6-(chroman-6-yloxy)-pyridazin-4-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 6-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yloxy}-3H-benzoxazol-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methyl-pyrimidin-4-yl)-pent-1-yn-3-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-{5-[1-(4-fluoro-phenyl)-cyclopropylethynyl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4 -isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-piperidine-1-carboxylic acid tert-butyl ester; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methyl-pyrimidin-4-yl)-pentan-3-ol; 2-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-benzoic acid methyl ester; (R)-(1,3-dimethyl-azetidin-3-yl)-{5-[2-(2-hydroxymethyl-phenyl)-ethyl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin-4-yl)-butan-2-ol; 3-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[2-(1H-pyrrolo[2,3-b]pyridin-2-yl)-ethyl]-pyridin-3-yl}-methanol; 4-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-piperidine-1-carboxylic acid tert-butyl ester; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-pyridin-2-yl-butan-2-ol; 1-Cyclopropyl-3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-pyridin-2-yl-propan-1-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-pyridin-3-yl)-butan-2-ol; 8-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-ethyl)-5,6,7,8-tetrahydro-quinolin-8-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-2-(6-methoxy-pyridin-2-yl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-2-(6-methyl-pyridin-2-yl)-butan-2-ol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(6-pyrrolidin-1-yl-pyridin-2-yl)-methanol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-4-fluoro-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-4-methyl-piperidin-1-yl]-ethanone ; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-cyclohexanone; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclohexanol; (R)-(5-cyclopentyloxymethyl-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 1-(4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylmethoxy}-piperidin-1-yl)-ethanone; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[6-(tetrahydro-pyran-4-yl)-pyridazin-4-yl]-methanol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-2-phenyl-butan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{6-[(S)-(tetrahydro-furan-3-yl)oxy]-pyridazin-4-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{6-[(R)-(tetrahydro-furan-3-yl)oxy]-pyridazin-4-yl}-methanol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-4-methyl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-3-isopropyl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-3,3-dimethyl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-4,4-dimethyl-pyrrolidin-2-one; 5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-5-aza-spiro[2.4]heptan-6-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-4-trifluoromethyl-pyrrolidin-2-one; 4-Cyclopropyl-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-pyrrolidin-2-one; 2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-8-oxa-2-aza-spiro[4.5]decan-3-one; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-1-oxa-3-aza-spiro[4.5]decan-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-4-pyridin-2-yl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-3-(2-methoxy-ethyl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-4-phenyl-pyrrolidin-2-one; 2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-2,3-dihydro-isoindol-1-one; 2-(3-{5-[(S)-(3-fluoro-1-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(S)-(1-cyclopropyl-3-fluoro-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 1-[4-(3-{5-[(S)-(3-fluoro-1-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(S)-(1-cyclopropyl-3-fluoro-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 2-(3-{5-[(R)-(1-cyclopropyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 1-[4-(3-{5-[(R)-(1-cyclopropyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; (R)-(1-cyclopropyl-3-methyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; trans-4-(3-{5-[(R)-(1-cyclopropyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-cyclohexanol; (R)-(1-cyclopropyl-3-methyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-oxetan-3-yl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-methanol; 1-[(R)-3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-pyrrolidin-1-yl]-ethanone; 1-[3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2 ,4]oxadiazol-5-yl)-3-hydroxy-piperidin-1-yl]-ethanone; 1-[3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-3-methyl-piperidin-1-yl]-ethanone; 1-[3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-4-hydroxy-piperidin-1-yl]-ethanone; N-[1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-cyclopropyl]-acetamide; Tetrahydro-pyran-4-carboxylic acid [1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-cyclopropyl]-amide; N-[1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-cyclopropyl]-2-methoxy-acetamide; N-[1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-cyclopropyl]-N-methyl-acetamide; N-[2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1,1-dimethyl-ethyl]-propionamide; N-[2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1,1-dimethyl-ethyl]-2-methoxy-acetamide; Tetrahydro-pyran-4-carboxylic acid [2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1,1-dimethyl-ethyl]-amide; N-[2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1,1-dimethyl-ethyl]-isobutyramide; Cyclopropanecarboxylic acid [2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1,1-dimethyl-ethyl]-amide; 1-[cis-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}- [1,2,4]oxadiazol-5-yl)-2-methyl-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-4-hydroxy-piperidin-1-yl]-2-methyl-propan-1-one; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-4-hydroxy-piperidin-1-yl]-propan-1-one; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-4-methoxy-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-3,3,3-trifluoro-propan-1-one; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-2-oxetan-3-yl-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-4-ethyl-piperidin-1-yl]-ethanone; [4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-oxetan-3-yl-methanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-4-isopropyl-piperidin-1-yl]-2-methoxy-ethanone; 1-[cis-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-3-methyl-piperidin-1-yl]-ethanone; 5-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-methyl-piperidin-2-one; 5-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-5-methyl-piperidin-2-one; 5-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-2-one; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-4-methyl-pyrrolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-3,3-dimethyl-pyrrolidine-2,5-dione; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-imidazolidine-2,4-dione; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-pyrrolidin-2-one; 3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-imidazolidine-2,4-dione; 3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-1-methyl-imidazolidine-2,4-dione;1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-1-methyl-imidazolidine-2,4-dione )-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-3-methyl-imidazolidine-2,4-dione; 3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-oxazolidin-2-one; 1-Cyclopropyl-3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-imidazolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-pyrrolidine-2,5-dione; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-3-methyl-imidazolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-imidazolidin-2-one; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propane-1,2-diol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-pyridin-3-yl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-methanol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-piperidin-1-yl]-ethanone; (3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-acetonitrile; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-4-hydroxy-piperidin-1-yl]-ethanoate Non; 3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propylonitrile; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-3-methoxy-piperidin-1-yl]-ethanone; 1-[(R)-3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-tetrahydro-pyran-4-ol; (R)-(1,3-Dimethyl-azetidin-3-yl)-{5-[5-(3-hydroxymethyl-bicyclo[1.1.1]pent-1-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-methyl-piperidine-2,6-dione; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-2,2-difluoro-ethanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(3-methoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-(5-isopropyl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-methyl-pyrrolidin-2-one; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-methyl-pyrrolidin-2-one; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-ethyl-pyrrolidin-2-one; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-ethyl-pyrrolidin-2-one; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-ethyl-pyrrolidin-2-one; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-ethyl-pyrrolidin-2-one; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-isopropyl-pyrrolidin-2-one; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-isopropyl-pyrrolidin-2-one; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-isopropyl-pyrrolidin-2-one; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-isopropyl-pyrrolidin-2-one; 1-[(S)-3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-pyrrolidin-1-yl]-ethanone; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-2-one; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-2-one; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-2-one; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-2-one; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-methyl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-methanol; (R)-{5-[5-(1,1-difluoro-ethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 4-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-tetrahydro-pyran-4-ol; (R)-[5-(3-tert-butoxymethyl-[1,2,4]oxadiazol-5-yl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-(3-hydroxymethyl-[1,2,4]oxadiazol-5-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; 1-[4-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-piperazin-1-yl]-ethanone; 1-[3-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-ylmethyl)-azetidin-1-yl]-ethanone; 4-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy -(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-ylmethyl)-tetrahydro-pyran-4-ol; [4-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-[1,4]dioxan-2-yl-methanone; 1-[4-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-2-methoxy-ethanone; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(1-methanesulfonyl-piperidin-4-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{3-[1-(2-methoxy-ethanesulfonyl)-piperidin-4-yl]-[1,2,4]oxadiazol-5-yl}-pyridin-3-yl)-methanol; 1-[4-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-2-hydroxy-ethanone; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-[1,2,4]oxadiazol-3-yl-pyridin-3-yl)-methanol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 2-(3-{5-[(R)-(4-bromo-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-naphthalen-2-yl-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-[3-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2-ol; 2-[3-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropoxy-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-[3-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2-ol; (R)-2-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-(pentafluoro-λ6-sulfanyl)phenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-(3-fluoro-4-isopropyl-phenyl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(4-tert-butyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-benzo[b]thiophen-5-yl-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-pentafluoroethyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-[3-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(1-methyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-3-methyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-trifluoromethoxy-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 1-[4-(3-{5-[(R)-(4-Bromo-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 2-[3-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-[4-(1-fluoro-1-methyl-ethyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2-ol; 2-(3-{5-[(R)-[4-(1,1-difluoro-ethyl)-phenyl]-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(4-bicyclo[1.1.1]pent-1-yl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-{5-[5-(tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-[4-(2,2,2-trifluoro-ethyl)-phenyl]-methanol; 2-[3-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-[4-(1,1-dimethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2-ol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-(3-fluoro-4-isopropyl-phenyl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-{4-[3-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-trifluoromethoxy-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropoxy-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 2-(3-{5-[(R)-(3-chloro-4-isopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(4-cyclobutyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 1-[4-(3-{5-[(R)-(4-cyclobutyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(3,5-difluoro-4-isopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 2-(3-{5-[(R)-(3,5-difluoro-4-isopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 1-[4-(3-{5-[(R)-(4-cyclobutoxy-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 2-[3-(5-{(1,3-dimethyl-azetidin-3-yl)-[4-(1-ethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2-ol; 1-{4-[3-(5-{(1,3-dimethyl-azetidin-3-yl)-[4-(1-ethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone; 2-[3-(5-{(1,3-dimethyl-azetidin-3-yl)-[4-(2,2-dimethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2-ol; 1-{4-[3-(5-{(1,3-dimethyl-azetidin-3-yl)-[4-(2,2-dimethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone;1-{4-[3-(5-{(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(1-methyl-cyclohexyl) 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-propyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-(4-ethyl-phenyl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(4-butyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy -(4-trifluoromethyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-[3-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(2,2,2-trifluoro-ethyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isobutyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(4-cyclobutoxy-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropenyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 1-{4-[3-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(2,2,2-trifluoro-ethyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-propyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-hydroxy-(1-isopropyl-3-methyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-[1-(2,2-difluoro-ethyl)-3-methyl-azetidin-3-yl]-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-hydroxy-[1-(2-hydroxy-ethyl)-3-methyl-azetidin-3-yl]-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1-cyclopropylmethyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-{4-[3-(5-{(R)-hydroxy-(4-isopropyl-phenyl)-[1-(2-methoxy-ethyl)-3-methyl-azetidin-3-yl]-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone; 1-{4-[3-(5-{(R)-hydroxy-(4-isopropyl-phenyl)-[3-methyl-1-(3,3,3-trifluoro-propyl)-azetidin-3-yl]-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone; 1-[4-(3-{5-[(R)-hydroxy-(4-isopropyl-phenyl)-(3-methyl-1-propyl-azetidin-3-yl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1-ethyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[ 1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-(4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-piperidin-1-yl)-ethanone; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1,1-trifluoro-2-methyl-but-3-yn-2-ol; Cyclopropanecarboxylic acid (3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-amide; N-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-isobutyramide; N-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-2-methoxy-acetamide; 3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-oxazolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-pyrrolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-3-methyl-imidazolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-imidazolidin-2-one; 3-(1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopropyl)-oxazolidin-2-one; 1-((R)-2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-2-methyl-pyrrolidin-1-yl)-ethanone; 1-(4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-4-hydroxy-piperidin-1-yl)-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-hydroxy-1-methyl-prop-2-ynyl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-hydroxy-prop-2-ynyl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-prop-2-ynyl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-hydroxy-prop-2-ynyl)-4-methyl-piperidin-1-yl]-ethanone; 1-(4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy -(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-4-methyl-piperidin-1-yl)-ethanone; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(1-methanesulfonyl-piperidin-4-ylethynyl)-pyridin-3-yl]-methanol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-4-methyl-piperidine-1-sulfonic acid methylamide; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-methanesulfonyl-3-methyl-but-1-ynyl)-pyridin-3-yl]-methanol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopropanesulfonic acid dimethylamide; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopropanesulfonic acid amide; (R)-[5-(3-cyclopropanesulfonyl-3-methyl-but-1-ynyl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-1-methyl-pyrrolidin-2-one; (S)-3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-1-methyl-pyrrolidin-2-one; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-ol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-1-methyl-1,3-dihydro-indol-2-one; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1H-indazol-3-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-indazol-3-yl)-but-3-yn-2-ol; 2-(1-cyclopropyl-1H-pyrazol-3-yl)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-pyrazin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazol-5-yl)-but-3-yn-2-ol; 2-(6-cyclopropyl-pyrimidin-4-yl)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; N-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-acetamide; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2,6-dimethyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2,6-dimethyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-(S)-2-(2,6-dimethoxy-pyrimidin-4-yl)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; (S)-2-(2,6-dimethoxy-pyrimidin-4-yl)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; (R)-2-(2,6-dimethoxy-pyrimidin-4-yl)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl (6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol; 2-(6-Difluoromethyl-pyrimidin-4-yl)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(1-pyridin-2-yl-cyclopropylethynyl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[1-(6-methyl-pyrimidin-4-yl)-cyclopropylethynyl]-pyridin-3-yl}-methanol; 1-[4-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-piperidin-1-yl]-ethanone; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1,1-trifluoro-2-methyl-butan-2-ol; 3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-propyl)-oxazolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-propyl)-pyrrolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-propyl)-3-methyl-imidazolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-propyl)-imidazolidin-2-one; 1-[(S)-2-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-2-methyl-pyrrolidin-1-yl]-ethanone; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1H-indazol-3-yl)-butan-2-ol; 2-(1-cyclopropyl-1H-pyrazol-3-yl)-4-{5-[(R)-(1 ,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-pyrimidin-4-yl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-pyrazin-2-yl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazol-5-yl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(3-methyl-isoxazol-5-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-imidazol-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-thiophen-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrrol-2-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-(R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol; 4-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(1-methyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-trifluoromethyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-(4-ethyl-phenyl)-hydroxy-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(4-tert-butyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(3-ethyl-1-methyl-azetidin-3-yl)-hydroxy-(4-trifluoromethoxy-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(2,2,2-trifluoro-ethyl)-phenyl]-methyl}-pyridin-3-yl)-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(S)-(3-fluoro-1-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 1-(4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-ylethynyl}-piperidin-1-yl)-ethanone; N-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-1,1-dimethyl-prop-2-ynyl)-acetamide; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-1,1-dimethyl-prop-2-ynyl)-pyrrolidin-2-one; 4-{5-[(R)-hydroxy-(1-isopropyl-3-methyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-hydroxy-[1-(2-hydroxy-ethyl)-3-methyl-azetidin-3-yl]-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-[1-(2,2-difluoro-ethyl)-3-methyl-azetidin-3-yl]-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 1-(4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxymethyl}-piperidin-1-yl)-ethanone; 4-{5-[(R)-(1-cyclopropyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(2-isopropyl-pyrimidin-4-yl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(2-methyl-thiazol-5-yl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(6-methyl-pyridin-3-yl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(6-isopropyl-pyridin-2-yl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(6-trifluoromethyl)- (trimethyl-pyridin-3-yl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(1-methyl-1H-pyrazol-4-yl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrrolidin-2-one; 4-(1-Difluoromethyl-1H-pyrazol-4-yl)-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(2-methyl-2H-[1,2,3]triazol-4-yl)-pyrrolidin-2-one; 4-(1-acetyl-piperidin-4-yl)-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-pyrrolidin-2-one; 5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-hexahydro-furo[2,3-c]pyrrol-4-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-4-(6-isopropyl-pyridin-2-yl)-pyrrolidin-2-one; 1-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)-ethanone; 1-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-ethanone; 1-[4-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrimidin-5-yl)-piperidin-1-yl]-ethanone; and 1-[4-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrimidin-4-yl)-piperidin-1-yl]-ethanone.

[0115] 35) Another embodiment relates to a compound according to embodiment 1), selected from the group consisting of the following compounds: (R)-2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1,1,1-trifluoro-propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(S)-(1-cyclopropyl-3-fluoro-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; and 2-(3-{5-[(R)-(4-Butyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol.

[0116] 36) Another embodiment relates to a compound according to embodiment 1), selected from the group consisting of the following compounds: 4-{5-[(R)-hydroxy-[1-(2-hydroxy-ethyl)-3-methyl-azetidin-3-yl]-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-trifluoromethyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; and 4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-ethyl-phenyl)-hydroxy-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol.

[0117] 37) Another embodiment relates to a compound according to embodiment 1), selected from the group consisting of the following compounds: 1-[4-(3-{5-[(R)-(1-cyclopropyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-propyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; and 1-[4-(3-{5-[(R)-Hydroxy-(1-isopropyl-3-methyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone.

[0118] 38) Another aspect of the invention relates to compounds of embodiment 1), which are also compounds of formula (Ip):

[0119] [ka]

[0120] wherein A represents a 6-membered heteroaryl having 1 to 3 ring nitrogen atoms (particularly 1 or 2 ring nitrogen atoms; especially 1 or 2 ring nitrogen atoms in the meta and / or para positions of A relative to the point of attachment of A to the remainder of the molecule), and the 6-membered heteroaryl is independently unsubstituted or substituted with 1, 2, or 3 substituents (particularly substituted with 1 or 2 substituents at the meta and / or para positions of A relative to the point of attachment of A to the remainder of the molecule), and when such substituents are present, they are - halogens (especially fluorine); - Cyano; - C 1-4 alkyl (especially methyl, ethyl, propyl or isopropyl; especially methyl, ethyl or propyl), unsubstituted or containing one -- C 1-3 -alkoxy (especially methoxy); -- Fluoro-phenoxy (especially 4-fluoro-phenoxy); -- benzyl-oxy; -- C optionally fused to a pyridine ring (especially at positions 2 and 3 adjacent to the nitrogen atom of the pyridine ring) 3-6 -cycloalkyl, wherein the C 3-6 -cycloalkyl is unsubstituted or (especially as defined above in C 1-4 -C to alkyl 3-6 -substituted by one hydroxy at the point of attachment of the cycloalkyl, C 3-6 -cycloalkyl; -- unsubstituted or one C 1-3 -pyrazolyl (especially pyrazol-4-yl) substituted by alkyl (especially methyl); tetrahydropyranyl (especially tetrahydropyran-4-yl) which is unsubstituted or substituted by one hydroxyl (especially 4-hydroxy-tetrahydropyran-4-yl); -- indolyl (especially indol-2-yl); -- N-(C 1-3 -alkyl)-amino-carbonyl-oxy; or -- 1-(C 1-4 -alkyl-oxy-carbonyl)-3-hydroxyazetidin-3-yl; C replaced by 1-4 - alkyl; [In particular, such C is unsubstituted or substituted by one substituent as defined above. 1-4-Alkyl is methyl, ethyl, isopropyl, 2-(1-hydroxy-cyclopropyl)-ethyl, 2-(1-hydroxy-cyclobutyl)-ethyl, 2-(1-hydroxy-cyclopentyl)-ethyl, 3-methoxy-propyl, 4-fluoro-phenoxy-methyl, benzyl-oxy-methyl, N-(isopropyl)-amino-carbonyl-oxy-methyl, 2-(1-(tert-butoxy-carbonyl)-3-hydroxyazetidine -3-yl)-ethyl, 2-(1-methyl-pyrazol-4-yl)-ethyl, 2-(tetrahydropyran-4-yl)-ethyl, 2-(4-hydroxy-tetrahydropyran-4-yl)-ethyl, 2-(indol-2-yl)-ethyl, 2-(8-hydroxy-5,6,7,8-tetrahydroquinolin-8-yl)-ethyl or 2-(7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)-ethyl. - C 3-5 -alkenyl, unsubstituted (especially isopropenyl) or substituted by one hydroxy (especially 4-hydroxy-but-1-en-2-yl), C 3-5 -alkenyl; - tetrahydropyranyl (especially tetrahydropyran-4-yl); - hydroxy-C optionally further substituted by one or more fluorine atoms 1-6 - alkyl (in particular 3-hydroxypropyl, 4-hydroxybutyl, 3-hydroxybutyl, 3-hydroxy-3-methylbutyl, 3-hydroxy-4-methylpentyl or 2,2-difluoro-3-hydroxyprop-1-yl); - C 3-5 - alkyl (especially n-propyl, n-butyl or n-pentyl), and hydroxy and R A1 (especially if both substituents are attached to the remainder of the molecule) 3-5 - in the 3-position relative to the point of attachment of the alkyl; -- R A1 but, --- tetrahydropyranyl (especially tetrahydropyran-4-yl); --- unsubstituted or containing one fluorine (especially 3-fluoro-phenyl) or C1 -3 phenyl substituted by -alkoxy (in particular 2-methoxy-phenyl or 4-methoxy-phenyl); or 5- or 6-membered heteroaryl having 1 or 2 ring heteroatoms independently selected from nitrogen and sulfur (particularly thiazolyl, pyrazolyl, pyridinyl or pyrimidinyl; especially thiazol-4-yl, pyrazol-3-yl, pyrazol-4-yl, pyridin-2-yl, pyrimidin-2-yl or pyrimidin-4-yl), which 5- or 6-membered heteroaryl is independently unsubstituted or substituted by 1 or 2 substituents, if present, which are selected from the group consisting of: C 1-3 -Alkyl (especially methyl) or C 1-3 - 5- or 6-membered heteroaryl independently selected from alkoxy (especially methoxy); C represents 3-5 - alkyl; [In particular, such C 3-5-Alkyl is 3-hydroxy-3-(tetrahydropyran-4-yl)-propyl, 3-hydroxy-3-phenyl-propyl, 3-hydroxy-3-phenyl-butyl, 3-hydroxy-3-(m-fluoro-phenyl)-butyl, 3-hydroxy-3-(o-methoxy-phenyl)-butyl, 3-hydroxy-3-(p-methoxy-phenyl)-butyl, 3-hydroxy-3-(1,5-dimethyl-pyrazol-3-yl)-butyl, 3-hydroxy-3-(1-methyl-pyrazol-3-yl)-butyl, 3-hydroxy-3-(1,5-dimethyl-pyrazol-3-yl)-propyl pyrazol-4-yl, 3-hydroxy-3-(2-methyl-thiazol-4-yl)-butyl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-butyl, 3-hydroxy-3-(pyrimidin-2-yl)-butyl, 3-hydroxy-3-(6-methoxy-pyrimidin-4-yl)-butyl, 3-hydroxy-3-(1,3-dimethyl-pyrazol-4-yl)-propyl, 3-hydroxy-3-(2-methyl-thiazol-4-yl)-propyl, 3-hydroxy-3-(pyridin-2-yl)-pentyl or 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-pentyl. - C 3-6 -cycloalkyl, unsubstituted or substituted with 1 or 2 C 1-3 -Alkyl (especially methyl, ethyl, isopropyl), hydroxy or hydroxy-C 1-3 -alkyl (especially 1-hydroxy-1-methyl-ethyl), 3-6 -cycloalkyl, one ring carbon atom of which is optionally replaced by an oxygen atom, C 3-6 -cycloalkyl; [In particular, such C 3-6-cycloalkyl is cyclopropyl, cyclopentyl, 3-hydroxy-cyclopentyl, 3-hydroxy-3-methyl-cyclopentyl, 3-hydroxy-3-ethyl-cyclopentyl, 3-hydroxy-3-isopropyl-cyclopentyl, 2-(2-hydroxy-isopropyl)-cyclopropyl, 4-hydroxy-4-methyl-cyclohexyl, tetrahydrofuran-3-yl, tetrahydrofuran-2-yl, tetrahydropyran-4-yl, 5-methyl-tetrahydrofuran-2-yl or 5,5-dimethyl-tetrahydrofuran-2-yl. - C 4-6 -cycloalkenyl (especially cyclopentenyl; especially cyclopent-1-en-1-yl), unsubstituted or containing one or two C 1-3 -substituted by alkyl, oxo (i.e., =O) or hydroxy, 4-6 -cycloalkenyl, one ring carbon atom of which is optionally replaced by an oxygen atom, C 4-6 -cycloalkenyl; [In particular, such C 4-6 -cycloalkenyl is 3-oxo-cyclopent-1-en-1-yl, 3-hydroxy-3-methyl-cyclopent-1-en-1-yl, 2,3-dihydro-furan-3-yl or 5-methyl-furan-2-yl. - -OR O2 (-- R O2 teeth, --- C 1-4 - alkyl (especially methyl, ethyl, isopropyl, sec-butyl or isobutyl); --- Hydroxy-C 1-5 - alkyl (in particular 2-hydroxy-ethyl, 3-hydroxy-propyl, 2-hydroxy-2-methyl-propyl or 3-hydroxy-3-methyl-butyl); --- C 1-3 -Alkoxy-C 2-3 - alkyl (especially 2-methoxy-ethyl); --- unsubstituted or 1 or 2 C 1-3 -Alkyl (especially methyl), hydroxy or C 1-3 -C substituted by alkoxy (especially methoxy) 3-6 cycloalkyl (especially cyclopentyl or cyclohexyl); --- tetrahydropyranyl (especially tetrahydropyran-4-yl); --- Tetrahydropyranyl-C 1-3 - alkyl (especially tetrahydropyran-4-yl-methyl); --- Oxetanyl-C 1-3 - alkyl (especially oxetan-3-yl-methyl); --- phenyl; --- Benzyl; --- Benzyl-oxy-C 1-3 - alkyl (especially 2-(benzyl-oxy)-ethyl); --- Pyridinyl-C 1-3 - alkyl (especially 2-(pyridin-2-yl)-ethyl); --- (3-cyclopropyl-1,2,4-oxadiazol-5-yl)-methyl; or --- 2-(3,5-dimethyl-1,2,4-triazol-1-yl)-ethyl; represents. ); [Especially, such -OR Ois methoxy, ethoxy, isopropoxy, isobutoxy, sec-butoxy, phenoxy, benzyloxy, 2-(benzyloxy)-ethoxy, 2-methoxy-ethoxy, oxetan-3-yl-methoxy, 3-hydroxy-propoxy, cyclohexyl-oxy, 4-hydroxy-cyclohexyl-oxy, 4-methyl-4-hydroxy-cyclohexyl-oxy, 2-hydroxy-2-methyl-propoxy, 2-hydroxy-ethoxy, 3-hydroxy-3-methyl-butoxy, tetrahydropyran-4-yl-oxy, tetrahydropyran-4-yl-methoxy, 3-methoxy-cyclopentyl-oxy, (3-cyclopropyl-1,2,4-oxadiazol-5-yl)-methoxy or 2-(3,5-dimethyl-1,2,4-triazol-1-yl)-ethoxy. - -C≡CR T1 (-- R T1 teeth, --- Hydroxy-C 1-4 - alkyl (in particular hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxy-2-methylpropyl or 1-hydroxy-1-methylethyl); --- C 1-3 -Alkoxy-C 1-3 - alkyl (especially methoxy-methyl); --- C substituted by one hydroxy 3-6 -cycloalkyl (especially the above C to the rest of the molecule) 3-6 - at the attachment point of cycloalkyl; in particular 1-hydroxy-cyclopropyl, 1-hydroxy-cyclobutyl or 1-hydroxy-cyclopentyl); --- C fused to a pyridine ring (especially at the 2- and 3-positions of the pyridine ring) 3-6 -cycloalkyl (especially cyclopentyl or cyclohexyl), 3-6 -cycloalkyl (especially the above C 3-6 -C substituted by one hydroxyl at the 1-position of the cycloalkyl ring 3-6-cycloalkyl (in particular 8-hydroxy-5,6,7,8-tetrahydroquinolin-8-yl or 7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl); --- pyrazolyl (especially pyrazol-4-yl) substituted by one methyl (especially 1-methyl-pyrazol-4-yl); --- tetrahydropyranyl (especially tetrahydropyran-4-yl), which is unsubstituted or substituted by one hydroxy, tetrahydropyranyl (especially 4-hydroxy-tetrahydropyran-4-yl); --- indolyl (especially indol-2-yl); or --- Hydroxy-azetidinyl (especially 3-hydroxy-azetidin-3-yl), 1-4 -hydroxy-azetidinyl N-substituted by alkoxy-carbonyl (in particular isopropyl-carbonyl or tert-butoxy-carbonyl); represents. ); [In particular, such -C≡CR T1 are 3-hydroxy-prop-1-yn-1-yl, 4-hydroxy-but-1-yn-1-yl, 3-hydroxy-but-1-yn-1-yl, 3-hydroxy-3-methyl-but-1-yn-1-yl, 3-hydroxy-4-methyl-pent-1-yn-1-yl, 3-methoxy-prop-1-yn-1-yl, (1-hydroxy-cyclopropyl)-ethynyl, (1-hydroxy-cyclobutyl)-ethynyl, (1-hydroxy-cyclopentyl)-ethynyl, (8-hydroxy-5,6,7,8-tetrahydroquinoline-8- (7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)-ethynyl, (1-methyl-pyrazol-4-yl)-ethynyl, (tetrahydropyran-4-yl)-ethynyl, (4-hydroxy-tetrahydropyran-4-yl)-ethynyl, indol-2-yl-ethynyl, (1-(isopropyl-carbonyl)-3-hydroxy-azetidin-3-yl)-ethynyl or (1-(tert-butoxy-carbonyl)-3-hydroxy-azetidin-3-yl)-ethynyl. - -C≡CC(OH)(R T2 )(R T3 ) (-- R T2 is hydrogen or C 1-3 - alkyl (in particular methyl or ethyl); -- R T3 teeth, --- Phenyl which is unsubstituted or substituted by one substituent, if said substituent is present, is C 1-3 - phenyl, independently selected from alkoxy (especially methoxy) or halogen (especially fluorine); [In particular, such phenyl, unsubstituted or substituted by one substituent, is 3-fluoro-phenyl, 4-methoxy-phenyl or 2-methoxy-phenyl.] --- 5-6 membered heteroaryl having 1 or 2 ring heteroatoms independently selected from nitrogen or sulfur (particularly thiazolyl, pyrazolyl, pyridinyl or pyrimidinyl; especially thiazol-4-yl, pyrazol-3-yl, pyrazol-4-yl, pyridin-2-yl, pyrimidin-2-yl or pyrimidin-4-yl), which 5 or 6 membered heteroaryl is independently unsubstituted or substituted by 1 or 2 substituents, if present, which are selected from the group consisting of C 1-3 -Alkyl (especially methyl) and C 1-3 - 5-6 membered heteroaryl independently selected from alkoxy (especially methoxy); [In particular, such 5- to 6-membered heteroaryl is 1-methyl-pyrazol-3-yl, 1,3-dimethyl-pyrazol-4-yl, 1,5-dimethyl-pyrazol-3-yl, 2-methyl-thiazol-4-yl, pyridin-2-yl, 6-methoxy-pyridin-2-yl, pyrimidin-2-yl, pyrimidin-4-yl or 1,5-dimethyl-pyrazol-3-yl.] --- tetrahydropyranyl (especially tetrahydropyran-4-yl); represents. ); [In particular, such -C≡CC(OH)(R T2 )(R T3) is 3-hydroxy-3-(tetrahydropyran-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-phenyl-prop-1-yn-1-yl, 3-hydroxy-3-(2-methyl-thiazol-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-(1,3-dimethyl-pyrazol-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-phenyl-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-pyrazole- 3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1,5-dimethyl-pyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-pyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(pyrimidin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-pyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(3-fluoro-phenyl)-but-1-yn-1-yl, 3-hydroxy-3- (6-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(pyridin-2-yl)-pent-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-pent-1-yn-1-yl, 3-hydroxy-3-(4-methoxy-phenyl)-but-1-yn-1-yl or 3-hydroxy-3-(2-methoxy-phenyl)-but-1-yn-1-yl. -NR N1 R N2 (-- R N1 is C 1-3 - represents alkyl (especially methyl); R N2 is hydroxy-C 1-3 -alkyl (especially 2-hydroxyethyl) or 2-(benzyloxy)-C 1-3 - alkyl (especially 2-(benzyl-oxy)-ethyl); -- or R N1 and R N2together with the nitrogen to which they are attached form a 4- to 6-membered (particularly 5- to 6-membered) heterocycle, and the ring members necessary to complete the heterocycle are -CH2-, -O-, -(C=O)-, -CHR X - and -C(R Y )2-; the heterocycle has no more than one ring member independently selected from the group consisting of -O- and -(C=O)-; the heterocycle is -CHR X -; the heterocycle has no more than two ring members selected from the group consisting of -C(R Y )2-; R X independently represent fluorine, methyl, isopropyl, isobutyl, tert-butyl, hydroxy, trifluoromethyl, hydroxymethyl, 1-hydroxyethyl, 1-hydroxy-1-methylethyl, cyclopropyl, 2-methoxyethyl, 4-methylthiazol-2-yl, phenyl, benzyl, tetrahydropyran-4-yl, 1,2,4-oxadiazolyl, 3-methyl-1,2,4-oxadiazol-5-yl, pyridin-2-yl or 1-methoxymethyl; R Y independently represent fluorine, hydroxy, cyclopropyl, methyl, hydroxy-methyl or trifluoromethyl; in particular, such -NR N1 R N2 is pyrrolidinyl; 2-pyrrolidonyl; oxazolidinonyl (especially 1,3-oxazolidin-2-one-3-yl); piperidinyl; or R X and R Y and morpholinyl optionally substituted independently by 1 or 2 substituents independently selected from the group consisting of: [Especially, such -NR N1 R N2are pyrrolidin-1-yl, 3-fluoro-pyrrolidin-1-yl, 3,3-difluoro-pyrrolidin-1-yl, 3,4-difluoro-pyrrolidin-1-yl, 3-isopropyl-pyrrolidin-1-yl, 3,3-dimethyl-pyrrolidin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 2-methyl-pyrrolidin-1-yl, 3-hydroxy-3-methyl-pyrrolidin-1-yl, 3-(hydroxy-methyl)-pyrrolidin-1-yl, 2-(hydroxy-methyl)-pyrrolidin-1-yl, 3-(1-hydroxy-ethyl)-pyrrolidin-1-yl, 3-hydroxy-3-cyclopropyl-pyrrolidin-1-yl, 3-hydroxy-3-trifluoromethyl-pyrrolidin-1-yl, 3 -trifluoromethyl-pyrrolidin-1-yl, 3-(1-hydroxy-1-methyl-ethyl)-pyrrolidin-1-yl, 3-(1-hydroxy-ethyl)-pyrrolidin-1-yl, 3-(hydroxy-methyl)-3-methyl-pyrrolidin-1-yl, 1,3-oxazolidin-2-one-3-yl, 5-(tert-butyl)-1,3-oxazolidin-2-one-3-yl, 5-phenyl-1,3-oxazolidin-2-one-3-yl, 5-benzyl-1,3-oxazolidin-2-one-3-yl, 5-isopropyl-1,3-oxazolidin-2-one-3-yl, 5-(tetrahydropyran-4-yl)-1,3-oxazolidin-2-one-3-yl, 5,5-dimethyl-1,3 -oxazolidin-2-one-3-yl, morpholin-4-yl, piperidin-1-yl, 4-hydroxy-piperidin-1-yl, 3-hydroxy-piperidin-1-yl, 3-(tetrahydropyran-4-yl)-pyrrolid-2-one-1-yl, N-methyl-N-(2-(benzyl-oxy)-ethyl)-amino, N-methyl-N-(2-hydroxy-ethyl)-amino, pyrrolid-2-one-1-yl, 4-phenyl-pyrrolid-2-one-1-yl, 4-isopropyl-pyrrolid-2-one-1-yl, 3-isopropyl-pyrrolid-2-one-1-yl, 4,4-dimethyl-pyrrolid-2-one-1-yl, 3-(piperidin-4-yl)-pyrrolid-2-one-1- yl, 4-isobutyl-pyrrolidin-2-one-1-yl, 4-cyclopropyl-pyrrolidin-2-one-1-yl, 4-trifluoromethyl-pyrrolidin-2-one-1-yl, 3-(2-methoxy-ethyl)-pyrrolidin-2-one-1-yl, 4-(2-methoxy-ethyl)-pyrrolidin-2-one-1-yl, 2,2,6,6-tetrafluoro-morpholin-4-yl, 2,6-dimethyl-morpholin-4-yl, 2-(methoxy-methyl)-morpholin-4-yl, 3-(3-methyl-1,2,4-oxadiazol-5-yl)-pyrrolidin-1-yl, 3-(4-methyl-thiazol-2-yl)-pyrrolidin-1-yl or 3-(phenyl)-pyrrolidin-1-yl. - -(C=O)-N(R N3 )(R N4 ) (-- R N3 represents hydrogen; and R N4 is C 3-6 -cycloalkyl (especially cyclopentyl) or tetrahydropyranyl (especially tetrahydropyran-4-yl); or -- R N3 and R N4 form pyrrolidinyl together with the nitrogen to which they are attached; [In particular, such -(C=O)-N(R N3 )(R N4) is N-cyclopentyl-amino-carbonyl, N-(tetrahydropyran-4-yl)-amino-carbonyl or pyrrolidinyl-carbonyl. piperidin-4-yl or pyrrolidin-3-yl, independently substituted at the nitrogen ring atom by one substituent, said substituent being C 1-4 - piperidin-4-yl or pyrrolidin-3-yl selected from alkoxy-carbonyl (especially tert-butoxy-carbonyl), pyridinyl (especially pyridin-2-yl), phenyl and (4-methylphenyl)-sulfonyl; [In particular, such piperidin-4-yl or pyrrolidin-3-yl is N-(tert-butoxy-carbonyl)-piperidin-4-yl, N-(tert-butoxy-carbonyl)-pyrrolidin-3-yl, N-(pyridin-2-yl)-piperidin-4-yl, N-(phenyl)-piperidin-4-yl or N-((4-methylphenyl)-sulfonyl)-piperidin-4-yl.] - a 5-membered heteroaryl having 1 to 3 (particularly 2 or 3; more particularly 3) ring heteroatoms independently selected from nitrogen, oxygen and sulfur (particularly pyrazolyl, triazolyl, oxazolyl, thiazolyl, oxadiazolyl; especially pyrazol-1-yl, 1,2,3-triazol-1-yl, oxazol-2-yl, thiazol-2-yl, 1,2,4-oxadiazol-5-yl or 1,2,4-oxadiazol-3-yl); the 5-membered heteroaryl is independently unsubstituted or substituted by 1, 2 or 3 substituents (particularly substituted by 1 substituent; especially substituted by 1 substituent at the 3-position relative to the point of attachment of the 5-membered heteroaryl to A), if present, -- unsubstituted or containing one hydroxy or C 1-4 -C substituted by alkoxy (especially methoxy and tert-butoxy) 1-4 - alkyl; [In particular, such C is unsubstituted or substituted by one substituent as defined above. 1-4-Alkyl is methyl, 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, 2-hydroxy-1,1-dimethyl-ethyl, methoxy-methyl, 2-methoxy-ethyl, 1-methoxy-1-methyl-ethyl, 2-methoxy-2 -methyl-propyl, 2-methoxy-1,1-dimethyl-ethyl, tert-butoxy-methyl; preferably, such C 1-4 -alkyl group is 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl or 2-hydroxy-1,1-dimethyl-ethyl. -- Amino-C 1-4 -alkyl (in particular 2-amino-ethyl or 2-amino-2,2-dimethyl-ethyl), in which the amino group is one or two (in particular one) C 1-3 -Alkyl (especially methyl), C 1-3 -Alkyl-carbonyl (deuterated C 1-3 -alkyl-carbonyl) (especially acetyl or acetyl-2,2,2-d3) or hydroxy-C 1-3 -substituted by alkyl-carbonyl (especially hydroxy-methyl-carbonyl), 1-4 - alkyl; [In particular, such amino-C 1-4 -Alkyl is N-acetyl-2-amino-ethyl, N-(acetyl-2,2,2-d3)-2-amino-ethyl, N-acetyl-2-amino-2,2-dimethyl-ethyl, N-(acetyl-2,2,2-d3)-2-amino-2,2-dimethyl-ethyl, N-methyl-N-(hydroxymethyl-carbonyl)-2-amino-ethyl, N-methyl-N-acetyl-2-amino-ethyl or N-methyl-N-(acetyl-2,2,2-d3)-2-amino-ethyl. -- C 3-6 -cycloalkyl-L 2 - (--- -L 2 - is a bond (i.e., C 3-6 -Cycloalkyl is directly bonded to the rest of the molecule.), oxygen, C 1-3- alkylene (especially -CH2-, -CH2-CH2- or -C(CH3)2-), hydroxy-C 1-2 -Alkylene (especially -CH(OH)-) or oxy-C 1-2 -Alkylene (especially -O-CH2-) (see above C 3-6 -cycloalkyl is the oxy-C 1-2 -bonded to the oxygen atom of the alkylene; --- C 3-6 -cycloalkyl is unsubstituted or substituted with 1 or 2 fluorines, C 1-3 -Alkyl (especially methyl), C 1-3 -Alkoxy (especially methoxy), hydroxy, hydroxy-C 1-3 -alkyl or C 1-3 -Alkoxy-C 1-3 -substituted by alkyl; 3-6 -one ring carbon atom of the cycloalkyl is optionally replaced by an oxygen atom; [Especially, such C 3-6 -cycloalkyl-L 2- represents oxetan-3-yl, cyclobutoxy-methyl, 1-hydroxy-cyclopropyl, 1-hydroxy-cyclobutyl, 3-hydroxy-cyclobutyl, 1-hydroxy-cyclopentyl, 3-hydroxy-3-methyl-cyclopentyl, 1-hydroxy-cyclohexyl, 4-hydroxy-cyclohexyl, (1-hydroxy-cyclohexyl)-methyl, (1-hydroxy-cyclobutyl)-methyl, 1-hydroxy-1-cyclohexylmethyl, 1-methoxy-cyclobutyl, 1-methoxy-cyclopentyl, 1-(1-(methoxy-methyl)-cyclopropyl)-methyl, tetrahydrofuran-2-yl-methyl ethyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, 4-methyl-tetrahydropyran-4-yl, 2,6-dimethyl-tetrahydropyran-4-yl, 4-methoxy-tetrahydropyran-4-yl, 4-fluoro-tetrahydropyran-4-yl, tetrahydropyran-4-yl-methyl, 2-(tetrahydropyran-4-yl)-ethyl, 1-(tetrahydropyran-4-yl)-1-methyl-ethyl, tetrahydropyran-4-yl-oxy-methyl or (4-methyl-tetrahydropyran-4-yl)-oxy-methyl. -- piperidin-4-yl, C 1-3 -Alkyl-carbonyl (especially acetyl), (hydroxy-C 1-3 -alkyl)-carbonyl (especially hydroxymethyl-carbonyl) or C 3-5 -piperidine-4-yl N-substituted by cycloalkyl-sulfonyl; [In particular, such piperidin-4-yl is N-acetyl-piperidin-4-yl, N-(hydroxymethyl-carbonyl)-piperidin-4-yl or N-(cyclopropyl-sulfonyl)-piperidin-4-yl.] -- Morpholinyl-L 3 -(especially, (morpholin-4-yl)-L 3 -)(-L 3 - represents a bond (i.e., the morpholinyl is directly attached to the rest of the molecule) or C 1-2-alkylene; the morpholinyl is unsubstituted or substituted by two methyl groups; [In particular, such morpholinyl-L 3 - is morpholin-4-yl, morpholin-4-yl-methyl or (2,6-dimethyl-morpholin-4-yl)-methyl. -- Pyrazolyl-C 1-3 - alkyl (especially 2-(pyrazol-1-yl)-ethyl); -- C 1-3 -Alkyl-sulfonyl-C 1-3 - alkyl (especially methyl-sulfonyl-methyl); -- 2,2,2-trifluoro-1-hydroxy-1-methyl-ethyl; -- 3-hydroxymethyl-bicyclo[1.1.1]pent-1-yl; 7-oxa-bicyclo[2.2.1]hept-2-yl; and -- 6-oxa-spiro[2.5]oct-1-yl; a 5-membered heteroaryl independently selected from 5-oxo-4-oxa-6-azaspiro[2.4]hept-6-yl, 2,2-dimethyl-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl, 2-cyclopropyl-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl, 2-oxo-1-oxa-3-azaspiro[4.4]non-3-yl, 8,8-difluoro-2-oxo-1-oxa-3-azaspiro[4.5]dec-3-yl or 8-oxo-7-oxa-9-azadispiro[3.1.4.1]undec-9-yl; 7-aza-bicyclo[2.2.1]hept-7-yl, 2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl, 6-oxa-3-aza-bicyclo[3.1.1]hept-3-yl or 8-oxa-3-azabicyclo[3.2.1]oct-3-yl; 5-oxo-6-azaspiro[3.4]oct-6-yl, 3-oxo-2-azaspiro[4.4]non-2-yl, 1-oxo-2-azaspiro[4.5]dec-2-yl, 1-oxo-8-oxa-2-azaspiro[4.5]dec-2-yl, 3-oxo-8-oxa-2-azaspiro[4.5]dec-2-yl or 4-oxo-hexahydro-5H-furo[2,3-c]pyrrol-5-yl; 3-(7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)propyl or 3-(8-hydroxy-5,6,7,8-tetrahydroquinolin-8-yl)propyl); and 2-(6,7-dihydro-5H-[1]pyrindin-7-ol)-ethyl or 2-(8-hydroxy-5,6,7,8-tetrahydro-quinolin-8-yl)-ethyl; are independently selected from; B represents phenyl unsubstituted or substituted with 1, 2 or 3 substituents (particularly substituted with one substituent in the para position relative to the point of attachment of B to the remainder of the molecule), said substituents, if present, being - C 1-5 - alkyl (especially methyl, ethyl, n-propyl, isopropyl or tert-butyl; especially isopropyl); - C 1-3 alkoxy (especially methoxy, ethoxy or isopropoxy); - C 1-3 -Alkoxy-C 1-4 - alkyl (especially 3-methoxy-propyl); - C 1-3 - fluoroalkyl (especially trifluoromethyl); - C 3-5 -cycloalkyl (especially cyclopropyl or cyclobutyl), which are independently unsubstituted or (especially those C3-5 -One C at the attachment point of the cycloalkyl 1-3 -Alkyl (especially methyl) or C 1-3 -substituted by fluoroalkyl (especially trifluoromethyl), 3-5 -cycloalkyl;- C 3-5 -cycloalkoxy (especially cyclopropoxy or cyclobutoxy); and - C 1-3 - fluoroalkoxy (especially trifluoromethoxy); are independently selected from; [In particular, B is phenyl, 4-methyl-phenyl, 4-ethyl-phenyl, 4-propyl-phenyl, 4-isopropyl-phenyl, 4-tert-butyl-phenyl, 4-cyclopropyl-phenyl, 4-methoxy-phenyl, 4-ethoxy-phenyl, 4-isopropoxy-phenyl, 4-trifluoromethyl-phenyl, 4-(1-methyl-cyclopropyl)-phenyl, 4-cyclobutyl-phenyl, 4-cyclopropoxy-phenyl, 4-cyclobutoxy-phenyl, 4-(trifluoromethoxy)-phenyl, 4-(3-methoxy-propyl)-phenyl or 4-(1-trifluoromethyl-cyclopropyl)-phenyl.] R 1 is C 1-3 - represents alkyl (especially methyl), cyano or halogen (especially fluorine); R 2 is C 1-4 - alkyl (especially methyl, ethyl, n-propyl, isopropyl, tert-butyl or isobutyl), C 3-5 -cycloalkyl (especially cyclopropyl or cyclobutyl), C 3-5 -Cycloalkyl-C 1-3 -alkyl (especially cyclopropyl-methyl) or C 1-3 -fluoroalkyl (in particular 2,2-difluoroethyl or 2-fluoroethyl).

[0121] 39) A further embodiment is a compound of formula (I) according to embodiment 38), in which the features of any one of embodiments 2) to 32) apply mutatis mutandis. P ) relates to the compound

[0122] 40) One embodiment of the invention relates to compounds according to embodiment 38), in which A represents pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl (particularly pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl, pyrazin-2-yl or pyridazin-4-yl; especially pyridin-3-yl), and A is independently unsubstituted or substituted by 1, 2 or 3 substituents (particularly substituted by 1 or 2 substituents in the meta and / or para positions of A relative to the point of attachment of A to the remainder of the molecule; especially substituted by 1 substituent in the meta position of A relative to the point of attachment of A to the remainder of the molecule), and said substituents, if present, are as defined in embodiment 38).

[0123] 41) Another embodiment of the invention relates to compounds according to embodiment 38), in which A represents pyridin-3-yl or pyridin-4-yl, and A is independently unsubstituted or substituted with 1, 2 or 3 substituents (particularly substituted with 1 or 2 substituents in the meta and / or para positions of A relative to the point of attachment of A to the remainder of the molecule; especially substituted with 1 substituent in the meta position of A relative to the point of attachment of A to the remainder of the molecule), and wherein said substituents, if present, are as defined in embodiment 38).

[0124] 42) Another aspect of the invention is that A is - Is it unsubstituted? - substituted by one substituent (especially in the meta position of A relative to the point of attachment of A to the rest of the molecule), said substituent being as defined in embodiment 38); - relates to compounds according to embodiment 38) which are substituted by two substituents, the first substituent (particularly in the meta position of A relative to the point of attachment of A to the rest of the molecule) being selected from the substituents defined in embodiment 38) (particularly excluding halogen (especially fluorine) or cyano); and the second substituent (particularly in the para position of A relative to the point of attachment of A to the rest of the molecule) being selected from halogen (especially fluorine) and cyano.

[0125] In a subembodiment of embodiment 4), A is pyridin-3-yl. 43) Another embodiment of the present invention is a compound in which A is substituted with one substituent at the meta position of A relative to the point of attachment of A to the rest of the molecule, and said substituent on A is: - 5-membered heteroaryl (especially pyrazolyl, triazolyl, oxazolyl, oxazolyl) having 1 to 3 (especially 2 or 3; especially 3) ring heteroatoms independently selected from nitrogen, oxygen and sulfur; and 1,2,4-oxadiazol-5-yl or 1,2,4-oxadiazol-3-yl; preferably 1,2,4-oxadiazol-5-yl or 1,2,4-oxadiazol-3-yl); wherein the 5-membered heteroaryl is independently unsubstituted or substituted by 1, 2 or 3 substituents (particularly substituted by 1 substituent; especially substituted by 1 substituent at the 3-position relative to the point of attachment of the 5-membered heteroaryl to A), and wherein the substituents, if present, are -- unsubstituted or containing one hydroxy or C 1-4 -C substituted by alkoxy (especially methoxy and tert-butoxy) 1-4 - alkyl; [In particular, such C is unsubstituted or substituted by one substituent as defined above. 1-4 -Alkyl is methyl, 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, 2-hydroxy-1,1-dimethyl-ethyl, methoxy-methyl, 2-methoxy-ethyl, 1-methoxy-1-methyl-ethyl, 2-methoxy-2-methyl-propyl, 2-methoxy-1,1-dimethyl-ethyl, tert-butoxy-methyl; preferably, such C 1-4 -alkyl group is 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl or 2-hydroxy-1,1-dimethyl-ethyl. -- Amino-C1-4 -alkyl (in particular 2-amino-ethyl or 2-amino-2,2-dimethyl-ethyl), in which the amino group is one or two (in particular one) C 1-3 -Alkyl (especially methyl), C 1-3 -Alkyl-carbonyl (deuterated C 1-3 -alkyl-carbonyl) (especially acetyl or acetyl-2,2,2-d3) or hydroxy-C 1-3 -substituted by alkyl-carbonyl (especially hydroxy-methyl-carbonyl), 1-4 - alkyl; [In particular, such amino-C 1-4 -Alkyl is N-acetyl-2-amino-ethyl, N-(acetyl-2,2,2-d3)-2-amino-ethyl, N-acetyl-2-amino-2,2-dimethyl-ethyl, N-(acetyl-2,2,2-d3)-2-amino-2,2-dimethyl-ethyl, N-methyl-N-(hydroxymethyl-carbonyl)-2-amino-ethyl, N-methyl-N-acetyl-2-amino-ethyl or N-methyl-N-(acetyl-2,2,2-d3)-2-amino-ethyl. -- C 3-6 -cycloalkyl-L 2 - (--- -L 2 - is a bond (i.e., C 3-6 -Cycloalkyl is directly bonded to the rest of the molecule.), oxygen, C 1-3 - alkylene (especially -CH2-, -CH2-CH2- or -C(CH3)2-), hydroxy-C 1-2 -Alkylene (especially -CH(OH)-) or oxy-C 1-2 -Alkylene (especially -O-CH2-) (see above C 3-6 -cycloalkyl is the oxy-C 1-2 -bonded to the oxygen atom of the alkylene; --- Above C 3-6 -cycloalkyl is unsubstituted or substituted with 1 or 2 fluorines, C 1-3 -Alkyl (especially methyl), C 1-3 -Alkoxy (especially methoxy), hydroxy, hydroxy-C1-3 -alkyl or C 1-3 -Alkoxy-C 1-3 -substituted by alkyl; 3-6 - one ring carbon atom of the cycloalkyl is optionally replaced by an oxygen atom); [Especially, such C 3-6 -cycloalkyl-L 2 - represents oxetan-3-yl, cyclobutoxy-methyl, 1-hydroxy-cyclopropyl, 1-hydroxy-cyclobutyl, 3-hydroxy-cyclobutyl, 1-hydroxy-cyclopentyl, 3-hydroxy-3-methyl-cyclopentyl, 1-hydroxy-cyclohexyl, 4-hydroxy-cyclohexyl, (1-hydroxy-cyclohexyl)-methyl, (1-hydroxy-cyclobutyl)-methyl, 1-hydroxy-1-cyclohexylmethyl, 1-methoxy-cyclobutyl, 1-methoxy-cyclopentyl, 1-(1-(methoxy-methyl)-cyclopropyl)-methyl, tetrahydrofuran-2-yl-methyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, 4-methyl-tetrahydropyran-4-yl, 2,6-dimethyl-tetrahydropyran-4-yl, 4-methoxy-tetrahydropyran-4-yl, 4-fluoro-tetrahydropyran-4-yl, tetrahydropyran-4-yl-methyl, 2-(tetrahydropyran-4-yl)-ethyl, 1-(tetrahydropyran-4-yl)-1-methyl-ethyl, tetrahydropyran-4-yl-oxy-methyl or (4-methyl-tetrahydropyran-4-yl)-oxy-methyl. -- piperidin-4-yl, C 1-3 -Alkyl-carbonyl (especially acetyl), (hydroxy-C 1-3 -alkyl)-carbonyl (especially hydroxymethyl-carbonyl) or C 3-5 -piperidine-4-yl N-substituted by cycloalkyl-sulfonyl; [In particular, such piperidin-4-yl is N-acetyl-piperidin-4-yl, N-(hydroxymethyl-carbonyl)-piperidin-4-yl or N-(cyclopropyl-sulfonyl)-piperidin-4-yl.] -- Morpholinyl-L 3 -(especially (morpholin-4-yl)-L 3 -)(-L 3 - represents a bond (i.e., the morpholinyl is directly attached to the rest of the molecule) or C 1-2 -alkylene; the morpholinyl is unsubstituted or substituted by two methyl groups; [In particular, such morpholinyl-L 3 - is morpholin-4-yl, morpholin-4-yl-methyl or (2,6-dimethyl-morpholin-4-yl)-methyl. -- Pyrazolyl-C 1-3 - alkyl (especially 2-(pyrazol-1-yl)-ethyl); -- C 1-3 -Alkyl-sulfonyl-C 1-3 - alkyl (especially methyl-sulfonyl-methyl); -- 2,2,2-trifluoro-1-hydroxy-1-methyl-ethyl; -- 3-hydroxymethyl-bicyclo[1.1.1]pent-1-yl; 7-oxa-bicyclo[2.2.1]hept-2-yl; and -- 6-oxa-spiro[2.5]oct-1-yl; is a 5-membered heteroaryl independently selected from:

[0126] 44) Another embodiment of the present invention is a compound wherein A is substituted with one substituent at the meta position of A relative to the point of attachment of A to the remainder of the molecule, and said substituent on A is: - a 5-membered heteroaryl having 1 to 3 (particularly 2 or 3; more particularly 3) ring heteroatoms independently selected from nitrogen, oxygen and sulfur (particularly pyrazolyl, triazolyl, oxazolyl, thiazolyl, oxadiazolyl; especially pyrazol-1-yl, 1,2,3-triazol-1-yl, oxazol-2-yl, thiazol-2-yl, 1,2,4-oxadiazol-5-yl or 1,2,4-oxadiazol-3-yl; most preferably 1,2,4-oxadiazol-5-yl or 1,2,4-oxadiazol-3-yl); the 5-membered heteroaryl is independently unsubstituted or substituted by 1, 2 or 3 substituents (particularly substituted by 1 substituent; especially substituted by 1 substituent at the 3-position relative to the point of attachment of the 5-membered heteroaryl to A), if present, -- Amino-C 1-4 -alkyl (in particular 2-amino-ethyl or 2-amino-2,2-dimethyl-ethyl), in which the amino group is one or two (in particular one) C 1-3 -Alkyl (especially methyl), C 1-3 -Alkyl-carbonyl (deuterated C 1-3 -alkyl-carbonyl) (especially acetyl or acetyl-2,2,2-d3) or hydroxy-C 1-3 -substituted by alkyl-carbonyl (especially hydroxy-methyl-carbonyl), 1-4 - alkyl; [In particular, such amino-C 1-4 -Alkyl is N-acetyl-2-amino-ethyl, N -(acetyl-2,2,2-d3)-2-amino-ethyl, N-acetyl-2-amino-2,2-dimethyl-ethyl, N-(acetyl-2,2,2-d3)-2-amino-2,2-dimethyl-ethyl, N-methyl-N-(hydroxymethyl-carbonyl)-2-amino-ethyl, N-methyl-N-acetyl-2-amino-ethyl or N-methyl-N-(acetyl-2,2,2-d3)-2-amino-ethyl. -- piperidin-4-yl, C 1-3-Alkyl-carbonyl (especially acetyl), (hydroxy-C 1-3 -alkyl)-carbonyl (especially hydroxymethyl-carbonyl) or C 3-5 -piperidine-4-yl N-substituted by cycloalkyl-sulfonyl; [In particular, such piperidin-4-yl is N-acetyl-piperidin-4-yl, N-(hydroxymethyl-carbonyl)-piperidin-4-yl or N-(cyclopropyl-sulfonyl)-piperidin-4-yl.] is a 5-membered heteroaryl independently selected from:

[0127] 45) Another embodiment of the present invention is a compound wherein A is substituted with one substituent at the meta position of A relative to the point of attachment of A to the rest of the molecule, said substituent being: 1,2,4-oxadiazol-3-yl, substituted by one substituent, said substituent being -- Amino-C 1-4 -alkyl (in particular 2-amino-ethyl or 2-amino-2,2-dimethyl-ethyl), in which the amino group is --- 1 C 1-3 -Alkyl-carbonyl (deuterated C 1-3 -alkyl-carbonyl) (especially acetyl or acetyl-2,2,2-d3); --- substituted with two substituents, the first of which is C 1-3 -alkyl (especially methyl) and the second substituent is C 1-3 -Alkyl-carbonyl (especially acetyl) or C 1-3 -Alkyl-carbonyl (deuterated C 1-3 -alkyl-carbonyl) (especially acetyl or acetyl-2,2,2-d3); or --- substituted with two substituents, the first of which is C 1-3 -alkyl (especially methyl) and the second substituent is hydroxy-C 1-3- alkyl-carbonyl (especially hydroxy-methyl-carbonyl); Amino-C 1-4 - alkyl; [In particular, such amino-C 1-4 -Alkyl is N-acetyl-2-amino-ethyl, N-(acetyl-2,2,2-d3)-2-amino-ethyl, N-acetyl-2-amino-2,2-dimethyl-ethyl, N-(acetyl-2,2,2-d3)-2-amino-2,2-dimethyl-ethyl, N-methyl-N-(hydroxymethyl-carbonyl)-2-amino-ethyl, N-methyl-N-acetyl-2-amino-ethyl or N-methyl-N-(acetyl-2,2,2-d3)-2-amino-ethyl. -- piperidin-4-yl, C 1-3 -Alkyl-carbonyl (especially acetyl), (hydroxy-C 1-3 -alkyl)-carbonyl (especially hydroxymethyl-carbonyl) or C 3-5 -piperidine-4-yl N-substituted by cycloalkyl-sulfonyl; [In particular, such piperidin-4-yl is N-acetyl-piperidin-4-yl, N-(hydroxymethyl-carbonyl)-piperidin-4-yl or N-(cyclopropyl-sulfonyl)-piperidin-4-yl.] The compound according to any one of embodiments 40) to 42) is 1,2,4-oxadiazol-3-yl independently selected from:

[0128] 46) Another embodiment of the invention is where A represents pyridinyl (especially pyridin-3-yl) substituted with one substituent in the meta position relative to the point of attachment of A to the rest of the molecule. the substituent is oxadiazolyl (particularly 1,2,4-oxadiazol-3-yl), the oxadiazolyl is substituted with one substituent, and the oxadiazolyl substituent is unsubstituted or has one hydroxy or C 1-4 -C substituted by alkoxy 1-4 -alkyl (especially such C 1-4-alkyl is 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl or 2-hydroxy-1,1-dimethyl-ethyl.

[0129] 47) Another embodiment of the present invention is a compound wherein A is substituted with one substituent at the meta position of A relative to the point of attachment of A to the remainder of the molecule, and said substituent on A is: - -C≡CR T1 (-- R T1 teeth, --- Hydroxy-C 1-4 - alkyl (in particular hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxy-2-methylpropyl or 1-hydroxy-1-methylethyl); --- C 1-3 -Alkoxy-C 1-3 - alkyl (especially methoxy-methyl); --- C substituted by one hydroxy 3-6 -cycloalkyl (especially the above C to the rest of the molecule) 3-6 - at the attachment point of cycloalkyl; in particular 1-hydroxy-cyclopropyl, 1-hydroxy-cyclobutyl or 1-hydroxy-cyclopentyl); --- C fused to a pyridine ring (especially at the 2- and 3-positions of the pyridine ring) 3-6 -cycloalkyl (especially cyclopentyl or cyclohexyl), 3-6 -cycloalkyl (especially the above C 3-6 -C substituted by one hydroxyl at the 1-position of the cycloalkyl ring 3-6 -cycloalkyl (in particular 8-hydroxy-5,6,7,8-tetrahydroquinolin-8-yl or 7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl); --- pyrazolyl (especially pyrazol-4-yl) substituted by one methyl (especially 1-methyl-pyrazol-4-yl); --- tetrahydropyranyl (especially tetrahydropyran-4-yl), which is unsubstituted or substituted by one hydroxy, tetrahydropyranyl (especially 4-hydroxy-tetrahydropyran-4-yl); --- indolyl (especially indol-2-yl); or --- Hydroxy-azetidinyl (especially 3-hydroxy-azetidin-3-yl), 1-4 -hydroxy-azetidinyl N-substituted by alkoxy-carbonyl (in particular isopropyl-carbonyl or tert-butoxy-carbonyl); represents. ); [In particular, such -C≡CR T1 are 3-hydroxy-prop-1-yn-1-yl, 4-hydroxy-but-1-yn-1-yl, 3-hydroxy-but-1-yn-1-yl, 3-hydroxy-3-methyl-but-1-yn-1-yl, 3-hydroxy-4-methyl-pent-1-yn-1-yl, 3-methoxy-prop-1-yn-1-yl, (1-hydroxy-cyclopropyl)-ethynyl, (1-hydroxy-cyclobutyl)-ethynyl, (1-hydroxy-cyclopentyl)-ethynyl, (8-hydroxy-5,6,7,8-tetrahydroquinoline-8- (7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)-ethynyl, (1-methyl-pyrazol-4-yl)-ethynyl, (tetrahydropyran-4-yl)-ethynyl, (4-hydroxy-tetrahydropyran-4-yl)-ethynyl, indol-2-yl-ethynyl, (1-(isopropyl-carbonyl)-3-hydroxy-azetidin-3-yl)-ethynyl or (1-(tert-butoxy-carbonyl)-3-hydroxy-azetidin-3-yl)-ethynyl. - -C≡CC(OH)(R T2 )(R T3 ) (-- R T2 is hydrogen or C 1-3 - alkyl (in particular methyl or ethyl); -- R T3 teeth, --- Phenyl, unsubstituted or substituted by one substituent, if present, and wherein said substituent is C 1-3 phenyl selected from alkoxy (especially methoxy) or halogen (especially fluorine); [In particular, such groups are 3-fluoro-phenyl, 4-methoxy-phenyl or 2-methoxy-phenyl.] --- 5-6 membered heteroaryl having 1 or 2 ring heteroatoms independently selected from nitrogen and sulfur (particularly thiazolyl, pyrazolyl, pyridinyl or pyrimidinyl; especially thiazol-4-yl, pyrazol-3-yl, pyrazol-4-yl, pyridin-2-yl, pyrimidin-2-yl or pyrimidin-4-yl), which 5 or 6 membered heteroaryl is independently unsubstituted or substituted by 1 or 2 substituents, if present, which are selected from the group consisting of C 1-3 -Alkyl (especially methyl) and C 1-3 -5-6 membered heteroaryl independently selected from alkoxy (especially methoxy); or [In particular, such 5- to 6-membered heteroaryl groups are 1-methyl-pyrazol-3-yl, 1,3-dimethyl-pyrazol-4-yl, 1,5-dimethyl-pyrazol-3-yl, 2-methyl-thiazol-4-yl, pyridin-2-yl, 6-methoxy-pyridin-2-yl, pyrimidin-2-yl, pyrimidin-4-yl or 1,5-dimethyl-pyrazol-3-yl.] --- tetrahydropyranyl (especially tetrahydropyran-4-yl); represents. ); [In particular, such -C≡CC(OH)(R T2 )(R T3) is 3-hydroxy-3-(tetrahydropyran-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-phenyl-prop-1-yn-1-yl, 3-hydroxy-3-(2-methyl-thiazol-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-(1,3-dimethyl-pyrazol-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-phenyl-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-pyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1,5-dimethyl-pyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-pyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(pyrimidin-2 -yl)-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-pyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(3-fluoro-phenyl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(pyridin-2-yl)-pent-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-pent-1-yn-1-yl, 3-hydroxy-3-(4-methoxy-phenyl)-but-1-yn-1-yl or 3-hydroxy-3-(2-methoxy-phenyl)-but-1-yn-1-yl. The present invention relates to a compound according to any one of embodiments 40) to 42), wherein

[0130] 48) Another embodiment of the invention relates to compounds according to any one of embodiments 38) to 42), wherein A is substituted with one substituent in the meta position of A relative to the point of attachment of A to the rest of the molecule, and said substituent of A is as defined in embodiment 42) or 46).

[0131] 49) Another embodiment of the present invention is one in which B is phenyl and is substituted with one substituent in the para position relative to the point of attachment of B to the remainder of the molecule, and said substituent is C 1-5-alkyl (in particular ethyl, n-propyl, isopropyl or tert-butyl; especially isopropyl), representing phenyl, according to any one of embodiments 38) to 48). This relates to compounds such as

[0132] [In particular, such B is 4-ethyl-phenyl, 4-propyl-phenyl, 4-isopropyl-phenyl, 4-tert-butyl-phenyl; especially 4-isopropyl-phenyl.] 50) Another aspect of the present invention is a compound comprising R 1 C 1-3 - alkyl (in particular methyl).

[0133] 51) Another aspect of the present invention is a compound comprising R 2 C 1-4 -alkyl (in particular methyl, ethyl, n-propyl, isopropyl, tert-butyl or isobutyl).

[0134] 52) Another aspect of the present invention is A represents pyridinyl (especially pyridin-3-yl) substituted by one substituent in the meta position relative to the point of attachment of A to the remainder of the molecule, said substituent being oxadiazolyl (especially 1,2,4-oxadiazol-3-yl) substituted by one substituent, said oxadiazolyl substituent being unsubstituted or substituted by one hydroxy or C 1-4 -C substituted by alkoxy 1-4 -alkyl (especially such C which are unsubstituted or substituted by one 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl or 2-hydroxy-1,1-dimethyl-ethyl). 1-4 -alkyl); B represents phenyl substituted with one substituent in the para position relative to the point of attachment of B to the remainder of the molecule, said substituent being C 1-5 - alkyl (especially isopropyl); R 1C 1-3 - represents alkyl (especially methyl); R 2 C 1-4 - represents alkyl (especially methyl); The compound according to embodiment 38).

[0135] 53) Another embodiment relates to a compound according to any one of embodiments 38) to 52), which is also a compound of formula (IIp) (i.e., the asymmetric carbon atom to which A and B are attached has the absolute configuration shown in formula (IIp)):

[0136] [ka]

[0137] For A being pyridin-3-yl, pyrimidin-5-yl, pyrazin-2-yl or pyridazin-4-yl (particularly pyridin-3-yl), it is understood that the asymmetric carbon atoms to which A and B are attached, as shown in formula (IIp), have the absolute configuration (R). When A represents pyridin-4-yl, the asymmetric carbon atoms to which A and B are attached, as shown in formula (II), have the absolute configuration (S).

[0138] Based on the dependency of the different embodiments 1) to 37) disclosed above, the following embodiments are therefore possible, contemplated, and specifically disclosed herein as individual embodiments: 2+1、3+1、4+1、11+1、11+2+1、11+3+1、11+4+1、12+11+1、12+11+2+1、12+11+3+1、12+11+4+1、13+11+1、13+11+2+1、13+11+3+1、13+11+4+1、14+11+1、14+11+2+1、14+11+3+1、14+11+4+1、15+11+1、15+11+2+1、15+11+3+1、15+11+4+1、16+1、16+2+1、16+3+1、16+4+1、17+16+1、17+16+2+1、17+16+3+1、17+16+4+1、18+16+1、18+16+2+1、18+16+3+1、18+16+4+1、19+16+1、19+16+2+1、19+16+3+1、19+16+4+1、20+1、20+2+1、20+3+1、20+4+1、21+20+1、21+20+2+1、21+20+3+1、21+20+4+1、22+20+1、22+20+2+1、22+20+3+1、22+20+4+1、23+1、23+2+1、23+3+1、23+4+1、23+5、23+6、23+7、23+8、23+9、23+10、23+11+1、23+11+2+1、23+11+3+1、23+11+4+1、23+12+11+1、23+12+11+2+1、23+12+11+3+1、23+12+11+4+1、23+13+11+1、23+13+11+2+1、23+13+11+3+1、23+13+11+4+1、23+14+11+1、23+14+11+2+1、23+14+11+3+1、23+14+11+4+1、23+15+11+1、23+15+11+2+1、23+15+11+3+1、23+15+11+4+1、23+16+1、23+16+2+1、23+16+3+1、23+16+4+1、23+17+16+1、23+17+16+2+1、23+17+16+3+1、23+17+16+4+1、23+18+16+1、23+18+16+2+1、23+18+16+3+1、23+18+16+4+1、23+19+16+1、23+19+16+2+1、23+19+16+3+1、23+19+16+4+1、23+20+1、23+20+2+1、23+20+3+1、23+20+4+1、23+21+20+1、23+21+20+2+1、23+21+20+3+1、23+21+20+4+1、23+22+20+1、23+22+20+2+1、23+22+20+3+1、23+22+20+4+1、 26+1、26+2+1、26+3+1、26+4+1、26+5、26+6、26+7、26+8、26+9、26+10、26+11+1、26+11+2+1、26+11+3+1、26+11+4+1、26+12+11+1、26+12+11+2+1、26+12+11+3+1、26+12+11+4+1、26+13+11+1、26+13+11+2+1、26+13+11+3+1、26+13+11+4+1、26+14+11+1、26+14+11+2+1、26+14+11+3+1、26+14+11+4+1、26+15+11+1、26+15+11+2+1、26+15+11+3+1、26+15+11+4+1、26+16+1、26+16+2+1、26+16+3+1、26+16+4+1、26+17+16+1、26+17+16+2+1、26+17+16+3+1、26+17+16+4+1、26+18+16+1、26+18+16+2+1、26+18+16+3+1、26+18+16+4+1、26+19+16+1、26+19+16+2+1、26+19+16+3+1、26+19+16+4+1、26+20+1、26+20+2+1、26+20+3+1、26+20+4+1、26+21+20+1、26+21+20+2+1、26+21+20+3+1、26+21+20+4+1、26+22+20+1、26+22+20+2+1、26+22+20+3+1、26+22+20+4+1、26+23+1、26+23+2+1、26+23+3+1、26+23+4+1、26+23+5、26+23+6、26+23+7、26+23+8、26+23+9、26+23+10、26+23+11+1、26+23+11+2+1、26+23+11+3+1、26+23+11+4+1、26+23+12+11+1、26+23+12+11+2+1、26+23+12+11+3+1、26+23+12+11+4+1、26+23+13+11+1、26+23+13+11+2+1、26+23+13+11+3+1、26+23+13+11+4+1、26+23+14+11+1、26+23+14+11+2+1、26+23+14 +11+3+1、26+23+14+11+4+1、26+23+15+11+1、26+23+15+11+2+1、26+23+15+11+3+1、26+23+15+11+4+1、26+23+16+1、26+23+16+2+1、26+23+16+3+1、26+23+16+4+1、26+23+17+16+1、26+23+17+16+2+1、26+23+17+16+3+1、26+23+17+16+4+1、26+23+18+16+1、26+23+18+16+2+1、26+23+18+16+3+1、26+23+18+16+4+1、26+23+19+16+1、26+23+19+16+2+1、26+23+19+16+3+1、26+23+19+16+4+1、26+23+20+1、26+23+20+2+1、26+23+20+3+1、26+23+20+4+1、26+23+21+20+1、26+23+21+20+2+1、26+23+21+20+3+1、26+23+21+20+4+1、26+23+22+20+1、26+23+22+20+2+1、26+23+22+20+3+1、26+23+22+20+4+1、26+24、26+25、 28+1、28+2+1、28+3+1、28+4+1、28+5、28+6、28+7、28+8、28+9、28+10、28+11+1、28+11+2+1、28+11+3+1、28+11+4+1、28+12+11+1、28+12+11+2+1、28+12+11+3+1、28+12+11+4+1、28+13+11+1、28+13+11+2+1、28+13+11+3+1、28+13+11+4+1、28+14+11+1、28+14+11+2+1、28+14+11+3+1、28+14+11+4+1、28+15+11+1、28+15+11+2+1、28+15+11+3+1、28+15+11+4+1、28+16+1、28+16+2+1、28+16+3+1、28+16+4+1、28+17+16+1、28+17+16+2+1、28+17+16+3+1、28+17+16+4+1、28+18+16+1、28+18+16+2+1、28+18+16+3+1、28+18+16+4+1、28+19+16+1、28+19+16+2+1、28+19+16+3+1、28+19+16+4+1、28+20+1、28+20+2+1、28+20+3+1、28+20+4+1、28+21+20+1、28+21+20+2+1、28+21+20+3+1、28+21+20+4+1、28+22+20+1、28+22+20+2+1、28+22+20+3+1、28+22+20+4+1、28+23+1、28+23+2+1、28+23+3+1、28+23+4+1、28+23+5、28+23+6、28+23+7、28+23+8、28+23+9、28+23+10、28+23+11+1、28+23+11+2+1、28+23+11+3+1、28+23+11+4+1、28+23+12+11+1、28+23+12+11+2+1、28+23+12+11+3+1、28+23+12+11+4+1、28+23+13+11+1、28+23+13+11+2+1、28+23+13+11+3+1、28+23+13+11+4+1、28+23+14+11+1、28+23+14+11+2+1、28+23+14+11+3+1、28+23+14+11+4+1、28+23+15+11+1、28+23+15+11+2+1、28+23+15+11+3+1、28+23+15+11+4+1、28+23+16+1、28+23+16+2+1、28+23+16+3+1、28+23+16+4+1、28+23+17+16+1、28+23+17+16+2+1、28+23+17+16+3+1、28+23+17+16+4+1、28+23+18+16+1、28+23+18+16+2+1、28+23+18+16+3+1、28+23+18+16+4+1、28+23+19+16+1、28+23+19+16+2+1、28+23+19+16+3+1、28+23+19+16+4+1、28+23+20+1、28+23+20+2+1、28+23+20+3+1、28+23+20+4+1、28+23+21+20+1、28+23+21+20+2+1、28+23+21+20+3+1、28+23+21+20+4+1、28+23+22+20+1、28+23+22+20+2+1、28+23+22+20+3+1、28+23+22+20+4+1、28+24、28+25、 28+26+1、28+26+2+1、28+26+3+1、28+26+4+1、28 +26+5、28+26+6、28+26+7、28+26+8、28+26+9、28+26+10、28+26+11+1、28+26+11+2+1、28+26+11+3+1、28+26+11+4+1、28+26+12+11+1、28+26+12+11+2+1、28+26+12+11+3+1、28+26+12+11+4+1、28+26+13+11+1、28+26+13+11+2+1、28+26+13+11+3+1、28+26+13+11+4+1、28+26+14+11+1、28+26+14+11+2+1、28+26+14+11+3+1、28+26+14+11+4+1、28+26+15+11+1、28+26+15+11+2+1、28+26+15+11+3+1、28+26+15+11+4+1、28+26+16+1、28+26+16+2+1、28+26+16+3+1、28+26+16+4+1、28+26+17+16+1、28+26+17+16+2+1、28+26+17+16+3+1、28+26+17+16+4+1、28+26+18+16+1、28+26+18+16+2+1、28+26+18+16+3+1、28+26+18+16+4+1、28+26+19+16+1、28+26+19+16+2+1、28+26+19+16+3+1、28+26+19+16+4+1、28+26+20+1、28+26+20+2+1、28+26+20+3+1、28+26+20+4+1、28+26+21+20+1、28+26+21+20+2+1、28+26+21+20+3+1、28+26+21+20+4+1、28+26+22+20+1、28+26+22+20+2+1、28+26+22+20+3+1、28+26+22+20+4+1、28+26+23+1、28+26+23+2+1、28+26+23+3+1、28+26+23+4+1、28+26+23+5、28+26+23+6、28+26+23+7、28+26+23+8、28+26+23+9、28+26+23+10、28+26+23+11+1、28+26+23+11+2+1、28+26+23+11+3+1、28+26+23+11+4+1、28+26+23+12+11+1、28+26+23+12+11+2+1、28+26+23+12+11+3+1、28+26+23+12+11+4+1, 28+26+23+13+11+1, 28+26+23+13+11+2+1, 28+26+23+13+11+3+1, 28+26+23+13+11+4+1, 28+26+23+14+11+1, 28+26+23+14+11+2+1, 28+26+23+14+11+3+1, 28+26+23+14+11+4+1, 28+26+23+15+11+1, 28+2 6+23+15+11+2+1, 28+26+23+15+11+3+1, 28+26+23+15+11+4+1, 28+26+23+16+1, 28+26+23+16+2+1, 28+26+23+16+3+1, 28+26+23+16+4+1, 28+26+23+17+16+1, 28+26+23+17+16+2+1, 28+26+23+17+16+3+1, 28+26+23+17+16+4+1, 28+26+23+18+16+1, 28+26+23+18+16+2+1, 28+26+23+18+16+3+1, 28+26+23+18+16+4+1, 28+26+23+19+16+1, 28+26+23+19+16+2+1, 28+26+23+19+16+3+1, 28+26+23+19+16+4+1, 28+26+23+20+1, 28+26+23+20+2+1, 28+26+23+2 0+3+1, 28+26+23+20+4+1, 28+26+23+21+20+1, 28+26+23+21+20+2+1, 28+26+23+21+20+3+1, 28+26+23+21+20+4+1, 28+26+23+22+20+1, 28+26+23+22+20+2+1, 28+26+23+22+20+3+1, 28+26+23+22+20+4+1 or 28+26+24, 28+26+25.

[0139] The present invention relates to compounds of formula (I) as defined in aspect 1), or such compounds further defined by the features of any one of aspects 2) to 53), according to their respective subdivisions; pharmaceutically acceptable salts thereof; and the use of such compounds as pharmaceuticals, in particular in the treatment of diseases or disorders involving the CCR6 receptor, as described below.

[0140] The present invention also provides isotopically labeled, especially 2 Also included are H (deuterium) labeled compounds of formula (I), which are identical to compounds of formula (I) except that one or more atoms have been replaced, respectively, by an atom having the same atomic number but an atomic mass different from that normally found in nature. 2 H (deuterium) labeled compounds of formula (I) and salts thereof are included within the scope of the present invention. 2 Substitution with H (deuterium) can increase metabolic stability, e.g., prolong in vivo half-life, or reduce the required dose, or reduce inhibition of cytochrome P450 enzymes, thereby improving, e.g., safety profile. In one embodiment of the present invention, compounds of formula (I) are not isotopically labeled, or they are labeled only with one or more deuterium atoms. In a subembodiment, compounds of formula (I) are not isotopically labeled at all. Isotopically labeled compounds of formula (I) may be prepared similarly to the methods described below, except for using appropriate isotopic species of the appropriate reagents or starting materials.

[0141] When the plural forms are used for compounds, salts, pharmaceutical compositions, diseases, etc., they are intended to refer to the singular compound, salt, pharmaceutical composition, disease, etc. as well.

[0142] Any reference to compounds of formula (I) according to embodiments 1) to 53) will be understood to also refer to salts (and in particular pharmaceutically acceptable salts) of such compounds, where appropriate.

[0143] The term "pharmaceutically acceptable salt" refers to a salt that retains the desired biological activity of the subject compound and exhibits minimal undesired toxicological effects. Such salts include inorganic or organic acid and / or base addition salts, depending on the presence of basic and / or acidic groups in the subject compound. References include, for example, "Handbook of Pharmaceutical Salts. Properties, Selection and Use.", P. Heinrich Stahl, Camille G. Wermuth (Eds.), Wiley-VCH, 2008; and "Pharmaceutical Salts and Co-crystals,” Johan Wouters and Luc Quere (Eds.), RSC Publishing, 2012.

[0144] The definitions set forth herein apply uniformly to compounds of formula (I) as defined in any one of embodiments 1) to 53) and apply mutatis mutandis throughout the specification and claims, unless a broader or narrower definition is given by a specific definition. It is to be understood that any definition or preferred definition of a term may independently (and together with) define and replace the respective term in any or all other terms or preferred definitions defined herein.

[0145] The compounds of formula (I) may include compounds having one or more asymmetric centers, such as one or more asymmetric carbon atoms, which may exist in the (R) and (S) configurations. The compounds of formula (I) may also include compounds having one or more double bonds, which may exist in the Z and E configurations, and / or compounds having substituents on ring systems, which may exist in the cis and trans configurations relative to each other. Thus, the compounds of formula (I) may exist as a mixture of stereoisomers, or preferably in a stereoisomerically enriched form, in particular as an essentially pure stereoisomer. Mixtures of stereoisomers may be separated by methods known to those skilled in the art.

[0146] When a particular compound (or generic structure) is designated as either the (R)- or (S)-enantiomer, such designation also includes the use of enriched, especially essentially pure, enantiomeric forms of each. " refers to the compound (or generic structure). Similarly, when a particular asymmetric center of a compound is designated as being in the (R)- or (S)-configuration, or as being in a particular relative configuration, such designation is understood to refer to said compound in enriched, especially essentially pure form, with respect to each configuration of said asymmetric center. Similarly, a designation of cis or trans is understood to refer to each stereoisomer in enriched, especially essentially pure form. Similarly, when a particular compound (or generic structure) is designated as a Z or E stereoisomer (or when a particular double bond in a compound is designated as being in the Z or E configuration), such designation is understood to refer to each compound (or generic structure) in enriched, especially essentially pure stereoisomeric form (or a compound in enriched, especially essentially pure form, with respect to each configuration of the double bond).

[0147] The term "enriched", when used in connection with stereoisomers, is intended in the context of the present invention to mean that each stereoisomer is present relative to each other stereoisomer / total of each other stereoisomer in an amount of at least 70:30, in particular at least 90:10 (i.e. in a purity of at least 70% by weight, in particular at least 90% by weight).

[0148] The term "essentially pure", when used in relation to stereoisomers, is intended in the context of the present invention to mean that each stereoisomer is present in a purity of at least 95% by weight, in particular at least 99% by weight, relative to each other stereoisomer / total of each other stereoisomer.

[0149] The compounds of formula (I) according to embodiments 1) to 53) and their pharmaceutically acceptable salts can be used as medicaments, for example in the form of pharmaceutical compositions for enteral (especially oral) or parenteral (including topical application or inhalation) administration.

[0150] Pharmaceutical compositions can be produced in a manner well known to anyone skilled in the art (see, for example, Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing" [published by Lippincott Williams & Wilkins]) by combining the above-described compounds of formula (I) or pharmaceutically acceptable salts thereof, optionally with other therapeutically valuable substances, with suitable non-toxic, inert, therapeutically acceptable solid or liquid carrier materials and, if necessary, conventional pharmaceutical adjuvants, to form a pharmaceutical dosage form.

[0151] Whenever the word "between" is used to describe a range of numerical values, the endpoints of the stated range are expressly included in that range. This means, for example, that when a temperature range is stated to be between 40°C and 80°C, the endpoints 40°C and 80°C are included in the range; or, when a variable is defined as an integer between 1 and 4, the variable is meant to be the integer 1, 2, 3, or 4.

[0152] When not used in reference to temperature, the term "about" (or alternatively the term "around") before a numerical value "X" refers in this application to a value between 10% of XX and 10% of X+X, preferably between 5% of XX and 5% of X+X. In the specific case of temperatures, the term "about" before a temperature "Y" refers in this application to a value between Y-10°C and Y+10°C, preferably between Y-5°C and Y+5°C.

[0153] The compounds of formula (I) as defined herein above are useful for the prevention or treatment of various diseases, illnesses or disorders that are ameliorated by modulating the CCR6 receptor. Such diseases, illnesses or disorders in which the CCR6 receptor is involved include inflammatory and / or autoimmune diseases, illnesses or disorders; and cancer.

[0154] The compounds of formula (I) as defined hereinabove are useful in the prevention or treatment of various diseases, conditions or disorders that are ameliorated by modulating the CCR6 receptor. Such diseases, conditions or disorders involving the CCR6 receptor may be defined as including: rheumatoid arthritis; ankylosing spondylitis; spondyloarthritis; psoriasis; psoriatic arthritis; inflammatory skin disorders such as rosacea; Crohn's disease; ulcerative colitis; inflammatory bowel disease; irritable bowel disease; dry eye disease; multiple sclerosis; systemic lupus erythematosus; Sjogren's syndrome; autoimmune hepatitis; primary sclerosing cholangitis; posterior uveitis; allergic conjunctivitis; gastrointestinal allergic diseases; type 1 diabetes mellitus and endometriosis; ocular surface diseases in which elevated IL-17A levels have been documented, such as meibomian gland dysfunction; GVHD; graft-versus-host disease; autoimmune keratitis; filamentous keratitis; dry eye syndrome associated with rheumatoid arthritis; dry eye syndrome without systemic disease; Stevens-Johnson syndrome; plaque psoriasis, guttate psoriasis, inverse psoriasis Psoriasis, including pustular psoriasis and erythrodermic psoriasis; autoimmune keratitis; filamentous keratitis; autoimmune uveitis; allergic conjunctivitis; asthma; allergic diseases of the gastrointestinal tract; T1D; endometriosis; meibomian gland dysfunction; graft-versus-host disease; juvenile arthritis; juvenile rheumatoid arthritis; systemic rheumatoid arthritis onset rheumatoid arthritis); oligoarticular rheumatoid arthritis; oligoarticular juvenile rheumatoid arthritis; polyarticular rheumatoid arthritis; enteropathic arthritis; juvenile Reiter's syndrome; ankylosing spondylitis; juvenile ankylosing spondylitis; SEA syndrome; reactive arthritis (reactive joint disease); psoriatic arthropathy; juvenile enteropathic arthritis; polymyalgia rheumatica; enteropathic spondylitis; juvenile idiopathic arthritis (JIA); juvenile psoriatic arthritis; juvenile rheumatoid arthritis; systemic-onset juvenile rheumatoid arthritis; acute pancreatitis; chronic pancreatitis; giant cell arteritis; and secondary osteoarthritis from inflammatory diseases.

[0155] Further, such diseases, conditions, or disorders involving the CCR6 receptor include skin cancer, e.g., malignant melanoma (superficial spreading, nodular, lentigo maligna, and acral lentiginous melanoma); advanced melanoma; metastatic melanoma; Merkel cell carcinoma; Kaposi's sarcoma; basal cell carcinoma; squamous cell carcinoma; and precancerous skin lesions such as actinic keratosis; lung cancer, including non-small cell (SCLC, NSCLC), such as small cell lung cancer and squamous and non-squamous NSCLC; pleuropulmonary blastoma and tracheobronchial tumors; urinary bladder cancer. urothelial cell carcinoma; mesothelioma; kidney cancer, including renal cell carcinoma (RCC) such as clear cell RCC; papillary RCC; chromophobe RCC; non- clear cell RCC; unclassified RCC; metastatic renal cell carcinoma; gastrointestinal cancer, including colorectal cancer; metastatic colorectal cancer; familial polyposis (FAP); rectal cancer; colon carcinoma; colorectal adenoma; colorectal adenocarcinoma; colorectal cancer liver metastases; hereditary non-polyposis colon cancer; advanced gastric cancer; gallbladder cancer; cholangiocellular carcinoma; hepatocellular carcinoma; pancreatic cancer such as pancreatic adenocarcinoma or pancreatic ductal (glandular) carcinoma; pancreatic neuroendocrine tumor tumors); endometrial cancer; ovarian cancer; prostate cancer, including castration-resistant prostate cancer; brain metastases, brain tumors, including malignant glioma, glioblastoma multiforme, medulloblastoma, meni...

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof: 【Chemistry 1】 (In the formula, A represents a 6-membered heteroaryl having 1 to 3 ring nitrogen atoms, which 6-membered heteroaryl is unsubstituted or substituted with 1, 2 or 3 substituents, if present, which are halogens; - cyano; hydroxy-C optionally substituted with 1 to 3 fluorine atoms １－６ - alkyl; - C １－５ alkyl, unsubstituted or containing one -- C １－３ -alkoxy; -- C optionally fused with a pyridine ring ３－６ -cycloalkyl, wherein the C ３－６ -cycloalkyl is unsubstituted or substituted by one hydroxy, C ３－６ -cycloalkyl; -- --O-R Ｏ１ (R Ｏ１ is C ３－６ -cycloalkyl or pyrrolidinyl, independently unsubstituted or containing one C １－３ -Alkyl or C １－４ -Alkyl- C substituted by carbonyl ３－６ -represents cycloalkyl or pyrrolidinyl; -- Phenyl-L １ - (the phenyl is unsubstituted or contains one fluorine, C １－４ -alkoxy-carbonyl or hydroxy-C １－４ -substituted by alkyl; -L １ - is a bond, oxygen or the group -CH ２ represents —O—; -- C having 1 or 2 ring heteroatoms independently selected from nitrogen and oxygen ４－６ -heterocyclyl, wherein the C ４－６ heterocyclyl is unsubstituted or has one or two oxo, hydroxy, C １－３ -Alkyl, C １－４ -alkyl-carbonyl or C １－４ -alkoxy-carbonyl substituted, C ４－６ -heterocyclyl; 5-membered heteroaryl having 1 or 2 ring nitrogen atoms, wherein the 5-membered heteroaryl is unsubstituted or has 1 C １－３ -5-membered heteroaryl substituted by alkyl; -- indolyl; -- pyrrolopyridinyl; -- N-(C １－３ -alkyl)-amino-carbonyl-oxy; Or, -- 1-hydroxy-1-C ３－５ -cycloalkyl-1-(pyridinyl)-methyl; １－５ - alkyl; - C ３－５ - alkyl, hydroxy and R Ａ１ and any such substituents are substituted by the C ３－５ - in the 3-position relative to the point of attachment of the alkyl; -- R Ａ１ but, --- tetrahydropyranyl; --- Unsubstituted or containing one fluorine or C １－３ phenyl substituted by alkoxy; --- A 5- or 6-membered heteroaryl having 1 or 2 ring heteroatoms independently selected from nitrogen and sulfur, said 5- or 6-membered heteroaryl being independently unsubstituted or substituted with 1 or 2 substituents, if present, each of which is selected from the group consisting of C １－３ -Alkyl, C ３－５ -cycloalkyl and C １－３ - a 5- or 6-membered heteroaryl independently selected from alkoxy; Or, --- Indazolyl represents C ３－５ - alkyl; - unsubstituted or substituted by one hydroxy ３－５ -alkenyl; - C ４－６ -cycloalkenyl, unsubstituted or having 1 or 2 C １－３ -substituted by alkyl, oxo or hydroxy; ４－６ - one ring carbon atom of cycloalkenyl optionally replaced by an oxygen atom, C ４－６ -cycloalkenyl; - C ３－６ - cycloalkyl, unsubstituted or having 1 or 2 C １－３ -Alkyl, hydroxy or hydroxy-C １－３ -substituted by alkyl, ３－６ - one ring carbon atom of cycloalkyl optionally replaced by an oxygen atom, C ３－６ -cycloalkyl; - -O-R Ｏ２ (-- R Ｏ２ teeth, --- C １－４ - alkyl; --- 1 hydroxy or C １－３ -C substituted by alkoxy ２－５ - alkyl; --- -L ２ -CY ２ (--- -L ２ - is independently a bond, -CH ２ - or -CH ２ -CH ２ represents -; ---CY ２ are, independently, --- Unsubstituted or one hydroxy-C １－３ - phenyl substituted by alkyl; --- benzyl-oxy; --- A 5- to 6-membered heteroaryl having 1 to 3 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the 5- or 6-membered heteroaryl is independently an unsubstituted or substituted by 1 or 2 substituents; if such substituents are present, they are １－３ -Alkyl and C １－３ -5-6 membered heteroaryl independently selected from cycloalkyl; --- C ３－６ - cycloalkyl, in which one carbon ring atom is optionally replaced by one heteroatom selected from oxygen and nitrogen; ３－６ -cycloalkyl is unsubstituted or substituted by 1 or 2 substituents, said substituents being C １－３ -Alkyl, hydroxy, fluoro, oxo, C １－３ -Alkyl-carbonyl and C １－３ -alkoxy, C ３－６ -cycloalkyl; --- Benzoxazolonyl; Or, --- Chromanyl; represents.) represents.) - -C≡C-R Ｔ１ (-- R Ｔ１ teeth, --- C １－４ -alkyl, and the C １－４ - alkyl is independently one --- Hydroxy; --- C １－３ -alkoxy; ---- -S (=O) ２ -R ＳＯＴ (R ＳＯＴ is C １－３ -Alkyl, C １－３ -Alkyl-amino or C ３－５ -represents cycloalkyl; --- NR ＮＴ１ R ＮＴ２ (R ＮＴ１ represents hydrogen, R ＮＴ２ is C １－３ -Alkyl-carbonyl, C １－３ -alkoxy-C １－３ -alkyl-carbonyl or C ３－５ -cycloalkyl-carbonyl; --- C having 1 or 2 ring heteroatoms independently selected from nitrogen and oxygen ４－６ -heterocyclyl; ４－６ heterocyclyl is substituted by one oxo; or by oxo and one C １－３ -substituted by two alkyl substituents, C ４－６ -heterocyclyl; Or, --- N-(C １－３ -alkyl-carbonyl)-piperidinyl-C １－３ - alkyl; C substituted by １－４ - alkyl; --- C substituted by two substituents １－４ -alkyl, one of the substituents being hydroxy and the second being trifluoromethyl; １－４ - alkyl; --- C ３－６ -cycloalkyl having one --- Hydroxy; --- amino-sulfonyl optionally substituted by two methyl; --- Phenyl substituted by one halogen; --- Pyridinyl; --- 1 C １－３ -pyrimidinyl substituted by alkyl; Or, --- Oxazolidinonyl; C substituted by ３－６ -cycloalkyl; --- C fused with pyridine ring ３－６ -cycloalkyl, wherein the C ３－６ -cycloalkyl is substituted by one hydroxy; ３－６ - one ring carbon atom in the cycloalkyl is optionally replaced by one oxygen atom, C ３－６ -cycloalkyl; --- C having one ring heteroatom independently selected from nitrogen and oxygen ４－６ -heterocyclyl; ４－６ -heterocyclyl is substituted by 1, 2 or 3 substituents, said substituents being C １－３ -Alkyl, hydroxy, oxo, C １－３ -Alkyl-carbonyl, C １－３ -alkoxy-carbonyl, C １－３ -Alkyl-sulfonyl and C １－３ -alkyl-amino-sulfonyl, C ４－６ -heterocyclyl; ---pyrazolyl N-substituted by methyl; --- Indolyl; --- 3-hydroxy-1-methyl-1,3-dihydro-indol-2-on-3-yl; Or, --- 4-hydroxy-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl; represents.) - -C≡C-C(OH)(R Ｔ２ )(R Ｔ３ ) (-- R Ｔ２ is hydrogen or C １－３ represents alkyl; --R Ｔ３ teeth, --- Phenyl is unsubstituted or substituted with one substituent, if present, and the substituent is selected from the group consisting of C １－３ - phenyl, selected from alkoxy and halogen; --- A 5-6 membered heteroaryl having 1 or 2 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the 5 or 6 membered heteroaryl is independently unsubstituted or substituted with 1 or 2 substituents, if present, which substituents are selected from the group consisting of: C １－３ -Alkyl, C １－３ -cycloalkyl, C １－３ -fluoroalkyl and C １－３ -5-6 membered heteroaryl independently selected from alkoxy; --- C having one ring heteroatom selected from nitrogen and oxygen ４－７ -heterocyclyl; ４－７ heterocyclyl is unsubstituted or substituted by 1 or 2 substituents, if present, which substituents are selected from the group consisting of C １－３ -Alkyl and C １－３ -alkyl-carbonyl, C ４－７ -heterocyclyl; Or, --- Indazolyl; represents.) - -NR Ｎ３ R Ｎ４ (-- R Ｎ３ is C １－３ represents alkyl; and, R Ｎ４ is hydroxy-C １－３ -alkyl or 2-(benzyloxy)-C １－３ - represents alkyl; Or, --R Ｎ３ and R Ｎ４ together with the nitrogen to which they are attached form a 4-6 membered heterocycle, and each of the ring members required to complete the heterocycle is —CH ２ -, -O-, -(C=O)-, -CHR Ｘ - and -C(R Ｙ ) ２ -, wherein the heterocycle has no more than one ring member independently selected from the group consisting of -O- and -(C=O)-; and the heterocycle is -CHR Ｘ -; the heterocycle has no more than two ring members selected from the group consisting of -C(R Ｙ ) ２ -, having no more than two ring members selected from the group consisting of; R Ｘ are independently fluorine, methyl, isopropyl, isobutyl, tert-butyl, hydroxy, trifluoromethyl, hydroxymethyl, 1-hydroxyethyl, 1-hydroxy-1-methylethyl, cyclopropyl, 2-methoxyethyl, 2-methylthiazol-5-yl, 4-methylthiazol-2-yl, phenyl, benzyl, tetrahydropyran-4-yl, N-acetyl-piperidin-4-yl, 1,2,4-oxadiazolyl, 3-methyl-1,2,4 -oxadiazol-5-yl, 2-methyl-2H-[1,2,3]triazol-4-yl, 1-methyl-1H-pyrazol-4-yl, 1-difluoromethyl-1H-pyrazol-4-yl, 1,3-dimethyl-1H-pyrazol-4-yl, pyridin-2-yl, 6-methyl-pyridin-3-yl, 6-isopropyl-pyridin-2-yl, 6-trifluoromethyl-pyridin-3-yl, 2-isopropyl-pyrimidin-4-yl or 1-methoxy-methyl; R Ｙ independently represent fluorine, hydroxy, cyclopropyl, methyl, hydroxy-methyl or trifluoromethyl; - -(C=O)-N(R Ｎ５ )(R Ｎ６ ) (-- R Ｎ５ represents hydrogen; and R Ｎ６ is C ３－６ - represents cycloalkyl or tetrahydropyranyl; Or, --R Ｎ５ and R Ｎ６ together with the nitrogen to which they are attached form pyrrolidinyl.) ； piperidin-4-yl or pyrrolidin-3-yl substituted by one substituent at the nitrogen ring atom, said substituent being C １－４ - piperidin-4-yl or pyrrolidin-3-yl independently selected from alkoxy-carbonyl, pyridinyl, phenyl and (4-methylphenyl)-sulfonyl; a 5- or 6-membered heteroaryl having 1 to 3 ring heteroatoms independently selected from nitrogen, oxygen and sulfur; said 5- or 6-membered heteroaryl is independently unsubstituted or substituted with 1, 2 or 3 substituents, if present, which are: -- C １－４ - alkyl, --- unsubstituted; --- 1 piece, --- Hydroxy; --- C １－４ -alkoxy; Or, --- -N(R Ｎ７ ) (R Ｎ８ ) (R Ｎ７ is hydrogen or C １－３ - represents alkyl; R Ｎ８ are independently ３－５ -cycloalkyl-carbonyl, C １－３ -Alkyl, C １－３ -Alkyl-carbonyl (deuterated C １－３ -alkyl-carbonyl), C １－３ -alkoxy-C １－３ -alkyl-carbonyl, tetrahydropyranyl-carbonyl or hydroxy-C １－３ - represents alkyl-carbonyl; is replaced by; --- Substituted with two substituents, one of which is hydroxy and the other of which is trifluoromethyl; or two of which are hydroxy; or --- Substituted with two or three substituents, two of which are fluorine and, if present, one of which is hydroxy; C １－４ - alkyl; -- -L ３ -CY ３ (--- -L ３ - is independently a bond, -CH ２ -, -CH ２ -CH ２ -, -C(CH ３ ) ２ -, -CH(OH)- or -O-CH ２ represents -, -L ３ -ga-O-CH ２ -, the CY ３ is the —O—CH ２ - attached to the oxygen atom; --- CY ３ are independently ３－６ -cycloalkyl or C ４－６ -represents heterocyclyl, ４－６ -heterocyclyl has 1 or 2 ring heteroatoms independently selected from nitrogen and oxygen; ３ is independently unsubstituted or substituted with 1, 2 or 3 substituents, said substituents being --- Halogen; --- oxo; --- Hydroxy; --- 1 C １－３ C optionally substituted with alkoxy １－３ - alkyl; --- C １－３ -alkoxy; -----(C=O)-R ＣＯ (R ＣＯ teeth, --- 1 hydroxy or C １－３ C optionally substituted with alkoxy １－３ - alkyl; --- C １－３ -fluoroalkyl; --- C １－３ -alkoxy, １－３ -C with one alkoxy １－３ C optionally substituted with alkoxy １－３ -alkoxy; --- C in which one or two carbon ring atoms are optionally replaced by one or two oxygen ring atoms ３－６ -cycloalkyl-(CH ２ ) ｎ - (n represents the integer 0, 1 or 2); or --- Phenyl; represents.) --- -N(R Ｎ９ ) (R Ｎ１０ ) (R Ｎ９ is hydrogen or C １－３ - represents alkyl ;R Ｎ１０ is C １－３ -Alkyl, C １－３ -Alkyl-carbonyl, C １－３ -alkyl-sulfonyl, C １－３ -alkoxy-carbonyl, C １－３ -alkoxy-C １－３ -alkyl-carbonyl or tetrahydropyranyl-carbonyl; ---- -S (=O) ２ -R ＳＯ (R ＳＯ teeth, --- 1 hydroxy, C １－３ C optionally substituted by alkoxy or amino １－３ -alkyl; or --- C in which one carbon ring atom is optionally replaced by one oxygen ring atom ３－５ -cycloalkyl; represents.) a 5-membered heteroaryl having one ring heteroatom selected from nitrogen, oxygen, and sulfur; wherein the 5-membered heteroaryl is unsubstituted; and --- Phenyl-(CH ２ ) ｐ - (p represents an integer of 0, 1 or 2); are independently selected from --phenyl or 6-membered heteroaryl having 1 or 2 ring nitrogen atoms; the phenyl or 6-membered heteroaryl is independently unsubstituted or １－３ -Alkyl or C １－３ phenyl or 6-membered heteroaryl having 1 or 2 ring nitrogen atoms substituted by alkoxy; -- Pyrazolyl-C １－３ - alkyl; -- C １－３ -Alkyl-sulfonyl-C １－３ - alkyl; -- 3-hydroxymethyl-bicyclo[1.1.1]pent-1-yl; 7-oxa-bicyclo[2.2.1]hept-2-yl; and --6-oxa-spiro[2.5]oct-1-yl; a 5- or 6-membered heteroaryl independently selected from 5-oxo-4-oxa-6-azaspiro[2.4]hept-6-yl, 5-aza-spiro[2.4]heptan-6-on-5yl, 2,2-dimethyl-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl, 2-cyclopropyl-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl, 2-oxo-1-oxa-3-azaspiro[4.4]non-3-yl, 8,8-difluoro-2-oxo-1-oxa-3-azaspiro[4.5]dec-3-yl or 8-oxo-7-oxa-9-azadispiro[3.1.4.1]undec-9-yl; 7-aza-bicyclo[2.2.1]hept-7-yl, 2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl, 6-oxa-3-aza-bicyclo[3.1.1]hept-3-yl or 8-oxa-3-azabicyclo[3.2.1]oct-3-yl; 5-oxo-6-azaspiro[3.4]oct-6-yl, 3-oxo-2-azaspiro[4.4]non-2-yl, 1-oxa-3-aza-spiro[4.5]decan-2-on-3-yl, 1-oxo-2-azaspiro[4.5]dec-2-yl, 1-oxo-8-oxa-2-azaspiro[4.5]dec-2-yl, 3-oxo-8-oxa-2-azaspiro[4.5]dec-2-yl or 4-oxo-hexahydro-5H-furo[2,3-c]pyrrol-5-yl; 3-(7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)propyl or 3-(8-hydroxy-5,6,7,8-tetrahydroquinolin-8-yl)propyl); 6-acetyl-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl; 2-(6,7-dihydro-5H-[1]pyrindin-7-ol)-ethyl; 2-(8-hydroxy-5,6,7,8-tetrahydro-quinolin-8-yl)-ethyl; 2,3-dihydro-isoindol-1-on-2-yl; and 6-acetyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-2-yl; are independently selected from B represents phenyl unsubstituted or substituted with 1, 2 or 3 substituents, and if a first substituent is present, said first substituent is halogens; - C １－５ - alkyl; - C ２－４ -alkenyl; - C １－３ -alkoxy; - C １－３ -alkoxy-C １－４ - alkyl; - C １－４ -fluoroalkyl; independently unsubstituted or 1 C １－３ -Alkyl or C １－３ -substituted by fluoroalkyl, C ３－５ -cycloalkyl; - -SF ５ ; bicyclo[1.1.1]pent-1-yl; - C ３－５ -cycloalkoxy; and - C １－３ -fluoroalkoxy; Selected from: The remaining substituents of B, if present, are halogen and C １－３ - independently selected from alkyl; Or B represents benzothiophenyl or naphthalenyl; R １ is C １－３ represents alkyl, cyano or halogen; R ２ is C １－４ -Alkyl, C ３－５ -cycloalkyl, C ３－５ -cycloalkyl-C １－３ -Alkyl, hydroxy-C １－３ -Alkyl, C １－３ -alkoxy-C １－３ -Alkyl or C １－３ -represents fluoroalkyl.

2. 2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein A represents pyridin-3-yl and A is substituted with one substituent at the meta position of A relative to the point of attachment of A to the remainder of the molecule, said substituent being as defined in claim 1.

3. The substituent on A or at least one of the substituents on A is a 5- or 6-membered heteroaryl as defined in claim 1, and the 5- or 6-membered heteroaryl substituent, if present, is selected from the group consisting of an optionally substituted C １－４ -alkyl; or a pharmaceutically acceptable salt thereof.

4. The substituent of A or at least one of the substituents of A is a 5- or 6-membered heteroaryl having 1 to 3 ring heteroatoms independently selected from nitrogen, oxygen and sulfur; said 5- or 6-membered heteroaryl is independently unsubstituted or substituted with 1, 2 or 3 substituents, if present, which are: -- C １－４ - alkyl, --- unsubstituted; --- 1 piece, --- Hydroxy; Or, --- C １－４ -alkoxy; is replaced by; --- is substituted with two substituents, one of which is hydroxy and the other of which is trifluoromethyl; or both of which are hydroxy; or --- substituted by 2 or 3 substituents, 2 of which are fluorine and, if present, 1 of which is hydroxy; C １－４ - alkyl; or a pharmaceutically acceptable salt thereof.

5. The substituent of A or at least one of the substituents of A is 1,2,4-oxadiazol-5-yl or 1,2,4-oxadiazol-3-yl, and the oxadiazolyl group is substituted with one substituent, and the substituent is C １－４ - alkyl with one hydroxy or C １－４ -C substituted by alkoxy １－４ -alkyl; or a pharmaceutically acceptable salt thereof.

6. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein A represents pyridin-3-yl substituted by one substituent at the meta position relative to the point of attachment of the pyridin-3-yl to the remainder of the molecule, said substituent being 5-(hydroxymethyl)-1,2,4-oxadiazol-3-yl, 5-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazol-3-yl, 5-(2-hydroxy-2-methyl-propyl)-1,2,4-oxadiazol-3-yl or 5-(2-hydroxy-1,1-dimethyl-ethyl)-1,2,4-oxadiazol-3-yl.

7. B is phenyl and is substituted with 1, 2, or 3 substituents, the first of which is attached at the para position relative to the point of attachment of B to the remainder of the molecule, and which is - C １－５ - alkyl; - C １－３ -alkoxy-C １－４ - alkyl; - C １－２ -fluoroalkyl; - C ３－５ -cycloalkyl, independently unsubstituted or containing one C １－３ -Alkyl or C １－３ -substituted by fluoroalkyl, C ３－５ -cycloalkyl; and - C １ -fluoroalkoxy; represents a phenyl selected from: The remaining substituents on B, if present, are independently selected from halogen; The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1, wherein B is phenyl substituted by one substituent attached at the para position relative to the point of attachment of B to the remainder of the molecule, and wherein said substituent represents isopropyl, trifluoromethyl, trifluoromethoxy, cyclopropyl, cyclobutyl, 1-methyl-cyclopropyl, or 1-trifluoromethyl-cyclopropyl, or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1, wherein B is phenyl substituted with one substituent, said substituent being attached at a para position relative to the point of attachment of B to the remainder of the molecule, and said substituent representing isopropyl, or a pharmaceutically acceptable salt thereof.

10. R １ The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein represents methyl.

11. R ２ But C １－４ -Alkyl, C ３－５ -cycloalkyl, C ３－５ -cycloalkyl-C １－３ -Alkyl or C １－３ 11. The compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R represents -fluoroalkyl.

12. The compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R 2 represents methyl.

13. A represents pyridin-3-yl, and said pyridin-3-yl is a compound of the formula (I) substituted with one substituent at the meta position relative to the attachment point of the pyridin-3-yl, said substituent being 5-(hydroxymethyl)-1,2,4-oxadiazol-3-yl, 5-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazol-3-yl, 5-(2-hydroxy-2-methyl-propyl)-1,2,4-oxadiazol-3-yl or 5-(2-hydroxy-1,1-dimethyl-ethyl)-1,2,4-oxadiazol-3-yl; B represents 4-propyl-phenyl, 4-isopropyl-phenyl, 4-isobutyl-phenyl, 4-tert-butyl-phenyl, 3-fluoro-4-isopropyl-phenyl, 3,5-difluoro-4-isopropyl-phenyl, 4-cyclopropyl-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 4-(2,2,2-trifluoro-ethyl)-phenyl, 4-cyclobutyl-phenyl or 4-(1-trifluoromethyl-cyclopropyl)-phenyl; R 1 represents methyl; 2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 represents methyl.

14. The compound of any one of claims 1 to 13, which is a compound of formula (II) or a pharmaceutically acceptable salt thereof: 【Chemistry 2】 (In the formula, A, B, R 1 and R 2 are as defined in any one of claims 1 to 13.

15. (3-fluoro-1-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; 3-[hydroxy-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methyl]-1-methyl-azetidine-3-carbonitrile; (R)-(1-Ethyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(3-methyl-1-propyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-Isopropyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-cyclopropylmethyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-cyclobutyl-3-methyl-azetidin-3-yl)-(5-pyrrolidine -1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-Isobutyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-cyclopropyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-[1-(2-fluoro-ethyl)-3-methyl-azetidin-3-yl]-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-[1-(2,2-difluoro-ethyl)-3-methyl-azetidin-3-yl]-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-tert-butyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-methoxy-prop-1-ynyl)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-prop-1-yn-1-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-methyl-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopentanol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopropanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-azetidine-1-carboxylic acid tert-butyl ester; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclobutanol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-1-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(1-methyl-1H-pyrazol-4-ylethynyl)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4 -isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-phenyl-prop-2-yn-1-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-phenyl-but-3-yn-2-ol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-methyl-pent-1-yn-3-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-tetrahydro-pyran-4-ol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(tetrahydro-pyran-4-yl)-prop-2-yn-1-ol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(1,3-dimethyl-1H-pyrazol-4-yl)-prop-2-yn-1-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-pyran-4-ylethynyl)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(2-methyl-thiazol-4-yl)-prop-2-yn-1-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(3-fluoro-phenyl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(4-methoxy-phenyl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-phenyl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazol-4-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-pyrimidin-2-yl-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(1,5-dimethyl-1H-pyrazol-3-yl)-prop-2-yn-1-ol; 8-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-5,6,7,8-tetrahydro-quinolin-8-ol; 7-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-6,7-dihydro-5H-[1]pyrindin-7-ol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-pyridin-2-yl-pent-1-yn-3-ol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methoxy-pyridin-2-yl)-pent-1-yn-3-ol; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-azetidin-1-yl)-2-methyl-propan-1-one; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-(1H-indol-2-ylethynyl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-methoxy-propyl)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-propan-1-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-methyl-butan-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-butan-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-butan-2-ol; 1-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-cyclopentanol; 1-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-cyclopropanol; 3-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-3-hydroxy-azetidine-1-carboxylic acid tert-butyl ester; 1-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-cyclobutanol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-butan-1-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl )-{5-[2-(1-methyl-1H-pyrazol-4-yl)-ethyl]-pyridin-3-yl}-methanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-phenyl-propan-1-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-phenyl-butan-2-ol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-methyl-pentan-3-ol; 4-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-tetrahydro-pyran-4-ol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(tetrahydro-pyran-4-yl)-propan-1-ol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(1,3-dimethyl-1H-pyrazol-4-yl)-propan-1-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[2-(tetrahydro-pyran-4-yl)-ethyl]-pyridin-3-yl}-methanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(2-methyl-thiazol-4-yl)-propan-1-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(3-fluoro-phenyl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(4-methoxy-phenyl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-phenyl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazol-4-yl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyridin-2-yl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-pyrimidin-2-yl-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl)-butan-2-ol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(1,5-dimethyl-1H-pyrazol-3-yl)-propan-1-ol; 8-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-5,6,7,8-tetrahydro-quinolin-8-ol; 7-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-6,7-dihydro-5H-[1]pyrindin-7-ol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-pyridin-2-yl-pentan-3-ol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methoxy-pyridin-2-yl)-pentan-3-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-{5-[2-(1H-indol-2-yl)-ethyl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (R)-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-{5-[3-(tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-{5-[3-(2-methoxy-1,1-dimethyl-ethyl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-[5-(3-cyclobutoxymethyl-[1,2,4]oxadiazol-5-yl)-pyridin-3-yl]-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-propyl-phenyl)-{5-[3-(tetrahydro-pyran-4-yloxymethyl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-propyl-phenyl)-{5-[3-(tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-[5-(3-cyclobutoxymethyl-[1,2,4]oxadiazol-5-yl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-propyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-morpholin-4-ylmethyl-[1,2,4]oxadiazol-5-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-{5-[3-(2,6-dimethyl-morpholin-4-ylmethyl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(4-methyl-tetrahydro-pyran-4-yl)-[1,2,4]o oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[(1S,2S,4R)-3-(7-oxa-bicyclo[2.2.1]hept-2-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(tetrahydro-pyran-4-yloxymethyl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-morpholin-4-yl-[1,2,4]oxadiazol-5-yl)-pyridin-3-yl]-methanol; (R)-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-{5-[3-(4-methoxy-tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-{5-[3-(3-hydroxymethyl-bicyclo[1.1.1]pent-1-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-{5-[3-(3-hydroxymethyl-bicyclo[1.1.1]pent-1-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 2-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-2-methyl-propan-1-ol; 2-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-propan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(1-methoxy-1-methyl-ethyl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(1-methoxy-cyclobutyl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; 1-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-2-methyl-propan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-methanesulfonylmethyl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(2-methoxy-ethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-methoxymethyl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-furan-3-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-pyran-4-yl)-[1,2,4]oxadiazo {pyridin-3-yl}-pyridin-3-yl}-methanol; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-cyclohexanol; (R)-[5-(5-tert-butoxymethyl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-pyran-4-ylmethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-cyclohexanol; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-cyclohexanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methoxy-cyclobutyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(6-oxa-spiro[2.5]oct-1-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-pyran-3-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(tetrahydro-furan-2-yl)methyl]-[1,2,4]oxadiazol-3-yl}-pyridin-3-yl)-methanol; (R)-2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1,1,1-trifluoro-propan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methoxy-1-methyl-ethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-{5-[5-((R)-cyclohexyl-hydroxy-methyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-cyclopropanol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-cyclopentanol; 3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-cyclobutanol; (R)-(1,3-dimethyl-azetidin-3-yl)-{5-[5-(4-fluoro-tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-{5-[5-((2R,4R,6S)-2,6-dimethyl-tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-pyran-4-yloxymethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-methyl-1-(tetrahydro-pyran-4-yl)-ethyl]-[1,2,4]oxadiazol-3-yl}-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{5-[2-(tetrahydro-pyran-4-yl)-ethyl]-[1,2,4]oxadiazol-3-yl}-pyridin-3-yl)-methanol; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-cyclobutanol; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-2-methyl-propan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(7-oxa-bicyclo[2.2.1]hept-2-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(4-methyl-tetrahydro-pyran-4-yloxymethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-oxetan-3-yl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(2-methoxy-1,1-dimethyl-ethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-2-methyl-propan-1-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(2-methoxy-2-methyl-propyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-cyclobutanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methoxymethyl-cyclopropylmethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(2-pyrazol-1-yl-ethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)—N-(2-(3-(5-((1,3-dimethylazetidin-3-yl)(hydrogen) 4-isopropylphenylmethylpyridin-3-yl-1,2,4-oxadiazol-5-ylethylacetamide-2,2,2-d ３ ; (R)—N-(1-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)-2-methylpropan-2-yl)acetamide-2,2,2-d ３ ; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-2-hydroxy-ethanone; (R)-1-(4-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)ethan-1-one-2,2,2-d ３ ; N-[2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-ethyl]-2-hydroxy-N-methyl-acetamide; (R)—N-(2-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)ethyl)-N-methylacetamide-d ３ ; (1,3-dimethyl-azetidin-3-yl)-(6-methoxy-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(6-phenoxy-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(6-ethoxy-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(5-methyl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-propyl-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-methoxy-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-ethyl-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1,3-dimethyl-azetidin-3-yl)-phenyl-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (4-Cyclobutyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (4-Cyclobutoxy-phenyl)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-ethoxy-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (4-tert-butyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropoxy-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methanol; (1,3-dimethyl-azetidin-3-yl)-[4-(1-methyl-cyclopropyl)-phenyl]-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (4-Cyclopropoxy-phenyl)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (S)-[2-(3,3-difluoro-pyrrolidin-1-yl)-pyridin-4-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (S)-[2-((3R,4S)-3,4-difluoro-pyrrolidin-1-yl)-pyridin-4-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (S)-(1,3-dimethyl-azetidin-3-yl)-(2-isobutoxy-pyridin-4-yl)-(4-isopropyl-phenyl)-methanol; 4-{4-[(S)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-2-yl}-2-methyl-butan-2-ol; (R)-[6-(3,3-difluoro-pyrrolidin-1-yl)-pyridazin-4-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (S)-5-tert-butyl-3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-oxazolidin-2-one; (R)-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-ol; (S)-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-((S)-3-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (S)-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-methyl-pyrrolidin-3-ol; 3-Cyclopropyl-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-ol; 2-((S)-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-yl)-propan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-morpholin-4-yl-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(3,4,5,6-tetrahydro-2H-[1,3′]bipyridinyl-5′-yl)-methanol; (R)-[5-(7-Aza-bicyclo[2.2.1]hept-7-yl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl )-[5-((S)-2-methyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-trifluoromethyl-pyrrolidin-3-ol; (R)-[5-(3,3-difluoro-pyrrolidin-1-yl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 5'-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-4-ol; 5'-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-3-ol: (R)-{5-[(2-benzyloxy-ethyl)-methyl-amino]-pyridin-3-yl}-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[4-(1-methyl-cyclopropyl)-phenyl]-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (R)-[5-((3R,4S)-3,4-difluoro-pyrrolidin-1-yl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methanol; 2-[(S)-1-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-pyrrolidin-3-yl]-propan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methanol; (R)-(4-tert-butyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-(3,4,5,6-tetrahydro-2H-[1,3′]bipyridinyl-5′-yl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-{5-[5-(1-cyclopropanesulfonyl-piperidin-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 2-({5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-methyl-amino)-ethanol; (R)-1-((S)-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-yl)-ethanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-oxazolidin-2-one; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5-phenyl-oxazolidin-2-one; 5-benzyl-3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxybenzoate {hydroxy-(4-isopropyl-phenyl)-methyl}-pyridin-3-yl}-oxazolidin-2-one; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5-isopropyl-oxazolidin-2-one; 6-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-oxa-6-aza-spiro[2.4]heptan-5-one; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-oxa-3-aza-spiro[4.4]nonan-2-one; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5-(tetrahydro-pyran-4-yl)-oxazolidin-2-one; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5,5-dimethyl-oxazolidin-2-one; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-8,8-difluoro-1-oxa-3-aza-spiro[4.5]decan-2-one; 9-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-7-oxa-9-aza-dispiro[3.1.4.1]undecan-8-one; 2-cyclopropyl-7-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5-oxa-7-aza-spiro[3.4]octan-6-one; 7-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2,2-dimethyl-5-oxa-7-aza-spiro[3.4]octan-6-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-phenyl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-isopropyl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-isopropyl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4,4-dimethyl-pyrrolidin-2-one; 5-(5-((R)-(1,3-dimethyl-azetidin-3-yl)(hydroxy)(4-isopropyl-phenyl)methyl)pyridin-3-yl)hexahydro-4H-furo[2,3-c]pyrrol-4-one; 2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-aza-spiro[4.4]nonan-3-one; 6-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-6-aza-spiro[3.4]octan-5-one; 2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-8-oxa-2-aza-spiro[4.5]decan-3-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(tetrahydro-pyran-4-yl)-pyrrolidin-2-one; 2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-aza-spiro[4.5]decan-1-one; 2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-8-oxa-2-aza-spiro[4.5]decan-1-one; (S)-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-isobutyl-pyrrolidin-2-one; 4-cyclopropyl-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-trifluoromethyl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(2-methoxy-ethyl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(2-methoxy-ethyl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-pyrrolidin-2-one; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-((R)-3-isopropyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-((2R,6S)-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(6-oxa-3-aza-bicyclo[3.1.1]hept-3-yl)-pyridin-3-yl]-methanol; (R)-[5-((3R,4S)-3,4-difluoro-pyrrolidin-1-yl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-[5-((3S,4S)-3,4-difluoro-pyrrolidin-1-yl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-((2S,6S)-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-(4-isopropyl- (phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-((2R,6R)-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrrolidin-1-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(4-methyl-thiazol-2-yl)-pyrrolidin-1-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-phenyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-(3,3-dimethyl-pyrrolidin-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[(1S,4S)-5-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(2,2,6,6-tetrafluoro-morpholin-4-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-((R)-2-methoxymethyl-morpholin-4-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-((S)-2-methoxymethyl-morpholin-4-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-trifluoromethyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[(1R,4R)-5-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[(1S,5R)-5-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[(1S,4S)-5-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-pyridin-3-yl]-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-ethyl-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-ethyl-phenyl)-[5-(6-oxa-3-aza-bicyclo[3.1.1]hept-3-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-ethyl-phenyl)-[(1S,4S)-5-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-pyridin-3-yl]-methanol; (R)-(5-benzyloxy-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(2-pyridin-2-yl-ethoxy)-pyridin-3-yl]-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(2-methoxy-ethoxy)-pyridin-3-yl]-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(oxetan-3-ylmethoxy)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-propan-1-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(5-isopropoxy-pyridin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(5-cyclohexyloxy-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-2-methyl-propan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-methoxy-cyclopentyloxy)-pyridin-3-yl]-methanol; (R)-[5-(3-cyclopropyl-[1,2,4]oxadiazol-5-ylmethoxy)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-{5-[2-(3,5-dimethyl-[1,2,4]triazol-1-yl)-ethoxy]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-2-methyl-butan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-methoxy-pyridin-3-yl)-methanol; (R)-[5-(2-benzyloxy-ethoxy)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-pyran-4-yloxy)-pyridin-3-yl]-methanol; 2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-ethanol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-cyclohexanol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-1-methyl-cyclohexanol; (1,3-dimethyl-azetidin-3-yl)-(2-phenoxy-pyrimidin-5-yl)-(4-trifluoromethoxy-phenyl)-methanol; (6-benzyloxy-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(5-pyrazol-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(6-fluoro-5-pyrrolidine-1- 5-[(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-trifluoromethoxy-phenyl)-methyl]-3-pyrrolidin-1-yl-pyridine-2-carbonitrile; (1,3-dimethyl-azetidin-3-yl)-[6-(tetrahydro-pyran-4-yloxy)-pyridin-3-yl]-(4-trifluoromethoxy-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-[6-(oxetan-3-ylmethoxy)-pyridin-3-yl]-(4-trifluoromethoxy-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(4-methyl-thiazol-2-yl)-pyridin-3-yl]-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-methyl-thiazol-2-yl)-pyridin-3-yl]-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(2-methoxy-pyrimidin-5-yl)-methanol; (S)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(2-pyrrolidin-1-yl-pyridin-4-yl)-methanol; (1,3-dimethyl-azetidin-3-yl)-[2-((R)-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-4-yl]-(4-isopropyl-phenyl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4′-yl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(2-morpholin-4-yl-pyridin-4-yl)-methanol; (S)-(1,3-dimethyl-azetidin-3-yl)-(2-ethyl-pyridin-4-yl)-(4-isopropyl-phenyl)-methanol; (S)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[2-(tetrahydro-pyran-4-ylmethoxy)-pyridin-4-yl]-methanol; (S)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[2-(2-methoxy-ethoxy)-pyridin-4-yl]-methanol; (S)-(2-cyclopentyl-pyridin-4-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-((R)-3-hydroxymethyl-3-methyl-pyrrolidin-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-((S)-3-fluoro-pyrrolidin-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[4-(tetrahydro-pyran-4-yl)-[1,2,3]triazol-1-yl]-pyridin-3-yl}-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-methyl-pyridin-3-yl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(5-isopropenyl-pyridin-3-yl)-(4-isopropyl-phenyl)-methanol; (5-Cyclopropyl-pyridin-3-yl)-(1,3-dimethyl-azetidine-3-yl) (4-isopropyl-phenyl)-methanol; (5-cyclopent-1-enyl-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 3-{5-[(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclopent-2-enol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-isopropyl-pyridin-3-yl)-methanol; (5-cyclopentyl-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 3-{5-[(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclopentanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-pyridin-3-yl-methanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclopent-2-enone; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-methyl-cyclopent-2-enol; (3S)-3-(5-((R)-(1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1-methylcyclopentan-1-ol; (3R)-3-(5-((R)-(1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1-methylcyclopentan-1-ol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-ethyl-cyclopentanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-isopropyl-cyclopentanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(4-methyl-oxazol-2-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(5-ethyl-pyridin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-methyl-pyridin-3-yl)-methanol; (R)-[5-(4,5-dihydro-furan-3-yl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-furan-3-yl)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-en-1-ol; N-cyclopentyl-5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-nicotinamide; {5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-1-yl-methyl Thanong; 5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-N-(tetrahydro-pyran-4-yl)-nicotinamide; (1,3-dimethyl-azetidin-3-yl)-[4-(3-methoxy-propyl)-phenyl]-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (R)-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-p-tolyl-methanol; 5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1'-carboxylic acid tert-butyl ester; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidine-1-carboxylic acid tert-butyl ester; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-pyran-4-yl)-pyridin-3-yl]-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(3',4',5',6'-tetrahydro-2'H-[2,1';4',3'']terpyridin-5''-yl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(1′-phenyl-1′,2′,3′,4′,5′,6′-hexahydro-[3,4′]bipyridinyl-5-yl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[1'-(toluene-4-sulfonyl)-1',2',3',4',5',6'-hexahydro-[3,4']bipyridinyl-5-yl]-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-furan-2-yl)-pyridin-3-yl]-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-methyl-tetrahydro-furan-2-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-(5,5-dimethyl-tetrahydro-furan-2-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2,2-difluoro-propan-1-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-methyl-oxazol-2-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-pyran-4-yl)-oxazol-2-yl]-pyridin-3-yl}-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-[5-(4-fluoro-phenoxymethyl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; Isopropyl-carbamic acid 5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylmethyl ester; (R)-[5-(2-benzyloxy-ethyl)-pyridin-3-yl]-(1,3-di Methyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-methyl-cyclohexanol; 2-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclopropyl)-propan-2-ol; (S)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{2-[5-(tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-4-yl}-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(2-pyrrolidin-1-yl-pyrimidin-5-yl)-methanol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(6-pyrrolidin-1-yl-pyrazin-2-yl)-methanol; (R)—N-(1-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)cyclopropyl)acetamide-2,2,2-d ３ ; (R)—N-(1-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)cyclopropyl)-N-methylacetamide-d ３ ; (R)—N-((3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)methyl)-N-methylacetamide-d ３ ; N-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-2-hydroxy-acetamide; (R)—N-((3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)methyl)acetamide-2,2,2-d ３ ; 1-(3-{5-[(R)-hydroxy-(1-isopropyl-3-methyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-2-methyl-propan-2-ol; 1-(3-{5-[(R)-(1-ethyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-2-methyl-propan-2-ol; 2-(3-{5-[(R)-hydroxy-(1-isopropyl-3-methyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(1-ethyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 4-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-piperidine-1-carboxylic acid benzyl ester; 1-[4-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-ethanone; (R)-1-(3-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)azetidin-1-yl)ethan-1-one-2,2,2-d ３ ； (R)-1-(3-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)-3-methylazetidin-1-yl)ethan-1-one-2,2,2-d ３ ; (R)-1-(3-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)-3-fluoroazetidin-1-yl)ethan-1-one-2,2,2-d ３ ; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methyl-1-morpholin-4-yl-ethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-methyl-piperidin-2-one; 1-[(S)-3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-pyrrolidin-1-yl]-ethanone; 1-[(R)-3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-pyrrolidin-1-yl]-ethanone; N-[1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-methyl-ethyl]-acetamide; 1-benzyl-3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-pyrrolidin-2-one; 3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1,3-dimethyl-pyrrolidin-2-one; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-isobutyl-pyrrolidin-2-one; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-furan-2-ylmethyl-pyrrolidin-2-one; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-phenyl-pyrrolidin-2-one; 1-benzyl-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-pyrrolidin-2-one; 5-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-phenyl-pyrrolidin-2-one; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-pyrrolidin-2-one; (S)-5-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1, 2,4]oxadiazol-5-yl)-pyrrolidin-2-one; (R)-5-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-pyrrolidin-2-one; (S)-6-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-2-one; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-2-one; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-azetidin-2-one; (S)-3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-azetidin-2-one; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1,4-dimethyl-pyrrolidin-2-one; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1,4-dimethyl-pyrrolidin-2-one; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-piperidin-4-yl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(4-methyl-piperidin-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-{5-[5-(4-fluoro-piperidin-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-butan-1-one; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-2,2-dimethyl-propan-1-one; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-2-methoxy-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-3-methoxy-propan-1-one; Cyclopropyl-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone; Cyclopentyl-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone; [4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-(tetrahydro-pyran-4-yl)-methanone; [4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-phenyl-methanone; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidine-1-carboxylic acid methyl ester; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidine-1-carboxylic acid ethyl ester; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidine-1-carboxylic acid 2-methoxy-ethyl ester; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methanesulfonyl-piperidin-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(propane-2-sulfonyl)-piperidin-4-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(propane-1-sulfonyl)-piperidin-4-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-3-yl)-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(2-methoxy-ethanesulfonyl)-piperidin-4-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-3-yl)-methanol; 2-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidine-1-sulfonyl]-ethanol; (R)-{5-[5-(1-cyclopentanesulfonyl-piperidin-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(tetrahydro-pyran-4-sulfonyl)-piperidin-4-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-3-yl)-methanol; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidine-1-sulfonic acid methylamide; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methylamino-cyclopropyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; [1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy Ci-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-cyclopropyl]-methyl-carbamic acid ethyl ester; N-[1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-cyclopropyl]-N-methyl-methanesulfonamide; (R)-(1,3-dimethyl-azetidin-3-yl)-[6-(2,2-dimethyl-cyclopentyloxy)-pyridazin-4-yl]-(4-isopropyl-phenyl)-methanol; (R)-[6-(3,3-difluoro-cyclopentyloxy)-pyridazin-4-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 2-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yloxy}-phenyl)-ethanol; 2-(4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yloxy}-phenyl)-ethanol; (R)-[6-(chroman-6-yloxy)-pyridazin-4-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 6-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yloxy}-3H-benzoxazol-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methyl-pyrimidin-4-yl)-pent-1-yn-3-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-{5-[1-(4-fluoro-phenyl)-cyclopropylethynyl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy x-pyrrolidine-1-carboxylic acid tert-butyl ester; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-piperidine-1-carboxylic acid tert-butyl ester; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methyl-pyrimidin-4-yl)-pentan-3-ol; 2-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-benzoic acid methyl ester; (R)-(1,3-dimethyl-azetidin-3-yl)-{5-[2-(2-hydroxymethyl-phenyl)-ethyl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin-4-yl)-butan-2-ol; 3-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[2-(1H-pyrrolo[2,3-b]pyridin-2-yl)-ethyl]-pyridin-3-yl}-methanol; 4-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-piperidine-1-carboxylic acid tert-butyl ester; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-pyridin-2-yl-butan-2-ol; 1-cyclopropyl-3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-pyridin-2-yl-propan-1-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-pyridin-3-yl)-butan-2-ol; 8-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-ethyl)-5,6,7,8-tetrahydro-quinolin-8-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-2-(6-methoxy-pyridin-2-yl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-2-(6-methyl-pyridin-2-yl)-butan-2-ol; (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(6-pyrrolidin-1-yl-pyridin-2-yl)-methanol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-4-fluoro-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydrazine {(4-isopropyl-phenyl)-methyl)-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-4-methyl-piperidin-1-yl]-ethanone; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-cyclohexanone; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclohexanol; (R)-(5-cyclopentyloxymethyl-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 1-(4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylmethoxy}-piperidin-1-yl)-ethanone; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[6-(tetrahydro-pyran-4-yl)-pyridazin-4-yl]-methanol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-2-phenyl-butan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{6-[(S)-(tetrahydro-furan-3-yl)oxy]-pyridazin-4-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{6-[(R)-(tetrahydro-furan-3-yl)oxy]-pyridazin-4-yl}-methanol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-4-methyl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-3-isopropyl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-3,3-dimethyl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-4,4-dimethyl-pyrrolidin-2-one; 5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-5-aza-spiro[2.4]heptan-6-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-4-trifluoromethyl-pyrrolidin-2-one; 4-cyclopropyl-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-pyrrolidin-2-one; 2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-8-oxa-2-aza-spiro[4.5]decan-3-one; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4 -isopropyl-phenyl)-methyl]-pyridazin-3-yl}-1-oxa-3-aza-spiro[4.5]decan-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-4-pyridin-2-yl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-3-(2-methoxy-ethyl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-4-phenyl-pyrrolidin-2-one; 2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-2,3-dihydro-isoindol-1-one; 2-(3-{5-[(S)-(3-fluoro-1-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(S)-(1-cyclopropyl-3-fluoro-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 1-[4-(3-{5-[(S)-(3-fluoro-1-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(S)-(1-cyclopropyl-3-fluoro-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 2-(3-{5-[(R)-(1-cyclopropyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 1-[4-(3-{5-[(R)-(1-cyclopropyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; (R)-(1-cyclopropyl-3-methyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; trans-4-(3-{5-[(R)-(1-cyclopropyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-cyclohexanol; (R)-(1-cyclopropyl-3-methyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-oxetan-3-yl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-methanol; 1-[(R)-3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-pyrrolidin-1-yl]-ethanone; 1-[3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-3-hydroxy-piperidin-1-yl]-ethanone; 1-[3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-3-methyl-piperidin-1-yl]-ethanone; 1-[3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-4-hydroxy-piperidin-1-yl]-ethanone; N-[1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-cyclopropyl]-acetamide; Tetrahydro-pyran-4-carboxylic acid [1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-cyclopropyl]-amide; N-[1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-cyclopropyl]-2-methoxy-acetamide; N-[1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-cyclopropyl]-N-methyl-acetamide; N-[2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1,1-dimethyl-ethyl]-propionamide; N-[2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1,1-dimethyl-ethyl]-2-methoxy-acetamide; Tetrahydro-pyran-4-carboxylic acid [2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1,1-dimethyl-ethyl]-amide; N-[2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1,1-dimethyl-ethyl]-isobutyramide; Cyclopropanecarboxylic acid [2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1,1-dimethyl-ethyl]-amide; 1-[cis-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-2-methyl-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-4-hydroxy-piperidin-1-yl]-2-methyl-propan-1-one; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-4-hydroxy-piperidin-1-yl]-propan-1-one; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-4-methoxy-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-3,3,3-trifluoro-propan-1-one; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-2-oxetan-3-yl-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-4-ethyl-piperidin-1-yl]-ethanone; [4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-oxetan-3-yl-methanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-4-isopropyl-piperidin-1-yl]-2-methoxy-ethanone; 1-[cis-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-3-methyl-piperidin-1-yl]-ethanone; 5-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-methyl-piperidin-2-one; 5-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-5-methyl-piperidin-2-one; 5-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-2-one; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy -(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-4-methyl-pyrrolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-3,3-dimethyl-pyrrolidine-2,5-dione; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-imidazolidine-2,4-dione; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-pyrrolidin-2-one; 3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-imidazolidine-2,4-dione; 3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-1-methyl-imidazolidine-2,4-dione; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl) )-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-3-methyl-imidazolidine-2,4-dione; 3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-oxazolidin-2-one; 1-cyclopropyl-3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-imidazolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-pyrrolidine-2,5-dione; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-3-methyl-imidazolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-imidazolidin-2-one; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propane-1,2-diol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-pyridin-3-yl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-methanol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-piperidin-1-yl]-ethanone; (3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-acetonitrile; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydrazine {hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-4-hydroxy-piperidin-1-yl]-ethanone; 3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propylonitrile; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-3-methoxy-piperidin-1-yl]-ethanone; 1-[(R)-3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-tetrahydro-pyran-4-ol; (R)-(1,3-Dimethyl-azetidin-3-yl)-{5-[5-(3-hydroxymethyl-bicyclo[1.1.1]pent-1-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-methyl-piperidine-2,6-dione; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-2,2-difluoro-ethanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(3-methoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-(5-isopropyl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-methyl-pyrrolidin-2-one; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-methyl-pyrrolidin-2-one; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-ethyl-pyrrolidin-2-one; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-ethyl-pyrrolidin-2-one; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-isopropyl-pyrrolidin-2-one; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxybenzoate {hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1-isopropyl-pyrrolidin-2-one; 1-[(S)-3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-pyrrolidin-1-yl]-ethanone; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-2-one; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-2-one; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-methyl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-methanol; (R)-{5-[5-(1,1-difluoro-ethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 4-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-tetrahydro-pyran-4-ol; (R)-[5-(3-tert-butoxymethyl-[1,2,4]oxadiazol-5-yl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-[5-(3-hydroxymethyl-[1,2,4]oxadiazol-5-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; 1-[4-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-piperazin-1-yl]-ethanone; 1-[3-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-ylmethyl)-azetidin-1-yl]-ethanone; 4-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-ylmethyl)-tetrahydro-pyran-4-ol; [4-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-[1,4]dioxan-2-yl-methanone; 1-[4-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-2-methoxy-ethanone; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(1-methanesulfonyl-piperidin-4-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{3-[1-(2-methoxy-ethanesulfonyl)-piperidin-4-yl]-[1,2,4]oxadiazol-5-yl}-pyridin-3-yl)-methanol; 1-[4-(5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-2-hydroxy-ethanone; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-[1,2,4]oxadiazol-3-yl-pyridin-3-yl)-methanol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 2-(3-{5-[(R)-(4-bromo-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-naphthalen-2-yl-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-[3-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2-ol; 2-[3-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropoxy-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-[3-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2-ol; (R)-2-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-(pentafluoro-λ6-sulfanyl)phenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-(3-fluoro-4-isopropyl-phenyl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(4-tert-butyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-benzo[b]thiophen-5-yl-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-pentafluoroethyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-[3-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(1-methyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy -(4-isopropyl-3-methyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-trifluoromethoxy-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 1-[4-(3-{5-[(R)-(4-bromo-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 2-[3-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-[4-(1-fluoro-1-methyl-ethyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2-ol; 2-(3-{5-[(R)-[4-(1,1-difluoro-ethyl)-phenyl]-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(4-bicyclo[1.1.1]pent-1-yl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-{5-[5-(tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-[4-(2,2,2-trifluoro-ethyl)-phenyl]-methanol; 2-[3-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-[4-(1,1-dimethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2-ol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-(3-fluoro-4-isopropyl-phenyl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-{4-[3-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-trifluoromethoxy-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropoxy-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 2-(3-{5-[(R)-(3-chloro-4-isopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(4-cyclobutyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 1-[4-(3-{5-[(R)-(4-cyclobutyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(3,5-difluoro-4-isopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 2-(3-{5-[(R)-(3,5-difluoro-4-isopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 1-[4-(3-{5-[(R)-(4-cyclobutoxy-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 2-[3-(5-{(1,3-dimethyl-azetidin-3-yl)-[4-(1-ethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2-ol; 1-{4-[3-(5-{(1,3-dimethyl-azetidin-3-yl)-[4-(1-ethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone; 2-[3-(5-{(1,3-dimethyl-azetidin-3-yl)-[4-(2,2-dimethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2-ol; 1-{4-[3-(5-{(1,3-dimethyl-azetidin-3-yl)-[4-(2,2-dimethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone; 1-{4-[3-(5-{(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(1-methyl-cyclohexyl) 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-propyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-(4-ethyl-phenyl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(4-butyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-trifluoromethyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-[3-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(2,2,2-trifluoro-ethyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isobutyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(4-cyclobutoxy-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropenyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 1-{4-[3-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(2,2,2-trifluoro-ethyl)-phenyl]-methyl}-pyridin (1,2,4)oxadiazol-5-yl]-piperidin-1-yl}-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-propyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-hydroxy-(1-isopropyl-3-methyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-[1-(2,2-difluoro-ethyl)-3-methyl-azetidin-3-yl]-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-hydroxy-[1-(2-hydroxy-ethyl)-3-methyl-azetidin-3-yl]-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1-cyclopropylmethyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-{4-[3-(5-{(R)-hydroxy-(4-isopropyl-phenyl)-[1-(2-methoxy-ethyl)-3-methyl-azetidin-3-yl]-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone; 1-{4-[3-(5-{(R)-hydroxy-(4-isopropyl-phenyl)-[3-methyl-1-(3,3,3-trifluoro-propyl)-azetidin-3-yl]-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone; 1-[4-(3-{5-[(R)-hydroxy-(4-isopropyl-phenyl)-(3-methyl-1-propyl-azetidin-3-yl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1-ethyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-(4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-piperidin-1-yl)-ethanone; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1,1-trifluoro-2-methyl-but-3-yn-2-ol; Cyclopropanecarboxylic acid (3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-amide; N-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-isobutyramide; N-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-2-methoxy-acetamide; 3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-oxazolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-pyrrolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-3-methyl-imidazolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-imidazolidin-2-one; 3-(1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopropyl)-oxazolidin-2-one; 1-((R)-2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-2-methyl-pyrrolidin-1-yl)-ethanone; 1-(4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-4-hydroxy-piperidin-1-yl)-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-hydroxy-1-methyl-prop-2-ynyl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-hydroxy-prop-2-ynyl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-prop-2-ynyl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-hydroxy-prop-2-ynyl)-4-methyl-piperidin-1-yl]-ethanone; 1-(4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-4-methyl-piperidin-1-yl)-ethanone; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(1-methanesulfonyl-piperidin-4-ylethynyl)-pyridin-3-yl]-methanol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-4-methyl-piperidine-1-sulfonic acid methylamide; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-methanesulfonyl-3-methyl-but-1-ynyl)-pyridin-3-yl]-methanol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopropanesulfonic acid dimethylamide; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopropane sulfonic acid amides; (R)-[5-(3-cyclopropanesulfonyl-3-methyl-but-1-ynyl)-pyridin-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-1-methyl-pyrrolidin-2-one; (S)-3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-1-methyl-pyrrolidin-2-one; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-ol; 3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-1-methyl-1,3-dihydro-indol-2-one; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1H-indazol-3-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-indazol-3-yl)-but-3-yn-2-ol; 2-(1-cyclopropyl-1H-pyrazol-3-yl)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-pyrazin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazol-5-yl)-but-3-yn-2-ol; 2-(6-cyclopropyl-pyrimidin-4-yl)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; N-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-acetamide; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy Ci-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2,6-dimethyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2,6-dimethyl-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-2-(2,6-dimethoxy-pyrimidin-4-yl)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; (R)-2-(2,6-dimethoxy-pyrimidin-4-yl)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol; 2-(6-difluoromethyl-pyrimidin-4-yl)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(1-pyridin-2-yl-cyclopropylethynyl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[1-(6-methyl-pyrimidin-4-yl)-cyclopropylethynyl]-pyridin-3-yl}-methanol; 1-[4-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-piperidin-1-yl]-ethanone; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1,1-trifluoro-2-methyl-butan-2-ol; 3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-propyl)-oxazolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-propyl)-pyrrolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-propyl)-3-methyl-imidazolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-propyl)-imidazolidin-2-one; 1-[(S)-2-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-2-methyl-pyrrolidin-1-yl]-ethanone; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1H-indazol-3-yl)-butan-2-ol; 2-(1-cyclopropyl-1H-pyrazol-3-yl)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-pyrimidin-4-yl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-pyrazin-2-yl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazol-5-yl)-butan-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(3-methyl-isoxazol-5-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-imidazol-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-thiophen-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrrol-2-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol; 4-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(1-methyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-trifluoromethyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl (Il-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-(4-ethyl-phenyl)-hydroxy-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(4-tert-butyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(3-ethyl-1-methyl-azetidin-3-yl)-hydroxy-(4-trifluoromethoxy-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-(5-{(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-[4-(2,2,2-trifluoro-ethyl)-phenyl]-methyl}-pyridin-3-yl)-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(S)-(3-fluoro-1-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 1-(4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-ylethynyl}-piperidin-1-yl)-ethanone; N-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-1,1-dimethyl-prop-2-ynyl)-acetamide; 1-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-1,1-dimethyl-prop-2-ynyl)-pyrrolidin-2-one; 4-{5-[(R)-hydroxy-(1-isopropyl-3-methyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-hydroxy-[1-(2-hydroxy-ethyl)-3-methyl-azetidin-3-yl]-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-[1-(2,2-difluoro-ethyl)-3-methyl-azetidin-3-yl]-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 1-(4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxymethyl}-piperidin-1-yl)-ethanone; 4-{5-[(R)-(1-cyclopropyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(2-isopropyl-pyrimidin-4-yl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(2-methyl-thiazol-5-yl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4 -isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(6-methyl-pyridin-3-yl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(6-isopropyl-pyridin-2-yl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(6-trifluoromethyl-pyridin-3-yl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(1-methyl-1H-pyrazol-4-yl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrrolidin-2-one; 4-(1-difluoromethyl-1H-pyrazol-4-yl)-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(2-methyl-2H-[1,2,3]triazol-4-yl)-pyrrolidin-2-one; 4-(1-acetyl-piperidin-4-yl)-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-pyrrolidin-2-one; 5-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-hexahydro-furo[2,3-c]pyrrol-4-one; 1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-yl}-4-(6-isopropyl-pyridin-2-yl)-pyrrolidin-2-one; 1-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)-ethanone; 1-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-ethanone; 1-[4-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrimidin-5-yl)-piperidin-1-yl]-ethanone; Or, 1-[4-(2-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrimidin-4-yl)-piperidin-1-yl]-ethanone; 2. The compound of claim 1, wherein:

16. 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; or (S)-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy Ci-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; 2. The compound of claim 1, wherein:

17. 2. The compound of claim 1, which is 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol, or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition comprising the compound according to any one of claims 1 to 17 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

19. A compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical.

20. 20. A compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of inflammatory and / or autoimmune diseases and / or disorders or cancer.

21. Use of a compound according to any one of claims 1 to 17 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or treatment of inflammatory and / or autoimmune diseases and / or disorders; or cancer.

22. A pharmaceutical for the prevention or treatment of inflammatory and / or autoimmune diseases and / or disorders; or cancer, comprising as an active ingredient a compound according to any one of claims 1 to 17 or a pharmaceutically acceptable salt thereof. 【Request Item 23】 Psoriasis; Psoriatic arthritis; rheumatoid arthritis; ankylosing spondylitis; spondyloarthritis; Inflammatory skin disorders; rosacea; Crohn's disease; Ulcerative colitis; irritable bowel disease; dry eye disease; 18. The compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of an inflammatory and / or autoimmune disease and / or disorder selected from multiple sclerosis; systemic lupus erythematosus; Sjogren's syndrome; autoimmune hepatitis; and primary sclerosing cholangitis.

24. A compound according to any one of claims 1 to 17 or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of cancer selected from lymphoma; T-cell lymphoma; brain cancer; glioma; glioblastoma; breast cancer; colorectal cancer; hepatocellular carcinoma; renal cell carcinoma; lung cancer; and gastric cancer.

Images